ifosfamide has been researched along with Soft Tissue Neoplasms in 286 studies
Soft Tissue Neoplasms: Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The results of the association of doxorubicin plus ifosfamide in the treatment of locally advanced and/or metastatic adult soft tissue sarcomas as reported in the literature from 1986 up to the present time are reviewed." | 10.17 | Doxorubicin (or epidoxorubicin) combined with ifosfamide in the treatment of adult advanced soft tissue sarcomas. ( Palumbo, R; Santi, L; Sogno, G; Toma, S; Venturino, A, 1992) |
| "This randomised phase II/III trial aimed to determine whether perioperative chemotherapy with gemcitabine plus docetaxel (GD) is non-inferior to the standard Adriamycin plus ifosfamide (AI) in terms of overall survival (OS) in patients with soft tissue sarcoma (STS)." | 9.51 | Perioperative Adriamycin plus ifosfamide vs. gemcitabine plus docetaxel for high-risk soft tissue sarcomas: randomised, phase II/III study JCOG1306. ( Abe, S; Akisue, T; Asanuma, K; Emori, M; Fukuda, H; Furuta, T; Hatano, H; Hiraga, H; Hiraoka, K; Hiruma, T; Iwamoto, Y; Katagiri, H; Kataoka, T; Kawai, A; Kawano, M; Kawashima, H; Machida, R; Matsumoto, Y; Morii, T; Nagano, A; Nakayama, R; Nishida, Y; Okuma, T; Outani, H; Ozaki, T; Suehara, Y; Takenaka, S; Takeyama, M; Tanaka, K; Toguchida, J; Tsukushi, S; Watanuki, M; Yamamoto, T; Yonemoto, T, 2022) |
| "This prospective single-arm phase II clinical trial aimed to evaluate the efficacy and safety of pegylated liposomal doxorubicin (PLD) combined with ifosfamide (IFO) as the first-line treatment for patients with advanced or metastatic soft-tissue sarcoma (STS)." | 9.51 | Pegylated Liposomal Doxorubicin Combined with Ifosfamide for Treating Advanced or Metastatic Soft-tissue Sarcoma: A Prospective, Single-arm Phase II Study. ( Chen, H; Chen, Y; Huang, M; Jiang, S; Liu, X; Luo, Z; Miao, J; Wang, C; Wang, H; Wang, J; Wu, X; Xia, J; Xu, Y; Yan, W; Yao, W; Yu, L; Zhang, X, 2022) |
| "Doxorubicin and ifosfamide (AI) is standard therapy for high-risk soft tissue sarcoma (STS) but often causes severe toxicities resulting in hospitalisation." | 9.20 | A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma. ( Baker, LH; Biermann, JS; Chugh, R; Davis, EJ; Feng, M; Jacobson, J; Lucas, DR; Metko, G; Reinke, D; Schuetze, SM; Wong, SL; Zalupski, MM; Zhao, L; Zyczynski, L, 2015) |
| "Effective targeted treatment is unavailable for most sarcomas and doxorubicin and ifosfamide-which have been used to treat soft-tissue sarcoma for more than 30 years-still have an important role." | 9.19 | Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. ( Alcindor, T; Blay, JY; dei Tos, AP; Fisher, C; Gelderblom, H; Hartmann, JT; Hermans, C; Hogendoorn, PC; Hohenberger, P; Judson, I; Kerst, JM; Krarup-Hansen, A; Litière, S; Marreaud, S; Schöffski, P; Sufliarsky, J; van der Graaf, WT; Verweij, J; Whelan, J, 2014) |
| " Perioperative chemotherapy with adriamycin plus ifosfamide is the current standard treatment for T2bN0M0 high-grade non-round cell soft tissue sarcoma." | 9.19 | A randomized phase II/III trial of perioperative chemotherapy with adriamycin plus ifosfamide versus gemcitabine plus docetaxel for high-grade soft tissue sarcoma: Japan Clinical Oncology Group Study JCOG1306. ( Araki, N; Fukuda, H; Hiraga, H; Iwamoto, Y; Kataoka, K; Kawai, A; Kimura, A; Matsumine, A; Matsunobu, T; Mizusawa, J; Oda, Y; Tanaka, K, 2014) |
| "The objective of this Phase I dose escalation study was to explore the safety and tolerability of eltrombopag, an oral, nonpeptide, thrombopoietin receptor agonist, in patients with advanced soft tissue sarcoma (STS) and thrombocytopenia due to treatment with doxorubicin and ifosfamide (AI) combination chemotherapy." | 9.17 | Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide. ( Chawla, SP; Hendifar, A; Kamel, YM; Messam, CA; Patwardhan, R; Staddon, A, 2013) |
| "This multicenter, phase II trial evaluated the efficacy and safety of everolimus, an mTOR inhibitor, in patients with metastatic or recurrent bone and soft-tissue sarcoma after the failure of anthracycline- and ifosfamide-containing regimens." | 9.17 | Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide. ( Ahn, JH; Kim, TM; Kim, YJ; Lee, HJ; Lee, J; Lee, KH; Park, KH; Rha, SY; Yoo, C, 2013) |
| "Ifosfamide and doxorubicin combination is an active regimen for patients with advanced soft tissue sarcomas (STS) but is burdened by high toxicity." | 9.15 | Optimizing clinical care in patients with advanced soft tissue sarcoma: a phase II study of a new schedule of high-dose continuous infusion ifosfamide and doxorubicin combination. ( Boni, C; Boselli, S; Catania, C; de Braud, F; De Pas, T; Delmonte, A; Frustaci, S; Noberasco, C; Radice, D; Rosati, G; Scalamogna, R; Spitaleri, G; Toffalorio, F; Tucci, A; Vecchio, F, 2011) |
| "To assess the progression-free survival (PFS) and antitumor response to standard-dose doxorubicin compared with sequential dose-dense doxorubicin and ifosfamide in first-line treatment of advanced soft tissue sarcoma." | 9.14 | Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas. ( Andrés, R; Balañá, C; Buesa, JM; Casado, A; Cruz, J; Cubedo, R; de la Cruz, JJ; de Las Peñas, R; Del Muro, XG; Fra, J; Gallego, O; Gómez, MA; López-Pousa, A; Martín, J; Martínez-Trufero, J; Maurel, J; Poveda, A; Rubió, J; Rubio-Viqueira, B; Sevilla, I, 2009) |
| "Having determined in a phase I study the maximum tolerated dose of high-dose ifosfamide combined with high-dose doxorubicin, we now report the long-term results of a phase II trial in advanced soft-tissue sarcomas." | 9.12 | Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies. ( Cerny, T; Christinat, A; Dietrich, D; Fey, MF; Guillou, L; Herrmann, R; Honegger, HP; Leyvraz, S; Pestalozzi, B; Sessa, C; Wernli, M, 2006) |
| "Combinations of high-dose ifosfamide (IF; 10-12 g/m2) plus doxorubicin (DX; 50-90 mg/m2) have been administered to patients with advanced soft tissue sarcoma (ASTS) in an attempt to improve therapeutic efficacy." | 9.11 | Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS). ( Balañá, C; Buesa, JM; Casado, A; de las Peñas, R; Fra, J; García del Muro, X; López-Pousa, A; Martín, J; Martínez-Trufero, J; Maurel, J, 2004) |
| "The relative value of increasing ifosfamide dose in combination chemotherapy for patients with soft tissue sarcoma (STS) is unclear." | 9.11 | Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma. ( Baker, LH; Biermann, JS; Chugh, R; Leu, KM; McGinn, CJ; Sondak, VK; Taylor, JM; Worden, FP; Zalupski, MM, 2005) |
| "To describe the response rate and survival of children and adolescents with unresected or metastatic nonrhabdomyosarcomatous soft tissue sarcomas (NRSTS) treated with vincristine, ifosfamide, and doxorubicin." | 9.11 | Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study. ( Devidas, M; Gebhardt, M; Grier, HE; Jenkins, J; Marcus, R; Pappo, AS; Pratt, C; Rao, B; Thomas, P, 2005) |
| "Doxorubicin and ifosfamide are the two most active agents used to treat soft tissue sarcomas." | 9.11 | Alternating sequential chemotherapy with high-dose ifosfamide and doxorubicin/cyclophosphamide for adult non-small round cell soft tissue sarcomas. ( Abe, S; Araki, N; Beppu, Y; Hasegawa, T; Ihara, K; Ishii, T; Isu, K; Kawai, A; Ozaki, T; Sugiura, H; Tsugane, S; Umeda, T; Wada, T; Yabe, H, 2005) |
| "The aim of this phase II study was to evaluate the efficacy and toxicity of two regimens of ifosfamide in metastatic soft tissue sarcoma patients given as first- and second-line chemotherapy." | 9.10 | Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. ( Dombernowsky, P; Hermans, C; Judson, I; Krzemieniecki, K; Mouridsen, HT; Nielsen, OS; Spooner, D; Svancarova, L; Van Glabbeke, M; van Oosterom, AT; Verweij, J, 2002) |
| "We conducted our study to determine the pharmacokinetics (PK) and clinical efficacy of oral mesna in patients receiving ifosfamide for soft tissue sarcoma." | 9.10 | Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide. ( Baker, LH; Bernardy, H; Demetri, G; Junge, K; Keohan, ML; Mace, JR; Mueller, U; Niebch, G; Romeis, P; Thoma, A; Wagner, T, 2003) |
| "Between March 1994 and October 1997, 20 women and 19 men with primary extremity or limb girdle high-grade soft tissue sarcomas were registered to a study of preoperative ifosfamide, mitomycin, doxorubicin, cisplatin (IMAP) plus granulocyte macrophage-colony-stimulating factor (GM-CSF) followed by preoperative irradiation and subsequent limb-sparing surgery." | 9.10 | Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony-stimulating factor. ( Buckner, JC; Edmonson, JH; Foo, ML; Gunderson, LL; Haddock, MG; Mahoney, MR; Maples, WJ; O'Connor, MI; Petersen, IA; Pritchard, DJ; Rock, MG; Shives, TC; Sim, FH; Stafford, SL, 2002) |
| "The Soft Tissue and Bone Sarcoma Group (STBSG) of the EORTC ran a phase II study to assess the therapeutic activity of high-dose ifosfamide in patients with advanced soft tissue sarcomas by means of response rate (RR)." | 9.09 | Radiologist review versus group peer review of claimed responses in a phase II study on high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the EORTC Soft Tissue and Bone Sarcoma Group. ( Gwyther, SJ; Judson, IR; Nielsen, OS; van Glabbeke, M; Verweij, J, 2000) |
| "The efficacy and feasibility of a novel sequential schedule of high-dose ifosfamide (HD-IFO) and full-dose epirubicin (EPI) with granulocyte colony-stimulating factor (G-CSF) was evaluated in adult patients with soft tissue sarcomas (STS)." | 9.09 | A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule. ( Cognetti, F; Gamucci, T; Nardi, M; Serrone, L; Zeuli, M, 2001) |
| "The Epirubicin (EPI) and ifosfamide (IFO) combination has been widely tested in soft tissue sarcomas, even though the optimal schedule of drug administration has still to be defined." | 9.09 | Ifosfamide and epirubicin combination in untreated sarcomas: two treatment schedules. ( Cognetti, F; Nardoni, C; Pacetti, U; Papaldo, P; Serrone, L; Zeuli, M, 2001) |
| "Patients with locally advanced or metastatic soft tissue sarcoma refractory to treatment with anthracyclines and ifosfamide were enrolled into the present phase II study." | 9.09 | Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: results of a phase II trial. ( Amann, G; Attems, Y; Brodowicz, T; Fiebiger, WC; Hejna, M; Köstler, WJ; Krainer, M; Tomek, S; Wiltschke, CH; Zielinski, CC, 2001) |
| " ifosfamide and etoposide) and to improve overall survival of previously untreated patients with metastatic rhabdomyosarcoma." | 9.09 | Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group. ( Breitfeld, PP; Crist, WM; Donaldson, SS; Lobe, T; Lyden, E; Maurer, HM; Raney, RB; Ruymann, FB; Teot, LA; Wharam, M, 2001) |
| "Ifosfamide, an oxazaphosphorine analogue, is now commonly used in first-line anthracycline-containing regimens for advanced soft tissue sarcomas, based on its demonstrated single-agent activity in previously treated patients." | 9.08 | High-dose ifosfamide in the treatment of advanced soft tissue sarcomas. ( Tursz, T, 1996) |
| "To evaluate the efficacy and feasibility of high-dose ifosfamide (HDI) at a total dose of 14 g/m2 per cycle with mesna in combination with granulocyte colony-stimulating factor (G-CSF) in adult patients with sarcomas." | 9.08 | High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence. ( Benjamin, RS; Burgess, MA; Hays, C; Papadopolous, N; Patel, SR; Plager, C; Vadhan-Raj, S, 1997) |
| "The purpose of this study was to evaluate tumour response and toxicity to ifosfamide and continuous infusion etoposide in metastatic or locally advanced soft tissue sarcoma, with dose escalations under G-CSF (granulocyte colony-stimulating factor) support." | 9.08 | Ifosfamide and continuous infusion etoposide in advanced adult soft tissue sarcoma. A Scandinavian Sarcoma Group Phase II Study. ( Alvegård, TA; Erlanson, M; Hannisdal, E; Klepp, R; Monge, OR; Raabe, N; Saeter, G; Söderberg, M; Solheim, OP; Strander, H; Turesson, I; Wist, E, 1997) |
| "Ifosfamide has important activity in pretreated soft tissue sarcomas (STS), and recent data support a clinically significant dose-response relationship for this agent." | 9.08 | Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas. ( Antimi, M; Gatti, C; Palmeri, S; Palumbo, R; Raffo, P; Toma, S; Villani, G, 1997) |
| "The agent Ifosfamide (IFOS) is active against soft tissue sarcomas (STS), and patients who progress to IFOS at doses < or = 10 g/m2 show remissions when exposed to high-dose ifosfamide (HDI) (i." | 9.08 | Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS) ( Antón, A; Arranz, F; Bellmunt, J; Buesa, JM; Casado, A; Escudero, P; García del Muro, J; López-Pousa, A; Martín, J; Menéndez, D; Poveda, A; Valentí, V, 1998) |
| "Ifosfamide and doxorubicin are the most active agents in the treatment of sarcomas and are characterized by a marked dose-response relationship." | 9.08 | Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas. Swiss Group for Clinical Research (SAKK). ( Bacchi, M; Bressoud, A; Cerny, T; Hermann, R; Leyvraz, S; Lissoni, A; Sessa, C, 1998) |
| "Adriamycin (ADM) and ifosfamide (IFO) are the two most active agents in the treatment of soft tissue sarcomas (STS) with a clear dose-response relationship." | 9.08 | High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: is it feasible? ( Aapro, MS; De Braud, F; De Pas, T; Fazio, N; Goldhirsch, A; Munzone, E; Nolè, F; Orlando, L; Zampino, MG, 1998) |
| "The purpose of this review is to characterize the nephrotoxicity noted in newly diagnosed patients under 21 years of age after treatment with ifosfamide-containing chemotherapy regimens and local irradiation for localized gross residual rhabdomyosarcoma or undifferentiated sarcoma." | 9.07 | Renal toxicity of ifosfamide in pilot regimens of the intergroup rhabdomyosarcoma study for patients with gross residual tumor. ( Ensign, LG; Foreman, J; Khan, F; Maurer, H; Newton, W; Ortega, J; Ragab, A; Raney, B; Wharam, M; Wiener, E, 1994) |
| "5 g/m2 mesna was administered for 7 days, both by continuous infusion, in combination with 50 mg/m2/d oral etoposide for 8 days in 21 patients with sarcomas or other solid tumors." | 9.07 | Ambulatory continuous infusion ifosfamide with oral etoposide in advanced sarcomas. ( Hamdan, H; Skubitz, KM; Thompson, RC, 1993) |
| "To evaluate the feasibility, toxicity and efficacy of the combination of (IFO) ifosfamide and epirubicin (EPI) given at conventional doses for monochemotherapy, we started a phase II study in advanced/metastatic soft tissue sarcoma patients." | 9.07 | Epirubicin and ifosfamide in advanced soft tissue sarcomas. ( Buonadonna, A; Carbone, A; Crivellari, D; De Paoli, A; Foladore, S; Frustaci, S; Monfardini, S; Morassut, S; Sorio, R, 1993) |
| "This three-armed phase III study in adults with advanced soft tissue sarcomas was planned as a comparison of objective regression rates, toxicity, and survival of patients receiving doxorubicin alone, ifosfamide plus doxorubicin, and mitomycin plus doxorubicin plus cisplatin." | 9.07 | Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. ( Blum, RH; Brooks, JS; Edmonson, JH; Frytak, S; Parkinson, DR; Ryan, LM; Shiraki, M, 1993) |
| "Doxorubicin alone or with dacarbazine (DTIC; AD) is considered the best available therapy for metastatic adult sarcomas." | 9.07 | An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. ( Antman, K; Balcerzak, SP; Barlogie, B; Cooper, RM; Crowley, J; Elias, A; Natale, RB; Rivkin, SE; Trump, DL; Weiss, GR, 1993) |
| "The objective of this phase II trial was to assess the therapeutic activity and toxicity of doxorubicin plus ifosfamide in previously untreated patients with advanced soft-tissue sarcoma." | 9.07 | Ifosfamide plus doxorubicin in previously untreated patients with advanced soft-tissue sarcoma. ( Blackledge, G; Dombernowsky, P; Mouridsen, HT; Santoro, A; Schütte, J; Somers, R; Steward, W; Thomas, D; van Oosterom, AT; Verweij, J, 1993) |
| "A total of 51 patients with large, primary, high-grade soft-tissue sarcomas of the extremities were treated at our institute with two preoperative and three postoperative cycles of doxorubicin plus ifosfamide/mesna." | 9.07 | Preoperative doxorubicin plus ifosfamide in primary soft-tissue sarcomas of the extremities. ( Azzarelli, A; Casali, P; Fissi, S; Montalto, F; Quagliuolo, V; Santoro, A, 1993) |
| "The Southwest Oncology Group (SWOG) performed a phase II trial of a combination of ifosfamide/mesna/cisplatin in patients with metastatic soft-tissue sarcoma who had previously received one chemotherapeutic regimen." | 9.07 | Phase II trial of ifosfamide and cisplatin in the treatment of metastatic sarcomas: a Southwest Oncology Group study. ( Balcerzak, SP; Budd, GT; Fabian, C; Metch, B; Stephens, RL; Weick, JK; Weiss, SA, 1993) |
| "On the basis of ifosfamide's demonstrated single-agent activity in adult soft-tissue sarcoma, the Eastern Cooperative Oncology Group (ECOG) tested whether ifosfamide would add to the efficacy of doxorubicin in a three-regimen, controlled phase III trial." | 9.07 | Efficacy of ifosfamide in combination with doxorubicin for the treatment of metastatic soft-tissue sarcoma. The Eastern Cooperative Oncology Group. ( Blum, RH; Edmonson, J; Pelletier, L; Ryan, L, 1993) |
| "A total of 37 adult patients with locally advanced or metastatic soft-tissue sarcoma (STS) entered a pilot study of combination chemotherapy based on the CYVADIC (cyclophosphamide, vincristine, doxorubicin, and dacarbazine) regimen, in which cyclophosphamide was replaced by ifosfamide and mesna (1 g/m2 ifosfamide given daily on days 1-5 as 2-h infusions, 1." | 9.07 | Ifosfamide, vincristine, doxorubicin and dacarbazine in adult patients with advanced soft-tissue sarcoma. ( Blomqvist, CP; Elomaa, I; Virolainen, M; Wiklund, TA, 1992) |
| "Doxorubicin and ifosfamide are the two most active agents used in the treatment of advanced inoperable soft-tissue sarcoma, but their use in combination produces dose-limiting myelosuppression." | 9.07 | Doxorubicin plus ifosfamide with rhGM-CSF in the treatment of advanced adult soft-tissue sarcomas: preliminary results of a phase II study from the EORTC Soft-Tissue and Bone Sarcoma Group. ( Blackledge, G; Clavel, M; Greifenberg, B; Soedirman, J; Somers, R; Steward, WP; Thomas, D; Van Glabbeke, M; Van Oosterom, AT; Verweij, J, 1991) |
| "European and American investigators have reported response rates of 38% to 83% for ifosfamide alone in pretreated sarcomas." | 9.06 | Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. ( Antman, KH; Elias, A; Grier, HE; Ryan, L; Sherman, D, 1989) |
| "In this phase II trial, 105 eligible patients with no prior chemotherapy and advanced sarcoma received doxorubicin, ifosfamide, and dacarbazine (DTIC) with mesna uroprotection (MAID)." | 9.06 | Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. ( Aisner, J; Antman, KH; Collins, J; Elias, A; Ryan, L; Sulkes, A, 1989) |
| "One hundred and seventy-one patients with advanced soft tissue sarcoma entered a randomized crossover phase II study comparing cyclophosphamide (CYCLO) with a new analogue, ifosfamide (IFOS), both administered as 24 h i." | 9.06 | Cyclophosphamide versus ifosfamide: preliminary report of a randomized phase II trial in adult soft tissue sarcomas. ( Blackledge, G; Bramwell, VH; Mouridsen, HT; Santoro, A; Somers, R; Sylvester, R; Thomas, D; Van Oosterom, A, 1986) |
| "Alkylating agents, such as cyclophosphamide and ifosfamide, play a major role in the improved survival of children and young adults with bone and soft tissue sarcoma." | 8.91 | Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients. ( Kremer, LC; Langer, T; Mulder, RL; Paulides, M; van Dalen, EC, 2015) |
| "The authors report a retrospective analysis of high-dose ifosfamide, carboplatin, and etoposide (HD-ICE) for patients with refractory or relapsed neuroblastoma (NB)." | 8.89 | Ifosfamide, carboplatin, and etoposide for neuroblastoma: a high-dose salvage regimen and review of the literature. ( Basu, EM; Cheung, NK; Kramer, K; Kushner, BH; Modak, S; Roberts, SS, 2013) |
| "Alkylating agents, such as cyclophosphamide and ifosfamide, play a major role in the improved survival of children and young adults with bone and soft tissue sarcoma." | 8.88 | Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients. ( Kremer, LC; Langer, T; Mulder, RL; Paulides, M; van Dalen, EC, 2012) |
| "Independent favourable prognostic factors for overall survival (OS) were good performance status, female gender, low histological grade, extremity primary tumour site and locally advanced disease; for progression-free survival (PFS), the combination of doxorubicin and ifosfamide, locally advanced disease, and tumour entity with a lower risk to progress for synovial sarcoma patients compared to leiomyosarcoma." | 8.86 | Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Tr ( Blay, JY; Hogendoorn, PC; Krarup-Hansen, A; Le Cesne, A; Ouali, M; Rodenhuis, S; Sleijfer, S; van Glabbeke, M; Verweij, J, 2010) |
| "Ifosfamide is a chemotherapeutic prodrug used in the treatment of several tumor entities, including bone and soft-tissue sarcoma." | 8.86 | Palifosfamide, a bifunctional alkylator for the treatment of sarcomas. ( Jung, S; Kasper, B, 2010) |
| "Alkylating agents, such as cyclophosphamide and ifosfamide, play a major role in the improved survival of children and young adults with bone and soft tissue sarcoma." | 8.86 | Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients. ( Kremer, LC; Langer, T; Mulder, RL; Paulides, M; van Dalen, EC, 2010) |
| "The current study was performed to evaluate the toxicity profile of therapeutic doses of ifosfamide (IFX) given concurrently with full-dose external beam radiotherapy (EBRT) in patients with soft tissue and bone sarcomas." | 8.81 | Concurrent ifosfamide-based chemotherapy and irradiation. Analysis of treatment-related toxicity in 43 patients with sarcoma. ( Ballo, MT; Benjamin, RS; Burgess, MA; Cormier, JN; Feig, BW; Herzog, CE; Hunt, KK; Patel, SR; Pisters, PW; Raney, RB; Zagars, GK, 2001) |
| "Ifosfamide is an alkylating agent with clinical activity in the treatment of sarcomas, and data support a dose-response relationship in this disease." | 8.79 | High-dose ifosfamide in the treatment of sarcomas of soft tissues and bone. ( Demetri, GD, 1996) |
| "We have used ifosfamide to treat patients with sarcomas in four completed single-agent protocols and one pilot study since 1985." | 8.78 | Single-agent ifosfamide studies in sarcomas of soft tissue and bone: the M.D. Anderson experience. ( Benjamin, RS; Legha, SS; Nicaise, C; Patel, SR, 1993) |
| "Doxorubicin and ifosfamide are currently the two main drugs for the treatment of soft tissue sarcomas in adults." | 8.78 | Perspectives on anthracyclines plus ifosfamide in advanced soft tissue sarcomas. ( Azzarelli, A; Bertulli, R; Casali, P; Devizzi, L; Pastorino, U; Santoro, A; Zucchinelli, P, 1993) |
| "Ifosfamide is an analogue of cyclophosphamide that has been extensively investigated in sarcomas." | 8.78 | The role of ifosfamide in the treatment of adult soft tissue sarcomas, Ewing's sarcoma, and osteosarcoma: a review. ( Dirix, LY; Van Oosterom, AT, 1990) |
| "The alkylating agent ifosfamide has demonstrated significant activity against advanced sarcomas." | 8.77 | The role of ifosfamide in the treatment of sarcomas. ( Dirix, LY; Van Oosterom, AT, 1989) |
| "We conducted a multi-institutional retrospective study, identifying sarcoma patients who received anthracyclines and/or ifosfamide during pregnancy." | 8.12 | Pregnancy outcomes related to the treatment of sarcomas with anthracyclines and/or ifosfamide during pregnancy. ( Agulnik, M; Davis, LE; Godbole, S; Hirbe, AC; Livingston, JA; Miller, D; Park, Y; Parkes, A; Posey, K; Robinson, SI; Skubitz, K; Van Tine, BA, 2022) |
| "To investigate the value of contrast-enhanced computed tomography (CECT) radiomics features in predicting the efficacy of epirubicin combined with ifosfamide in patients with pulmonary metastases from soft tissue sarcoma." | 8.12 | Prediction of the therapeutic efficacy of epirubicin combined with ifosfamide in patients with lung metastases from soft tissue sarcoma based on contrast-enhanced CT radiomics features. ( Jiang, X; Li, M; Ma, ST; Miao, L; Wang, YM; Zhang, HH, 2022) |
| "To compare long-term outcomes of high-grade, primary soft-tissue-sarcoma (STS), using Ifosfamide-Doxorubicin vs local therapy alone, in histology-specific sarcomas." | 8.02 | The role of Ifosfamide-doxorubicin chemotherapy in histology-specific, high grade, locally advanced soft tissue sarcoma, a 14-year experience. ( Burchette, RJ; Goy, BW; Helmstedter, CS; Padmanabhan, A; Syed, S, 2021) |
| "We compared the outcomes in soft tissue sarcoma (STS) treated with olaratumab and doxorubicin (OD) versus doxorubicin, ifosfamide, and mesna (AIM) to assess whether OD could supersede AIM in STS therapy." | 7.96 | Doxorubicin and Olaratumab Versus Doxorubicin, Ifosfamide, and Mesna for Treatment of Advanced Soft Tissue Sarcomas. ( Copeland, VC; Cranmer, LD; Hammer, KJ; Loggers, ET; Pollack, SM; Wagner, MJ, 2020) |
| "A retrospective search of the Royal Marsden Sarcoma Unit Database was performed to identify patients initially treated with ifosfamide (as single agent or in combination) and who were subsequently rechallenged with single-agent ifosfamide." | 7.88 | Successful Ifosfamide Rechallenge in Soft-Tissue Sarcoma. ( Benson, C; Constantinidou, A; Jones, RL; Judson, I; Messiou, C; Miah, A; Noujaim, J; Thway, K, 2018) |
| "We retrospectively reviewed outcomes of treatment with VIP (combination of etoposide, ifosfamide, and cisplatin) in patients with previously treated soft tissue sarcoma (STS)." | 7.85 | VIP (etoposide, ifosfamide, and cisplatin) in patients with previously treated soft tissue sarcoma. ( Baek, SW; Choi, YS; Jo, DY; Kim, S; Lee, HJ; Moon, JY; Ryu, H; Song, IC; Yun, HJ, 2017) |
| "The combination of topotecan and cyclophosphamide is active in relapsed Ewing sarcoma family of tumors (ESFT)." | 7.83 | Pilot Study of Adding Vincristine, Topotecan, and Cyclophosphamide to Interval-Compressed Chemotherapy in Newly Diagnosed Patients With Localized Ewing Sarcoma: A Report From the Children's Oncology Group. ( Bond, MC; Felgenhauer, JL; Femino, JD; Gorlick, R; Krailo, MD; Laack, NN; Marina, N; Mascarenhas, L; Meyer, J; Ranganathan, S; Villaluna, D; Womer, RB, 2016) |
| "Adriamycin, dacarbazine and ifosfamide are three effective chemotherapy drugs in treating progressive soft tissue sarcoma." | 7.71 | [Continuous-infusion high dose ifosfamide as salvage treatment for pre-treated soft tissue sarcoma]. ( Chen, LK; Liang, Y; Liu, JL; Teng, XY; Xu, GC; Zhou, XM, 2002) |
| "Ifosfamide is a leading drug in soft tissue sarcoma therapy." | 7.70 | Pharmacokinetics of ifosfamide administered according to three different schedules in metastatic soft tissue and bone sarcomas. ( Bergnolo, P; Boglione, A; Bumma, C; Colussi, AM; Comandone, A; Dal Canton, O; Frustaci, S; Leone, L; Monteleone, M; Oliva, C, 1998) |
| "From January 1990 to December 1995 we treated 35 patients (pts) with bone and soft tissue sarcoma with ifosfamide (IFM)." | 7.69 | [The effects of high-dose ifosfamide in the treatment of bone and soft tissue sarcomas]. ( Ishii, T; Kitoh, M; Satoh, T; Tatezaki, S; Umeda, T; Yonemoto, T, 1997) |
| "A total of 64 courses of ifosfamide (IFM) treatments for sarcoma patients were evaluated for toxic effects." | 7.68 | [Toxic effects of ifosfamide in the treatment of bone and soft tissue sarcomas]. ( Ishii, T; Kitoh, M; Satoh, T; Tatezaki, S; Umeda, T, 1993) |
| "Between 1982 and 1986, 38 patients with soft-tissue sarcomas were treated with the combination doxorubicin/dacarbazine (group A); between 1986 and 1990, another 46 patients received doxorubicin/ifosfamide (group B); and between 1990 and 1991, 11 patients received an alternating regimen of doxorubicin and ifosfamide (group C)." | 7.68 | Treatment results obtained in metastatic soft-tissue sarcoma with a combination of doxorubicin and dacarbazine or doxorubicin and ifosfamide. ( Agarwal, K; Dietel, M; Hossfeld, DK; Schwarz, R; Weh, HJ; Zornig, C, 1993) |
| "Two trials using ifosfamide-based combination chemotherapy for advanced soft-tissue sarcoma have been completed." | 7.68 | Ifosfamide combination regimens for soft-tissue sarcoma. ( Bell, DR; Dalley, D; Levi, J; Simes, RJ; Stuart-Harris, R; Wiltshaw, E, 1993) |
| "The response of ifosfamide-based chemotherapeutic regimens was retrospectively analyzed in adult patients with advanced soft-tissue sarcoma who were treated at the West German Tumor Center, Essen, between 1978 and 1990." | 7.68 | Ifosfamide in the treatment of soft-tissue sarcomas: experience at the West German Tumor Center, Essen. ( Kellner, R; Schütte, J; Seeber, S, 1993) |
| "Currently, anthracyclines and ifosfamide are the most effective drugs for the treatment of disseminated soft-tissue sarcoma." | 7.68 | A pilot study of rapidly alternating epirubicin/dacarbazine and ifosfamide as first-line therapy for metastatic soft-tissue sarcoma in adults. ( Anagnou, J; Bokemeyer, C; Harstrick, A; Knipp, H; Köhne-Wömpner, CH; Neumann, S; Poliwoda, H; Schmoll, HJ; Schöffski, P; Wipperman, B, 1993) |
| "A total of 46 consecutive patients were entered into this study to assess the efficacy and toxicity of an epirubicin/ifosfamide combination in treating locally advanced and/or metastatic adult sarcomas (38 soft-tissue sarcomas and 7 bone sarcomas in 45 evaluable patients)." | 7.68 | Ifosfamide plus epirubicin at escalating doses in the treatment of locally advanced and/or metastatic sarcomas. ( Albanese, E; Barisone, A; Canavese, G; Cantoni, E; Palumbo, R; Reggiardo, G; Rosso, R; Santi, L; Toma, S, 1993) |
| "Twenty-eight patients with non-pretreated metastatic soft tissue sarcomas were entered on a treatment protocol of rapidly alternating epirubicin/dacarbazine and ifosfamide: Epirubicin 100 mg/m2 d1, dacarbazine 500 mg/m2 d1 + d2, ifosfamide 6000 mg/m2 24-h infusion d15; repeated d29." | 7.68 | Epirubicin/dacarbazine rapidly alternated with ifosfamide in the treatment of metastatic soft tissue sarcomas. ( Bokemeyer, C; Harstrick, A; Köhne-Wömpner, CH; Poliwoda, H; Schmoll, HJ; Schöffski, P, 1992) |
| "From July 1986 to July 1989, 40 patients (92% pretreated) with deep-seated, advanced soft tissue sarcomas (STS, 25 patients), Ewing's sarcomas (ES, eight patients), osteosarcomas (OS, three patients) and chondrosarcomas (ChS, four patients) were treated at the University of Munich in a protocol involving regional hyperthermia (RHT) combined with ifosfamide plus etoposide." | 7.68 | Ifosfamide plus etoposide combined with regional hyperthermia in patients with locally advanced sarcomas: a phase II study. ( Berger, H; Boehm, E; Denecke, H; Issels, RD; Jauch, KW; Nagele, A; Peter, K; Prenninger, SW; Sauer, H; Wilmanns, W, 1990) |
| "The objective of this phase II trial was to assess the therapeutic activity and toxicity of doxorubicin plus ifosfamide in previously untreated patients with advanced soft tissue sarcoma." | 7.68 | Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. The EORTC Soft Tissue and Bone Sarcoma Group. ( Blackledge, G; Dombernowsky, P; Mouridsen, HT; Santoro, A; Schütte, J; Somers, R; Stewart, W; Thomas, D; van Oosterom, AT; Verweij, J, 1990) |
| "Forty-three adult patients with locally advanced or metastatic soft tissue sarcoma entered a pilot study of combination chemotherapy comprising 50 mg of doxorubicin/m2 by intravenous bolus, 850 mg of dacarbazine/m2 by 1-hour infusion, and 5 g of ifosfamide/m2 by 24-hour infusion with mesna uroprotection." | 7.67 | Combination chemotherapy with doxorubicin, dacarbazine, and ifosfamide in advanced adult soft tissue sarcoma. Canadian Sarcoma Group--National Cancer Institute of Canada Clinical Trials Group. ( Bramwell, V; Eisenhauer, E; Knowling, M; Quirt, I; Verma, S; Warr, D; Young, V, 1989) |
| "Early results with ifosfamide plus mesna in soft tissue sarcoma showed an initial response rate of 38% in 42 patients." | 7.67 | Ifosfamide plus mesna with and without adriamycin in soft tissue sarcoma. ( Fisher, C; Harmer, C; McKinna, A; Westbury, G; Wiltshaw, E, 1986) |
| "Fifty-four patients with advanced soft tissue sarcoma were treated with a combination of ifosfamide (5 g/m2) and adriamycin (40-60 mg/m2) at 3 weekly intervals." | 7.67 | A phase I-II study of ifosfamide in combination with adriamycin in the treatment of adult soft tissue sarcoma. ( Fisher, C; King, M; MacMillan, S; Mansi, JL; Stuart-Harris, R; Wiltshaw, E, 1988) |
| "We have evaluated the activity of ifosfamide in 75 patients with recurrent sarcomas and pediatric solid tumors." | 7.67 | A phase II study of ifosfamide in the treatment of recurrent sarcomas in young people. ( Arasi, V; Magrath, I; Miser, J; Raynor, A; Rosenberg, S; Sandlund, J, 1986) |
| " Hemorrhagic cystitis was not observed in patients treated with 400-500 mg of mesna iv every 4 hours during ifosfamide treatment." | 7.67 | Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma. ( Antman, KH; Montella, D; Rosenbaum, C; Schwen, M, 1985) |
| "In a phase II study, 42 patients with advanced soft-tissue sarcoma were treated with ifosfamide by 24-h infusion and mesna by 4-h IV bolus, repeated every 3 weeks." | 7.66 | High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma. ( Gowing, NF; Harper, PG; Kaye, SB; Mooney, CA; Parsons, CA; Stuart-Harris, RC; Wiltshaw, E, 1983) |
| "Patients <30 years old with Ewing sarcoma were eligible." | 6.80 | Carboplatin in the treatment of Ewing sarcoma: Results of the first Brazilian collaborative study group for Ewing sarcoma family tumors-EWING1. ( Abujamra, AL; Almeida, MT; Benites, E; Boldrini, E; Brunetto, AL; Castillo, LA; Costa, C; Gadelha, A; Gregianin, LJ; Kirst, D; Macedo, CD; Morais, V; Nakasato, A; Pereira, WV; Petrilli, AS; Pizza, M; Rodriguez-Galindo, C; Watanabe, FM, 2015) |
| "Ifosfamide is a chemotherapeutic agent that requires cytochrome P450 3A (CYP3A) for bioactivation and metabolism." | 6.73 | Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma. ( Baker, LH; Chugh, R; Griffith, KA; Leu, KM; Taylor, JM; Thomas, DG; Wagner, T; Worden, FP; Zalupski, MM, 2007) |
| "Prognosis of patients with metastatic soft tissue sarcomas (MSTS) is poor even after response to doxorubicin-based chemotherapy." | 6.72 | Efficacy of consolidation high-dose chemotherapy with ifosfamide, carboplatin and etoposide (HD-ICE) followed by autologous peripheral blood stem cell rescue in chemosensitive patients with metastatic soft tissue sarcomas. ( Abdel-Rahman, S; Baumert, J; Falk, M; Hentrich, M; Hiddemann, W; Issels, RD; Licht, T; Salat, C; Schlemmer, M; Straka, C; Wendtner, CM, 2006) |
| "Etoposide monotherapy was successful in 8%; the effectiveness of cisplatin was 5-23%." | 6.69 | The efficacy of a combination of etoposide, ifosfamide, and cisplatin in the treatment of patients with soft tissue sarcoma. ( Bodoky, G; Eckhardt, S; Láng, I; Pápai, Z; Poller, I; Rahóty, P; Szántó, J; Szendroi, M, 2000) |
| "Gemcitabine was administered as a 360 min infusion on days 1, 8 and 15 of a 28 day cycle." | 6.69 | Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas. ( Dietzmann, A; Genvresse, I; Grunewald, R; Koschuth, A; Possinger, K; Späth-Schwalbe, E, 2000) |
| "Patients with non-resectable soft tissue sarcomas of the extremities do not live longer if they are treated by amputation or disarticulation." | 6.69 | Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities. ( Bejkos, D; Bischof-Delaloye, A; Chassot, PG; Chiolero, R; Genton, A; Guillou, L; Landry, M; Lejeune, FJ; Leyvraz, PF; Leyvraz, S; Liénard, D; Mirimanoff, RO; Mosimann, F; Pujol, N; Raffoul, W, 2000) |
| "Ifosfamide (5 g/m2) was compared with its parent analogue cyclophosphamide (1." | 6.67 | Cyclophosphamide versus ifosfamide: a randomized phase II trial in adult soft-tissue sarcomas. The European Organization for Research and Treatment of Cancer [EORTC], Soft Tissue and Bone Sarcoma Group. ( Blackledge, G; Bramwell, VH; Dombernowsky, P; Mouridsen, HT; Onsrud, M; Santoro, A; Somers, R; Sylvester, R; Thomas, D; Verweij, J, 1993) |
| "Ifosfamide dosage was not increased." | 6.67 | Epirubicin and ifosfamide in advanced soft tissue sarcoma: a phase II study. ( Chevallier, B; Facchini, T; Fargeot, P; Leyvraz, S; Olivier, JP; Vo Van, ML, 1993) |
| "The results of the association of doxorubicin plus ifosfamide in the treatment of locally advanced and/or metastatic adult soft tissue sarcomas as reported in the literature from 1986 up to the present time are reviewed." | 6.17 | Doxorubicin (or epidoxorubicin) combined with ifosfamide in the treatment of adult advanced soft tissue sarcomas. ( Palumbo, R; Santi, L; Sogno, G; Toma, S; Venturino, A, 1992) |
| "Thoracic sarcomas are rare malignancies, with limited data for unresectable/advanced scenarios." | 5.91 | Epirubicin, cisplatin plus ifosfamide versus standard chemotherapeutic regimens for advanced/unresectable primary thoracic sarcomas. ( Alatorre-Alexander, JA; Carrasco-CaraChards, S; Cruz-Zermeño, M; de Jesús Rodríguez-Zea, I; Godina-Flores, A; Green-Renner, D; Guzmán-Casta, J; Guzmán-Huesca, J; Imaz-Olguin, V; Juarez-Vignon Whaley, JJ; Martínez-Barrera, LM; Riera-Sala, R; Rodriguez-Cid, JR; Sánchez-Domínguez, G; Sánchez-Ríos, CP; Santillán-Doherty, PJ; Seidman-Sorsby, A; Sosa-Sánchez, R, 2023) |
| "CWS/RMS-96 was an international multicenter trial with randomization between two therapy arms of the standard four-drug therapy (vincristine, ifosfamide, adriamycin, dactinomycin [VAIA]) versus an intensified six-drug regimen (carboplatin, epirubicin, vincristine, dactinomycin, ifosfamide, and etoposide [CEVAIE]) for high-risk rhabdomyosarcoma (RMS), extraskeletal Ewing sarcoma (EES), and undifferentiated sarcoma (UDS) in children, adolescents, and young adults aiming to improve their survival." | 5.51 | Long-term results from the multicentric European randomized phase 3 trial CWS/RMS-96 for localized high-risk soft tissue sarcoma in children, adolescents, and young adults. ( Alaggio, R; Bisogno, G; Casanova, M; Cecchetto, G; Ferrari, A; Kazanowska, B; Klingebiel, T; Koscielniak, E; Kosztyla, D; Ladenstein, R; Ljungman, G; Milano, GM; Niggli, F; Scarzello, G; Sparber-Sauer, M; Vokuhl, C; Zin, A, 2022) |
| "This randomised phase II/III trial aimed to determine whether perioperative chemotherapy with gemcitabine plus docetaxel (GD) is non-inferior to the standard Adriamycin plus ifosfamide (AI) in terms of overall survival (OS) in patients with soft tissue sarcoma (STS)." | 5.51 | Perioperative Adriamycin plus ifosfamide vs. gemcitabine plus docetaxel for high-risk soft tissue sarcomas: randomised, phase II/III study JCOG1306. ( Abe, S; Akisue, T; Asanuma, K; Emori, M; Fukuda, H; Furuta, T; Hatano, H; Hiraga, H; Hiraoka, K; Hiruma, T; Iwamoto, Y; Katagiri, H; Kataoka, T; Kawai, A; Kawano, M; Kawashima, H; Machida, R; Matsumoto, Y; Morii, T; Nagano, A; Nakayama, R; Nishida, Y; Okuma, T; Outani, H; Ozaki, T; Suehara, Y; Takenaka, S; Takeyama, M; Tanaka, K; Toguchida, J; Tsukushi, S; Watanuki, M; Yamamoto, T; Yonemoto, T, 2022) |
| "This prospective single-arm phase II clinical trial aimed to evaluate the efficacy and safety of pegylated liposomal doxorubicin (PLD) combined with ifosfamide (IFO) as the first-line treatment for patients with advanced or metastatic soft-tissue sarcoma (STS)." | 5.51 | Pegylated Liposomal Doxorubicin Combined with Ifosfamide for Treating Advanced or Metastatic Soft-tissue Sarcoma: A Prospective, Single-arm Phase II Study. ( Chen, H; Chen, Y; Huang, M; Jiang, S; Liu, X; Luo, Z; Miao, J; Wang, C; Wang, H; Wang, J; Wu, X; Xia, J; Xu, Y; Yan, W; Yao, W; Yu, L; Zhang, X, 2022) |
| "Ifosfamide is an alkylating agent with well-demonstrated efficacy against STS, and dose-dependent activity." | 5.37 | High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients. ( Baek, KK; Chang, MH; Han, B; Lee, J; Lee, SH; Lim, T; Park, JO, 2011) |
| "Between 1982 and 1986, 38 patients with soft tissue sarcomas were treated with a combination of ADM/DTIC (group A), another 45 (group B) received ADM/IFO between 1986 and 1990." | 5.28 | Chemotherapy of metastatic soft tissue sarcoma with a combination of adriamycin and DTIC or adriamycin and ifosfamide. ( Dietel, M; Hossfeld, DK; Schwarz, R; Weh, HJ; Wingberg, D; Zornig, C; Zügel, M, 1990) |
| "Patients with high-grade soft tissue sarcomas were treated with 2 cycles of ifosfamide, mitomycin, doxorubicin, and cisplatin plus GM-CSF subcutaneous followed by 45 Gy irradiation with concurrent 2 cycles of mitomycin, doxorubicin, and cisplatin followed by surgery +/- intraoperative radiation or brachytherapy." | 5.22 | Chemotherapy, Irradiation, and Surgery for Function-preserving Curative Therapy of Primary Extremity Soft Tissue Sarcomas: Initial Treatment With I-MAP and Inhalation GM-CSF During Preoperative Irradiation and Postoperatively. ( Haddock, M; Mahoney, M; Maples, W; Markovic, SN; O'Connor, MI; Okuno, S; Petersen, I; Shives, T; Sim, F, 2016) |
| "Doxorubicin and ifosfamide (AI) is standard therapy for high-risk soft tissue sarcoma (STS) but often causes severe toxicities resulting in hospitalisation." | 5.20 | A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma. ( Baker, LH; Biermann, JS; Chugh, R; Davis, EJ; Feng, M; Jacobson, J; Lucas, DR; Metko, G; Reinke, D; Schuetze, SM; Wong, SL; Zalupski, MM; Zhao, L; Zyczynski, L, 2015) |
| "Effective targeted treatment is unavailable for most sarcomas and doxorubicin and ifosfamide-which have been used to treat soft-tissue sarcoma for more than 30 years-still have an important role." | 5.19 | Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. ( Alcindor, T; Blay, JY; dei Tos, AP; Fisher, C; Gelderblom, H; Hartmann, JT; Hermans, C; Hogendoorn, PC; Hohenberger, P; Judson, I; Kerst, JM; Krarup-Hansen, A; Litière, S; Marreaud, S; Schöffski, P; Sufliarsky, J; van der Graaf, WT; Verweij, J; Whelan, J, 2014) |
| " Perioperative chemotherapy with adriamycin plus ifosfamide is the current standard treatment for T2bN0M0 high-grade non-round cell soft tissue sarcoma." | 5.19 | A randomized phase II/III trial of perioperative chemotherapy with adriamycin plus ifosfamide versus gemcitabine plus docetaxel for high-grade soft tissue sarcoma: Japan Clinical Oncology Group Study JCOG1306. ( Araki, N; Fukuda, H; Hiraga, H; Iwamoto, Y; Kataoka, K; Kawai, A; Kimura, A; Matsumine, A; Matsunobu, T; Mizusawa, J; Oda, Y; Tanaka, K, 2014) |
| "The objective of this Phase I dose escalation study was to explore the safety and tolerability of eltrombopag, an oral, nonpeptide, thrombopoietin receptor agonist, in patients with advanced soft tissue sarcoma (STS) and thrombocytopenia due to treatment with doxorubicin and ifosfamide (AI) combination chemotherapy." | 5.17 | Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide. ( Chawla, SP; Hendifar, A; Kamel, YM; Messam, CA; Patwardhan, R; Staddon, A, 2013) |
| "This multicenter, phase II trial evaluated the efficacy and safety of everolimus, an mTOR inhibitor, in patients with metastatic or recurrent bone and soft-tissue sarcoma after the failure of anthracycline- and ifosfamide-containing regimens." | 5.17 | Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide. ( Ahn, JH; Kim, TM; Kim, YJ; Lee, HJ; Lee, J; Lee, KH; Park, KH; Rha, SY; Yoo, C, 2013) |
| "Ifosfamide and doxorubicin combination is an active regimen for patients with advanced soft tissue sarcomas (STS) but is burdened by high toxicity." | 5.15 | Optimizing clinical care in patients with advanced soft tissue sarcoma: a phase II study of a new schedule of high-dose continuous infusion ifosfamide and doxorubicin combination. ( Boni, C; Boselli, S; Catania, C; de Braud, F; De Pas, T; Delmonte, A; Frustaci, S; Noberasco, C; Radice, D; Rosati, G; Scalamogna, R; Spitaleri, G; Toffalorio, F; Tucci, A; Vecchio, F, 2011) |
| "To assess the progression-free survival (PFS) and antitumor response to standard-dose doxorubicin compared with sequential dose-dense doxorubicin and ifosfamide in first-line treatment of advanced soft tissue sarcoma." | 5.14 | Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas. ( Andrés, R; Balañá, C; Buesa, JM; Casado, A; Cruz, J; Cubedo, R; de la Cruz, JJ; de Las Peñas, R; Del Muro, XG; Fra, J; Gallego, O; Gómez, MA; López-Pousa, A; Martín, J; Martínez-Trufero, J; Maurel, J; Poveda, A; Rubió, J; Rubio-Viqueira, B; Sevilla, I, 2009) |
| "The authors studied a dose-intense regimen of epirubicin and ifosfamide with hypofractionated preoperative radiotherapy for high-risk soft tissue sarcomas." | 5.13 | Histologic response of dose-intense chemotherapy with preoperative hypofractionated radiotherapy for patients with high-risk soft tissue sarcomas. ( Hayden, JB; Hosenpud, JR; Hung, AY; Mansoor, A; Montag, AG; Mundt, AJ; Peabody, TD; Ryan, CW; Samuels, B; Undevia, S, 2008) |
| "Perioperative three cycles of full-dose of anthracycline and ifosfamide should be proposed on an individual basis, in reference sarcoma centres, to high-risk localized STS of limbs or trunk-wall in certain histologies." | 5.12 | What is the standard indication of adjuvant or neoadjuvant chemotherapy in localized soft-tissue sarcoma? ( Hindi, N; Martin-Broto, J, 2021) |
| "Having determined in a phase I study the maximum tolerated dose of high-dose ifosfamide combined with high-dose doxorubicin, we now report the long-term results of a phase II trial in advanced soft-tissue sarcomas." | 5.12 | Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies. ( Cerny, T; Christinat, A; Dietrich, D; Fey, MF; Guillou, L; Herrmann, R; Honegger, HP; Leyvraz, S; Pestalozzi, B; Sessa, C; Wernli, M, 2006) |
| "Combinations of high-dose ifosfamide (IF; 10-12 g/m2) plus doxorubicin (DX; 50-90 mg/m2) have been administered to patients with advanced soft tissue sarcoma (ASTS) in an attempt to improve therapeutic efficacy." | 5.11 | Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS). ( Balañá, C; Buesa, JM; Casado, A; de las Peñas, R; Fra, J; García del Muro, X; López-Pousa, A; Martín, J; Martínez-Trufero, J; Maurel, J, 2004) |
| "The relative value of increasing ifosfamide dose in combination chemotherapy for patients with soft tissue sarcoma (STS) is unclear." | 5.11 | Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma. ( Baker, LH; Biermann, JS; Chugh, R; Leu, KM; McGinn, CJ; Sondak, VK; Taylor, JM; Worden, FP; Zalupski, MM, 2005) |
| "To describe the response rate and survival of children and adolescents with unresected or metastatic nonrhabdomyosarcomatous soft tissue sarcomas (NRSTS) treated with vincristine, ifosfamide, and doxorubicin." | 5.11 | Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study. ( Devidas, M; Gebhardt, M; Grier, HE; Jenkins, J; Marcus, R; Pappo, AS; Pratt, C; Rao, B; Thomas, P, 2005) |
| "Doxorubicin and ifosfamide are the two most active agents used to treat soft tissue sarcomas." | 5.11 | Alternating sequential chemotherapy with high-dose ifosfamide and doxorubicin/cyclophosphamide for adult non-small round cell soft tissue sarcomas. ( Abe, S; Araki, N; Beppu, Y; Hasegawa, T; Ihara, K; Ishii, T; Isu, K; Kawai, A; Ozaki, T; Sugiura, H; Tsugane, S; Umeda, T; Wada, T; Yabe, H, 2005) |
| "The aim of this phase II study was to evaluate the efficacy and toxicity of two regimens of ifosfamide in metastatic soft tissue sarcoma patients given as first- and second-line chemotherapy." | 5.10 | Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. ( Dombernowsky, P; Hermans, C; Judson, I; Krzemieniecki, K; Mouridsen, HT; Nielsen, OS; Spooner, D; Svancarova, L; Van Glabbeke, M; van Oosterom, AT; Verweij, J, 2002) |
| "We conducted our study to determine the pharmacokinetics (PK) and clinical efficacy of oral mesna in patients receiving ifosfamide for soft tissue sarcoma." | 5.10 | Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide. ( Baker, LH; Bernardy, H; Demetri, G; Junge, K; Keohan, ML; Mace, JR; Mueller, U; Niebch, G; Romeis, P; Thoma, A; Wagner, T, 2003) |
| "Between March 1994 and October 1997, 20 women and 19 men with primary extremity or limb girdle high-grade soft tissue sarcomas were registered to a study of preoperative ifosfamide, mitomycin, doxorubicin, cisplatin (IMAP) plus granulocyte macrophage-colony-stimulating factor (GM-CSF) followed by preoperative irradiation and subsequent limb-sparing surgery." | 5.10 | Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony-stimulating factor. ( Buckner, JC; Edmonson, JH; Foo, ML; Gunderson, LL; Haddock, MG; Mahoney, MR; Maples, WJ; O'Connor, MI; Petersen, IA; Pritchard, DJ; Rock, MG; Shives, TC; Sim, FH; Stafford, SL, 2002) |
| "Twenty-four patients with soft tissue or bone sarcoma who were treated with high dose ifosfamide-based chemotherapy were enrolled in this study." | 5.09 | Prospective randomized comparison of morning versus night daily single subcutaneous administration of granulocyte-macrophage-colony stimulating factor in patients with soft tissue or bone sarcoma. ( Akbulut, H; Demirkazik, A; Dinçol, D; Içli, F; Onur, H; Pamir, A; Samur, M; Sencan, O; Senler, FC; Yalçin, B, 2000) |
| "This study investigated the population pharmacokinetics of ifosfamide in 15 patients treated for soft tissue sarcoma with 9 or 12 g m-2 ifosfamide by means of a 72 h continuous i." | 5.09 | Evaluation of the autoinduction of ifosfamide metabolism by a population pharmacokinetic approach using NONMEM. ( Beijnen, JH; Huitema, AD; Keizer, HJ; Kerbusch, T; Mathôt, RA; Ouwerkerk, J; Schellens, JH, 2000) |
| "The Soft Tissue and Bone Sarcoma Group (STBSG) of the EORTC ran a phase II study to assess the therapeutic activity of high-dose ifosfamide in patients with advanced soft tissue sarcomas by means of response rate (RR)." | 5.09 | Radiologist review versus group peer review of claimed responses in a phase II study on high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the EORTC Soft Tissue and Bone Sarcoma Group. ( Gwyther, SJ; Judson, IR; Nielsen, OS; van Glabbeke, M; Verweij, J, 2000) |
| "The efficacy and feasibility of a novel sequential schedule of high-dose ifosfamide (HD-IFO) and full-dose epirubicin (EPI) with granulocyte colony-stimulating factor (G-CSF) was evaluated in adult patients with soft tissue sarcomas (STS)." | 5.09 | A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule. ( Cognetti, F; Gamucci, T; Nardi, M; Serrone, L; Zeuli, M, 2001) |
| "The Epirubicin (EPI) and ifosfamide (IFO) combination has been widely tested in soft tissue sarcomas, even though the optimal schedule of drug administration has still to be defined." | 5.09 | Ifosfamide and epirubicin combination in untreated sarcomas: two treatment schedules. ( Cognetti, F; Nardoni, C; Pacetti, U; Papaldo, P; Serrone, L; Zeuli, M, 2001) |
| "Patients with locally advanced or metastatic soft tissue sarcoma refractory to treatment with anthracyclines and ifosfamide were enrolled into the present phase II study." | 5.09 | Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: results of a phase II trial. ( Amann, G; Attems, Y; Brodowicz, T; Fiebiger, WC; Hejna, M; Köstler, WJ; Krainer, M; Tomek, S; Wiltschke, CH; Zielinski, CC, 2001) |
| " ifosfamide and etoposide) and to improve overall survival of previously untreated patients with metastatic rhabdomyosarcoma." | 5.09 | Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group. ( Breitfeld, PP; Crist, WM; Donaldson, SS; Lobe, T; Lyden, E; Maurer, HM; Raney, RB; Ruymann, FB; Teot, LA; Wharam, M, 2001) |
| "The Intergroup Rhabdomyosarcoma Study (IRS) initiated an escalating-dose cyclophosphamide (Cyc) pilot without hematopoietic growth factor (HGF) support in combination with vincristine (Vcr) and actinomycin-D (Amd), known as VAC, to establish a Cyc dose with myelotoxicity comparable to an ifosfamide (Ifos), Vcr, and Amd combination regimen (VAI)." | 5.08 | Cyclophosphamide dose escalation in combination with vincristine and actinomycin-D (VAC) in gross residual sarcoma. A pilot study without hematopoietic growth factor support evaluating toxicity and response. ( Gehan, E; Maurer, H; Newton, WA; Ruymann, FB; Vietti, T; Wharam, M; Wiener, E, 1995) |
| "This two-arm, double-blind, randomized trial was conducted to determine the effects of lenograstim, a glycosylated recombinant human granulocyte colony-stimulating factor (rHu-G-CSF), on the hematologic tolerance of patients with sarcoma treated with mesna, doxorubicin, ifosfamide, and doxorubicin (MAID) chemotherapy." | 5.08 | Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity. ( Bonichon, F; Bui, BN; Chevallier, B; Chevreau, C; Cupissol, D; Fargeot, P; Krakowski, I; Maugard-Louboutin, C; Peny, AM; Thyss, A, 1995) |
| "Ifosfamide, an oxazaphosphorine analogue, is now commonly used in first-line anthracycline-containing regimens for advanced soft tissue sarcomas, based on its demonstrated single-agent activity in previously treated patients." | 5.08 | High-dose ifosfamide in the treatment of advanced soft tissue sarcomas. ( Tursz, T, 1996) |
| "Ten patients (three males and seven females) were treated for sarcoma with high-dose ifosfamide (IFO) according to a 4 g/m2 1 h i." | 5.08 | Phenobarbital administration does not affect high-dose ifosfamide pharmacokinetics in humans. ( Lokiec, F; Santoni, J; Tubiana-Hulin, M; Weill, S, 1996) |
| "Ifosfamide is one of the most efficient antimitotic in soft tissue sarcoma." | 5.08 | [High dose ifosfamide at 15 g/m2/cycle: a feasibility study in 10 patients]. ( Baranzelli, MC; Deligny, N; Demaille, MC; Gourmel, B; N'Guyen, M; Pichon, F, 1997) |
| "To evaluate the efficacy and feasibility of high-dose ifosfamide (HDI) at a total dose of 14 g/m2 per cycle with mesna in combination with granulocyte colony-stimulating factor (G-CSF) in adult patients with sarcomas." | 5.08 | High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence. ( Benjamin, RS; Burgess, MA; Hays, C; Papadopolous, N; Patel, SR; Plager, C; Vadhan-Raj, S, 1997) |
| "The purpose of this study was to evaluate tumour response and toxicity to ifosfamide and continuous infusion etoposide in metastatic or locally advanced soft tissue sarcoma, with dose escalations under G-CSF (granulocyte colony-stimulating factor) support." | 5.08 | Ifosfamide and continuous infusion etoposide in advanced adult soft tissue sarcoma. A Scandinavian Sarcoma Group Phase II Study. ( Alvegård, TA; Erlanson, M; Hannisdal, E; Klepp, R; Monge, OR; Raabe, N; Saeter, G; Söderberg, M; Solheim, OP; Strander, H; Turesson, I; Wist, E, 1997) |
| "Ifosfamide has important activity in pretreated soft tissue sarcomas (STS), and recent data support a clinically significant dose-response relationship for this agent." | 5.08 | Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas. ( Antimi, M; Gatti, C; Palmeri, S; Palumbo, R; Raffo, P; Toma, S; Villani, G, 1997) |
| "The agent Ifosfamide (IFOS) is active against soft tissue sarcomas (STS), and patients who progress to IFOS at doses < or = 10 g/m2 show remissions when exposed to high-dose ifosfamide (HDI) (i." | 5.08 | Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS) ( Antón, A; Arranz, F; Bellmunt, J; Buesa, JM; Casado, A; Escudero, P; García del Muro, J; López-Pousa, A; Martín, J; Menéndez, D; Poveda, A; Valentí, V, 1998) |
| "Ifosfamide and doxorubicin are the most active agents in the treatment of sarcomas and are characterized by a marked dose-response relationship." | 5.08 | Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas. Swiss Group for Clinical Research (SAKK). ( Bacchi, M; Bressoud, A; Cerny, T; Hermann, R; Leyvraz, S; Lissoni, A; Sessa, C, 1998) |
| "Adriamycin (ADM) and ifosfamide (IFO) are the two most active agents in the treatment of soft tissue sarcomas (STS) with a clear dose-response relationship." | 5.08 | High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: is it feasible? ( Aapro, MS; De Braud, F; De Pas, T; Fazio, N; Goldhirsch, A; Munzone, E; Nolè, F; Orlando, L; Zampino, MG, 1998) |
| "The purpose of this review is to characterize the nephrotoxicity noted in newly diagnosed patients under 21 years of age after treatment with ifosfamide-containing chemotherapy regimens and local irradiation for localized gross residual rhabdomyosarcoma or undifferentiated sarcoma." | 5.07 | Renal toxicity of ifosfamide in pilot regimens of the intergroup rhabdomyosarcoma study for patients with gross residual tumor. ( Ensign, LG; Foreman, J; Khan, F; Maurer, H; Newton, W; Ortega, J; Ragab, A; Raney, B; Wharam, M; Wiener, E, 1994) |
| "5 g/m2 mesna was administered for 7 days, both by continuous infusion, in combination with 50 mg/m2/d oral etoposide for 8 days in 21 patients with sarcomas or other solid tumors." | 5.07 | Ambulatory continuous infusion ifosfamide with oral etoposide in advanced sarcomas. ( Hamdan, H; Skubitz, KM; Thompson, RC, 1993) |
| "To evaluate the feasibility, toxicity and efficacy of the combination of (IFO) ifosfamide and epirubicin (EPI) given at conventional doses for monochemotherapy, we started a phase II study in advanced/metastatic soft tissue sarcoma patients." | 5.07 | Epirubicin and ifosfamide in advanced soft tissue sarcomas. ( Buonadonna, A; Carbone, A; Crivellari, D; De Paoli, A; Foladore, S; Frustaci, S; Monfardini, S; Morassut, S; Sorio, R, 1993) |
| "This three-armed phase III study in adults with advanced soft tissue sarcomas was planned as a comparison of objective regression rates, toxicity, and survival of patients receiving doxorubicin alone, ifosfamide plus doxorubicin, and mitomycin plus doxorubicin plus cisplatin." | 5.07 | Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. ( Blum, RH; Brooks, JS; Edmonson, JH; Frytak, S; Parkinson, DR; Ryan, LM; Shiraki, M, 1993) |
| "Doxorubicin alone or with dacarbazine (DTIC; AD) is considered the best available therapy for metastatic adult sarcomas." | 5.07 | An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. ( Antman, K; Balcerzak, SP; Barlogie, B; Cooper, RM; Crowley, J; Elias, A; Natale, RB; Rivkin, SE; Trump, DL; Weiss, GR, 1993) |
| "The objective of this phase II trial was to assess the therapeutic activity and toxicity of doxorubicin plus ifosfamide in previously untreated patients with advanced soft-tissue sarcoma." | 5.07 | Ifosfamide plus doxorubicin in previously untreated patients with advanced soft-tissue sarcoma. ( Blackledge, G; Dombernowsky, P; Mouridsen, HT; Santoro, A; Schütte, J; Somers, R; Steward, W; Thomas, D; van Oosterom, AT; Verweij, J, 1993) |
| "A total of 51 patients with large, primary, high-grade soft-tissue sarcomas of the extremities were treated at our institute with two preoperative and three postoperative cycles of doxorubicin plus ifosfamide/mesna." | 5.07 | Preoperative doxorubicin plus ifosfamide in primary soft-tissue sarcomas of the extremities. ( Azzarelli, A; Casali, P; Fissi, S; Montalto, F; Quagliuolo, V; Santoro, A, 1993) |
| "The Southwest Oncology Group (SWOG) performed a phase II trial of a combination of ifosfamide/mesna/cisplatin in patients with metastatic soft-tissue sarcoma who had previously received one chemotherapeutic regimen." | 5.07 | Phase II trial of ifosfamide and cisplatin in the treatment of metastatic sarcomas: a Southwest Oncology Group study. ( Balcerzak, SP; Budd, GT; Fabian, C; Metch, B; Stephens, RL; Weick, JK; Weiss, SA, 1993) |
| "On the basis of ifosfamide's demonstrated single-agent activity in adult soft-tissue sarcoma, the Eastern Cooperative Oncology Group (ECOG) tested whether ifosfamide would add to the efficacy of doxorubicin in a three-regimen, controlled phase III trial." | 5.07 | Efficacy of ifosfamide in combination with doxorubicin for the treatment of metastatic soft-tissue sarcoma. The Eastern Cooperative Oncology Group. ( Blum, RH; Edmonson, J; Pelletier, L; Ryan, L, 1993) |
| "A total of 37 adult patients with locally advanced or metastatic soft-tissue sarcoma (STS) entered a pilot study of combination chemotherapy based on the CYVADIC (cyclophosphamide, vincristine, doxorubicin, and dacarbazine) regimen, in which cyclophosphamide was replaced by ifosfamide and mesna (1 g/m2 ifosfamide given daily on days 1-5 as 2-h infusions, 1." | 5.07 | Ifosfamide, vincristine, doxorubicin and dacarbazine in adult patients with advanced soft-tissue sarcoma. ( Blomqvist, CP; Elomaa, I; Virolainen, M; Wiklund, TA, 1992) |
| "Doxorubicin and ifosfamide are the two most active agents used in the treatment of advanced inoperable soft-tissue sarcoma, but their use in combination produces dose-limiting myelosuppression." | 5.07 | Doxorubicin plus ifosfamide with rhGM-CSF in the treatment of advanced adult soft-tissue sarcomas: preliminary results of a phase II study from the EORTC Soft-Tissue and Bone Sarcoma Group. ( Blackledge, G; Clavel, M; Greifenberg, B; Soedirman, J; Somers, R; Steward, WP; Thomas, D; Van Glabbeke, M; Van Oosterom, AT; Verweij, J, 1991) |
| "European and American investigators have reported response rates of 38% to 83% for ifosfamide alone in pretreated sarcomas." | 5.06 | Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. ( Antman, KH; Elias, A; Grier, HE; Ryan, L; Sherman, D, 1989) |
| "In this phase II trial, 105 eligible patients with no prior chemotherapy and advanced sarcoma received doxorubicin, ifosfamide, and dacarbazine (DTIC) with mesna uroprotection (MAID)." | 5.06 | Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. ( Aisner, J; Antman, KH; Collins, J; Elias, A; Ryan, L; Sulkes, A, 1989) |
| "One hundred and seventy-one patients with advanced soft tissue sarcoma entered a randomized crossover phase II study comparing cyclophosphamide (CYCLO) with a new analogue, ifosfamide (IFOS), both administered as 24 h i." | 5.06 | Cyclophosphamide versus ifosfamide: preliminary report of a randomized phase II trial in adult soft tissue sarcomas. ( Blackledge, G; Bramwell, VH; Mouridsen, HT; Santoro, A; Somers, R; Sylvester, R; Thomas, D; Van Oosterom, A, 1986) |
| "Alkylating agents, such as cyclophosphamide and ifosfamide, play a major role in the improved survival of children and young adults with bone and soft tissue sarcoma." | 4.91 | Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients. ( Kremer, LC; Langer, T; Mulder, RL; Paulides, M; van Dalen, EC, 2015) |
| "The authors report a retrospective analysis of high-dose ifosfamide, carboplatin, and etoposide (HD-ICE) for patients with refractory or relapsed neuroblastoma (NB)." | 4.89 | Ifosfamide, carboplatin, and etoposide for neuroblastoma: a high-dose salvage regimen and review of the literature. ( Basu, EM; Cheung, NK; Kramer, K; Kushner, BH; Modak, S; Roberts, SS, 2013) |
| " The BSTTSG has currently been conducting a Phase III trial, JCOG 0905, to investigate the superiority of the addition of ifosfamide to the standard chemotherapy with methotrexate, cisplatin and doxorubicin for operable, high-grade osteosarcoma." | 4.88 | The activity of the Bone and Soft Tissue Tumor Study Group of the Japan Clinical Oncology Group. ( Iwamoto, Y; Tanaka, K, 2012) |
| "Alkylating agents, such as cyclophosphamide and ifosfamide, play a major role in the improved survival of children and young adults with bone and soft tissue sarcoma." | 4.88 | Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients. ( Kremer, LC; Langer, T; Mulder, RL; Paulides, M; van Dalen, EC, 2012) |
| "Independent favourable prognostic factors for overall survival (OS) were good performance status, female gender, low histological grade, extremity primary tumour site and locally advanced disease; for progression-free survival (PFS), the combination of doxorubicin and ifosfamide, locally advanced disease, and tumour entity with a lower risk to progress for synovial sarcoma patients compared to leiomyosarcoma." | 4.86 | Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Tr ( Blay, JY; Hogendoorn, PC; Krarup-Hansen, A; Le Cesne, A; Ouali, M; Rodenhuis, S; Sleijfer, S; van Glabbeke, M; Verweij, J, 2010) |
| "Ifosfamide is a chemotherapeutic prodrug used in the treatment of several tumor entities, including bone and soft-tissue sarcoma." | 4.86 | Palifosfamide, a bifunctional alkylator for the treatment of sarcomas. ( Jung, S; Kasper, B, 2010) |
| "Alkylating agents, such as cyclophosphamide and ifosfamide, play a major role in the improved survival of children and young adults with bone and soft tissue sarcoma." | 4.86 | Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients. ( Kremer, LC; Langer, T; Mulder, RL; Paulides, M; van Dalen, EC, 2010) |
| " Therefore, gemcitabine should be considered as the best option after doxorubicin failure in leiomyosarcoma patients." | 4.86 | [Chemotherapy options for patients with advanced soft-tissue sarcoma beyond anthracyclines]. ( Bui-Nguyen, B; Italiano, A; Toulmonde, M, 2010) |
| "The current study was performed to evaluate the toxicity profile of therapeutic doses of ifosfamide (IFX) given concurrently with full-dose external beam radiotherapy (EBRT) in patients with soft tissue and bone sarcomas." | 4.81 | Concurrent ifosfamide-based chemotherapy and irradiation. Analysis of treatment-related toxicity in 43 patients with sarcoma. ( Ballo, MT; Benjamin, RS; Burgess, MA; Cormier, JN; Feig, BW; Herzog, CE; Hunt, KK; Patel, SR; Pisters, PW; Raney, RB; Zagars, GK, 2001) |
| "Ifosfamide is an alkylating agent with clinical activity in the treatment of sarcomas, and data support a dose-response relationship in this disease." | 4.79 | High-dose ifosfamide in the treatment of sarcomas of soft tissues and bone. ( Demetri, GD, 1996) |
| "We have used ifosfamide to treat patients with sarcomas in four completed single-agent protocols and one pilot study since 1985." | 4.78 | Single-agent ifosfamide studies in sarcomas of soft tissue and bone: the M.D. Anderson experience. ( Benjamin, RS; Legha, SS; Nicaise, C; Patel, SR, 1993) |
| "Doxorubicin and ifosfamide are currently the two main drugs for the treatment of soft tissue sarcomas in adults." | 4.78 | Perspectives on anthracyclines plus ifosfamide in advanced soft tissue sarcomas. ( Azzarelli, A; Bertulli, R; Casali, P; Devizzi, L; Pastorino, U; Santoro, A; Zucchinelli, P, 1993) |
| " The most active single agents against osteosarcoma are doxorubicin (overall response rate, 21%), methotrexate (30% to 40%), cisplatin (25%), and ifosfamide (28%)." | 4.78 | Chemotherapy of advanced sarcomas of bone and soft tissue. ( Antman, KH, 1992) |
| "Ifosfamide is an analogue of cyclophosphamide that has been extensively investigated in sarcomas." | 4.78 | The role of ifosfamide in the treatment of adult soft tissue sarcomas, Ewing's sarcoma, and osteosarcoma: a review. ( Dirix, LY; Van Oosterom, AT, 1990) |
| "The alkylating agent ifosfamide has demonstrated significant activity against advanced sarcomas." | 4.77 | The role of ifosfamide in the treatment of sarcomas. ( Dirix, LY; Van Oosterom, AT, 1989) |
| "The most active single agents in soft-tissue sarcomas are doxorubicin (Adriamycin) and ifosfamide, with response rates of 20-35%." | 4.77 | Chemotherapy of advanced soft-tissue sarcomas. ( Antman, KH; Elias, AD, 1988) |
| "We conducted a multi-institutional retrospective study, identifying sarcoma patients who received anthracyclines and/or ifosfamide during pregnancy." | 4.12 | Pregnancy outcomes related to the treatment of sarcomas with anthracyclines and/or ifosfamide during pregnancy. ( Agulnik, M; Davis, LE; Godbole, S; Hirbe, AC; Livingston, JA; Miller, D; Park, Y; Parkes, A; Posey, K; Robinson, SI; Skubitz, K; Van Tine, BA, 2022) |
| "To investigate the value of contrast-enhanced computed tomography (CECT) radiomics features in predicting the efficacy of epirubicin combined with ifosfamide in patients with pulmonary metastases from soft tissue sarcoma." | 4.12 | Prediction of the therapeutic efficacy of epirubicin combined with ifosfamide in patients with lung metastases from soft tissue sarcoma based on contrast-enhanced CT radiomics features. ( Jiang, X; Li, M; Ma, ST; Miao, L; Wang, YM; Zhang, HH, 2022) |
| "To compare long-term outcomes of high-grade, primary soft-tissue-sarcoma (STS), using Ifosfamide-Doxorubicin vs local therapy alone, in histology-specific sarcomas." | 4.02 | The role of Ifosfamide-doxorubicin chemotherapy in histology-specific, high grade, locally advanced soft tissue sarcoma, a 14-year experience. ( Burchette, RJ; Goy, BW; Helmstedter, CS; Padmanabhan, A; Syed, S, 2021) |
| "The usefulness of adjuvant chemotherapy for high-grade osteosarcoma was established by two randomized, controlled trials conducted in the 1980s, which used six drugs, doxorubicin, cisplatin, high-dose methotrexate, bleomycin, cyclophosphamide and actinomycin D." | 4.02 | Adjuvant and neoadjuvant chemotherapy for osteosarcoma: JCOG Bone and Soft Tissue Tumor Study Group. ( Hiraga, H; Ozaki, T, 2021) |
| "We compared the outcomes in soft tissue sarcoma (STS) treated with olaratumab and doxorubicin (OD) versus doxorubicin, ifosfamide, and mesna (AIM) to assess whether OD could supersede AIM in STS therapy." | 3.96 | Doxorubicin and Olaratumab Versus Doxorubicin, Ifosfamide, and Mesna for Treatment of Advanced Soft Tissue Sarcomas. ( Copeland, VC; Cranmer, LD; Hammer, KJ; Loggers, ET; Pollack, SM; Wagner, MJ, 2020) |
| "A retrospective search of the Royal Marsden Sarcoma Unit Database was performed to identify patients initially treated with ifosfamide (as single agent or in combination) and who were subsequently rechallenged with single-agent ifosfamide." | 3.88 | Successful Ifosfamide Rechallenge in Soft-Tissue Sarcoma. ( Benson, C; Constantinidou, A; Jones, RL; Judson, I; Messiou, C; Miah, A; Noujaim, J; Thway, K, 2018) |
| "We retrospectively reviewed outcomes of treatment with VIP (combination of etoposide, ifosfamide, and cisplatin) in patients with previously treated soft tissue sarcoma (STS)." | 3.85 | VIP (etoposide, ifosfamide, and cisplatin) in patients with previously treated soft tissue sarcoma. ( Baek, SW; Choi, YS; Jo, DY; Kim, S; Lee, HJ; Moon, JY; Ryu, H; Song, IC; Yun, HJ, 2017) |
| "The combination of topotecan and cyclophosphamide is active in relapsed Ewing sarcoma family of tumors (ESFT)." | 3.83 | Pilot Study of Adding Vincristine, Topotecan, and Cyclophosphamide to Interval-Compressed Chemotherapy in Newly Diagnosed Patients With Localized Ewing Sarcoma: A Report From the Children's Oncology Group. ( Bond, MC; Felgenhauer, JL; Femino, JD; Gorlick, R; Krailo, MD; Laack, NN; Marina, N; Mascarenhas, L; Meyer, J; Ranganathan, S; Villaluna, D; Womer, RB, 2016) |
| "5%) nonmetastatic soft tissue sarcoma received neoadjuvant chemoradiotherapy with ifosfamide (1." | 3.83 | Effective local control of advanced soft tissue sarcoma with neoadjuvant chemoradiotherapy and surgery: A single institutional experience. ( Agaimy, A; Croner, R; Fietkau, R; Hohenberger, W; Lettmaier, S; Ott, O; Semrau, S; Stubbe, F; Vassos, N, 2016) |
| "A 67-year-old male patient developed progressive renal failure following successful treatment of a soft tissue sarcoma that comprised surgical resection after neoadjuvant radiochemotherapy with the application of doxorubicin (cumulative dose 180 mg/m²) and ifosfamide (cumulative dose 33 g/m²)." | 3.80 | [End-stage renal disease after sarcoma therapy - case 3/2014]. ( Amann, K; Artunc, F; Bakos, G; Baumann, D; Bunz, H; Ciarimboli, G; Kluba, T; Kopp, HG; Müller, M; Schlatter, E; Steinke, I; Weyrich, P, 2014) |
| "Our data suggest that multimodal treatment with ifosfamide and/or locoregional hyperthermia in combination with neoadjuvant radiotherapy might improve outcome in high-risk soft tissue sarcomas." | 3.79 | Effect of concurrent chemotherapy and hyperthermia on outcome of preoperative radiotherapy of high-risk soft tissue sarcomas. ( Bamberg, M; Eckert, F; Gani, C; Kluba, T; Kopp, HG; Mayer, F; Müller, AC; Zips, D, 2013) |
| "Patients (≥18 years old) affected by soft tissue sarcoma and treated with epirubicin and ifosfamide, underwent prophylactic treatment with G-CSF (lenograstim at 263 μg) from day 5 to day 9." | 3.79 | Lenograstim in preventing chemotherapy-induced febrile neutropenia in patients with soft tissue sarcoma. ( Badalamenti, G; Bronte, G; Fulfaro, F; Incorvaia, L; Leto, G; Maltese, G; Provenzano, S, 2013) |
| " Doxorubicin should be administered preferably as 3-weekly bolus injections at doses higher than 60 mg/m2 because of its dose-response relationship." | 3.76 | The treatment of soft tissue sarcomas with focus on chemotherapy: a review. ( Pinedo, HM; Verweij, J, 1986) |
| "Twenty-three children and adolescents with metastatic sarcomas received vincristine, doxorubicin, cyclophosphamide, ifosfamide, sodium mercaptoethanesulfonate (mensa), and etoposide (VACIME) chemotherapy, consisting of 8 courses of vincristine 2 mg/m(2) on Day 0, doxorubicin 37." | 3.71 | Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas. ( Douglas, J; Felgenhauer, J; Gooley, T; Hawkins, DS; Kreissman, S; Park, J; Pendergrass, TW; Rowley, SD; Sanders, JE; Thomson, B, 2002) |
| "Adriamycin, dacarbazine and ifosfamide are three effective chemotherapy drugs in treating progressive soft tissue sarcoma." | 3.71 | [Continuous-infusion high dose ifosfamide as salvage treatment for pre-treated soft tissue sarcoma]. ( Chen, LK; Liang, Y; Liu, JL; Teng, XY; Xu, GC; Zhou, XM, 2002) |
| "Ifosfamide is a leading drug in soft tissue sarcoma therapy." | 3.70 | Pharmacokinetics of ifosfamide administered according to three different schedules in metastatic soft tissue and bone sarcomas. ( Bergnolo, P; Boglione, A; Bumma, C; Colussi, AM; Comandone, A; Dal Canton, O; Frustaci, S; Leone, L; Monteleone, M; Oliva, C, 1998) |
| "High-dose ifosfamide (HD-IFX) has shown significant antitumor activity in advanced sarcoma and breast carcinoma." | 3.69 | Feasibility trial of high-dose 7-day continuous-infusion ifosfamide given on an outpatient basis. ( Albanell, J; Baselga, J; Bellmunt, J; Casado, S; Eres, N; Ribas, A, 1997) |
| "From January 1990 to December 1995 we treated 35 patients (pts) with bone and soft tissue sarcoma with ifosfamide (IFM)." | 3.69 | [The effects of high-dose ifosfamide in the treatment of bone and soft tissue sarcomas]. ( Ishii, T; Kitoh, M; Satoh, T; Tatezaki, S; Umeda, T; Yonemoto, T, 1997) |
| "This study was designed to test the feasibility of administering doxorubicin at an optimal dose-intensity (> 70 mg/m2 per 21 days) in combination with ifosfamide under recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) cover in patients with metastatic soft tissue sarcomas." | 3.68 | Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Grou ( Clavel, M; Crowther, D; Kerbrat, P; Rouesse, J; Somers, R; Spooner, D; Steward, WP; Tueni, E; Tursz, T; Verweij, J, 1993) |
| "A total of 64 courses of ifosfamide (IFM) treatments for sarcoma patients were evaluated for toxic effects." | 3.68 | [Toxic effects of ifosfamide in the treatment of bone and soft tissue sarcomas]. ( Ishii, T; Kitoh, M; Satoh, T; Tatezaki, S; Umeda, T, 1993) |
| "Between 1982 and 1986, 38 patients with soft-tissue sarcomas were treated with the combination doxorubicin/dacarbazine (group A); between 1986 and 1990, another 46 patients received doxorubicin/ifosfamide (group B); and between 1990 and 1991, 11 patients received an alternating regimen of doxorubicin and ifosfamide (group C)." | 3.68 | Treatment results obtained in metastatic soft-tissue sarcoma with a combination of doxorubicin and dacarbazine or doxorubicin and ifosfamide. ( Agarwal, K; Dietel, M; Hossfeld, DK; Schwarz, R; Weh, HJ; Zornig, C, 1993) |
| "Two trials using ifosfamide-based combination chemotherapy for advanced soft-tissue sarcoma have been completed." | 3.68 | Ifosfamide combination regimens for soft-tissue sarcoma. ( Bell, DR; Dalley, D; Levi, J; Simes, RJ; Stuart-Harris, R; Wiltshaw, E, 1993) |
| "The response of ifosfamide-based chemotherapeutic regimens was retrospectively analyzed in adult patients with advanced soft-tissue sarcoma who were treated at the West German Tumor Center, Essen, between 1978 and 1990." | 3.68 | Ifosfamide in the treatment of soft-tissue sarcomas: experience at the West German Tumor Center, Essen. ( Kellner, R; Schütte, J; Seeber, S, 1993) |
| "Currently, anthracyclines and ifosfamide are the most effective drugs for the treatment of disseminated soft-tissue sarcoma." | 3.68 | A pilot study of rapidly alternating epirubicin/dacarbazine and ifosfamide as first-line therapy for metastatic soft-tissue sarcoma in adults. ( Anagnou, J; Bokemeyer, C; Harstrick, A; Knipp, H; Köhne-Wömpner, CH; Neumann, S; Poliwoda, H; Schmoll, HJ; Schöffski, P; Wipperman, B, 1993) |
| "A total of 46 consecutive patients were entered into this study to assess the efficacy and toxicity of an epirubicin/ifosfamide combination in treating locally advanced and/or metastatic adult sarcomas (38 soft-tissue sarcomas and 7 bone sarcomas in 45 evaluable patients)." | 3.68 | Ifosfamide plus epirubicin at escalating doses in the treatment of locally advanced and/or metastatic sarcomas. ( Albanese, E; Barisone, A; Canavese, G; Cantoni, E; Palumbo, R; Reggiardo, G; Rosso, R; Santi, L; Toma, S, 1993) |
| "We gave the "optimal" dose of doxorubicin (75 mg/m2) with ifosfamide (5 g/m2), the two most active agents against metastatic soft-tissue sarcomas, in an attempt to determine the feasibility of administration of these doses in combination." | 3.68 | The use of recombinant human granulocyte-macrophage colony-stimulating factor with combination chemotherapy in the treatment of advanced adult soft-tissue sarcomas: early results from the EORTC Soft-Tissue and Bone Sarcoma Group. ( Clavel, M; Crowther, D; Kerbrat, P; Rouesse, J; Somers, R; Spooner, D; Steward, WP; Tueni, E; Tursz, T; Verweij, J, 1993) |
| "Twenty-eight patients with non-pretreated metastatic soft tissue sarcomas were entered on a treatment protocol of rapidly alternating epirubicin/dacarbazine and ifosfamide: Epirubicin 100 mg/m2 d1, dacarbazine 500 mg/m2 d1 + d2, ifosfamide 6000 mg/m2 24-h infusion d15; repeated d29." | 3.68 | Epirubicin/dacarbazine rapidly alternated with ifosfamide in the treatment of metastatic soft tissue sarcomas. ( Bokemeyer, C; Harstrick, A; Köhne-Wömpner, CH; Poliwoda, H; Schmoll, HJ; Schöffski, P, 1992) |
| "From July 1986 to July 1989, 40 patients (92% pretreated) with deep-seated, advanced soft tissue sarcomas (STS, 25 patients), Ewing's sarcomas (ES, eight patients), osteosarcomas (OS, three patients) and chondrosarcomas (ChS, four patients) were treated at the University of Munich in a protocol involving regional hyperthermia (RHT) combined with ifosfamide plus etoposide." | 3.68 | Ifosfamide plus etoposide combined with regional hyperthermia in patients with locally advanced sarcomas: a phase II study. ( Berger, H; Boehm, E; Denecke, H; Issels, RD; Jauch, KW; Nagele, A; Peter, K; Prenninger, SW; Sauer, H; Wilmanns, W, 1990) |
| "The objective of this phase II trial was to assess the therapeutic activity and toxicity of doxorubicin plus ifosfamide in previously untreated patients with advanced soft tissue sarcoma." | 3.68 | Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. The EORTC Soft Tissue and Bone Sarcoma Group. ( Blackledge, G; Dombernowsky, P; Mouridsen, HT; Santoro, A; Schütte, J; Somers, R; Stewart, W; Thomas, D; van Oosterom, AT; Verweij, J, 1990) |
| "Forty-three adult patients with locally advanced or metastatic soft tissue sarcoma entered a pilot study of combination chemotherapy comprising 50 mg of doxorubicin/m2 by intravenous bolus, 850 mg of dacarbazine/m2 by 1-hour infusion, and 5 g of ifosfamide/m2 by 24-hour infusion with mesna uroprotection." | 3.67 | Combination chemotherapy with doxorubicin, dacarbazine, and ifosfamide in advanced adult soft tissue sarcoma. Canadian Sarcoma Group--National Cancer Institute of Canada Clinical Trials Group. ( Bramwell, V; Eisenhauer, E; Knowling, M; Quirt, I; Verma, S; Warr, D; Young, V, 1989) |
| "Early results with ifosfamide plus mesna in soft tissue sarcoma showed an initial response rate of 38% in 42 patients." | 3.67 | Ifosfamide plus mesna with and without adriamycin in soft tissue sarcoma. ( Fisher, C; Harmer, C; McKinna, A; Westbury, G; Wiltshaw, E, 1986) |
| "Fifty-four patients with advanced soft tissue sarcoma were treated with a combination of ifosfamide (5 g/m2) and adriamycin (40-60 mg/m2) at 3 weekly intervals." | 3.67 | A phase I-II study of ifosfamide in combination with adriamycin in the treatment of adult soft tissue sarcoma. ( Fisher, C; King, M; MacMillan, S; Mansi, JL; Stuart-Harris, R; Wiltshaw, E, 1988) |
| "We have evaluated the activity of ifosfamide in 75 patients with recurrent sarcomas and pediatric solid tumors." | 3.67 | A phase II study of ifosfamide in the treatment of recurrent sarcomas in young people. ( Arasi, V; Magrath, I; Miser, J; Raynor, A; Rosenberg, S; Sandlund, J, 1986) |
| " Hemorrhagic cystitis was not observed in patients treated with 400-500 mg of mesna iv every 4 hours during ifosfamide treatment." | 3.67 | Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma. ( Antman, KH; Montella, D; Rosenbaum, C; Schwen, M, 1985) |
| "In a phase II study, 42 patients with advanced soft-tissue sarcoma were treated with ifosfamide by 24-h infusion and mesna by 4-h IV bolus, repeated every 3 weeks." | 3.66 | High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma. ( Gowing, NF; Harper, PG; Kaye, SB; Mooney, CA; Parsons, CA; Stuart-Harris, RC; Wiltshaw, E, 1983) |
| "The value of neoadjuvant chemotherapy in soft tissue sarcoma (STS) is not completely understood." | 3.11 | Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trial. ( Bagué, S; Bianchi, G; Blay, JY; Braglia, L; Brunello, A; Bruzzi, P; Casali, PG; Coindre, JM; Dei Tos, AP; Diaz-Beveridge, R; Donati, DM; Ferraresi, V; Fontana, V; Grignani, G; Gronchi, A; Infante, G; Lopez-Pousa, A; Lugowska, I; Marchesi, E; Marrari, A; Martin-Broto, J; Merlo, DF; Miceli, R; Morosi, C; Palassini, E; Palmerini, E; Pasquali, S; Picci, P; Quagliuolo, V; Stacchiotti, S; Tendero, O, 2022) |
| "The therapy of high-risk soft tissue sarcomas (STS) remains an interdisciplinary challenge." | 3.01 | Hyperthermia in the treatment of high-risk soft tissue sarcomas: a systematic review. ( Ademaj, A; Corradini, S; Eckert, F; Flörcken, A; Ghadjar, P; Issels, R; Kaul, D; Lindner, LH; Oberacker, E; Ott, OJ; Pink, D; Potkrajcic, V; Reichardt, P; Riesterer, O; Roohani, S; Spalek, MJ; Veltsista, PD; Zips, D, 2023) |
| "The value of chemotherapy in soft tissue sarcoma (STS) remains controversial." | 2.94 | Value of peri-operative chemotherapy in patients with CINSARC high-risk localized grade 1 or 2 soft tissue sarcoma: study protocol of the target selection phase III CHIC-STS trial. ( Cabarrou, B; Chevreau, C; Chibon, F; Filleron, T; Le Guellec, S; Lesluyes, T; Lodin, S; Massoubre, A; Mounier, M; Poublanc, M; Valentin, T, 2020) |
| "Patients with soft tissue sarcoma are at risk for local recurrence and distant metastases despite optimal local treatment." | 2.87 | Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial. ( Abdel-Rahman, S; Angele, M; Belka, C; Daugaard, S; Dürr, HR; Ghadjar, P; Gronchi, A; Hiddemann, W; Hohenberger, P; Issels, RD; Jauch, KW; Knösel, T; Lindner, LH; Mansmann, U; Mella, O; Reichardt, P; Salat, C; Schmidt, M; Verweij, J; Vujaskovic, Z; Wessalowski, R; Wust, P, 2018) |
| "Patients <30 years old with Ewing sarcoma were eligible." | 2.80 | Carboplatin in the treatment of Ewing sarcoma: Results of the first Brazilian collaborative study group for Ewing sarcoma family tumors-EWING1. ( Abujamra, AL; Almeida, MT; Benites, E; Boldrini, E; Brunetto, AL; Castillo, LA; Costa, C; Gadelha, A; Gregianin, LJ; Kirst, D; Macedo, CD; Morais, V; Nakasato, A; Pereira, WV; Petrilli, AS; Pizza, M; Rodriguez-Galindo, C; Watanabe, FM, 2015) |
| "The role of chemotherapy in high-risk soft tissue sarcoma is controversial." | 2.76 | A phase II study evaluating neo-/adjuvant EIA chemotherapy, surgical resection and radiotherapy in high-risk soft tissue sarcoma. ( Bischof, M; Dietrich, S; Dimitrakopoulou-Strauss, A; Egerer, G; Ho, AD; Kasper, B; Lehner, B; Mechtersheimer, G; Roeder, F; Schmitt, T; Strauss, LG; Wuchter, P, 2011) |
| " A novel five-drug combination of etoposide, vincristine, dactinomycin, ifosfamide, and doxorubicin (EVAIA) was evaluated for high-risk patients, but cumulative chemotherapy dosage and treatment duration were reduced for the remaining individuals as compared with that of the previous trial CWS-86." | 2.74 | Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults. ( Bielack, SS; Brecht, I; Dantonello, TM; Dickerhoff, R; Gadner, H; Greiner, J; Greulich, M; Harms, D; Herbst, M; Int-Veen, C; Juergens, H; Kirsch, S; Klingebiel, T; Koscielniak, E; Leuschner, I; Marky, I; Scheel-Walter, HG; Schmelzle, R; Schmidt, BF; Treuner, J, 2009) |
| "To compare the radiological criteria RECIST, WHO, and tumor volume for evaluation of tumor response in patients with soft tissue sarcomas (STS) showing either good or poor pathohistological response to neoadjuvant chemotherapy combined with regional hyperthermia, and to examine the dependence of the findings on the applied thermal dose." | 2.74 | Comparison of radiological and pathohistological response to neoadjuvant chemotherapy combined with regional hyperthermia (RHT) and study of response dependence on the applied thermal parameters in patients with soft tissue sarcomas (STS). ( Abdel-Rahman, S; Issels, RD; Lindner, LH; Reiser, MF; Santl, M; Stahl, R; Wang, T, 2009) |
| "Ifosfamide is a chemotherapeutic agent that requires cytochrome P450 3A (CYP3A) for bioactivation and metabolism." | 2.73 | Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma. ( Baker, LH; Chugh, R; Griffith, KA; Leu, KM; Taylor, JM; Thomas, DG; Wagner, T; Worden, FP; Zalupski, MM, 2007) |
| "Prognosis of patients with metastatic soft tissue sarcomas (MSTS) is poor even after response to doxorubicin-based chemotherapy." | 2.72 | Efficacy of consolidation high-dose chemotherapy with ifosfamide, carboplatin and etoposide (HD-ICE) followed by autologous peripheral blood stem cell rescue in chemosensitive patients with metastatic soft tissue sarcomas. ( Abdel-Rahman, S; Baumert, J; Falk, M; Hentrich, M; Hiddemann, W; Issels, RD; Licht, T; Salat, C; Schlemmer, M; Straka, C; Wendtner, CM, 2006) |
| "Grade 3 thrombocytopenia was observed in five cases (36%)." | 2.71 | Combination chemotherapy of docetaxel, ifosfamide and cisplatin (DIP) in patients with metastatic urothelial cancer: a preliminary report. ( Kitamura, T; Kume, H; Matsumoto, S; Nishimatsu, H; Okamoto, N; Suzuki, M; Takahashi, S; Tomita, K, 2005) |
| "Adjuvant chemotherapy for soft tissue sarcoma is controversial because previous trials reported conflicting results." | 2.70 | Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. ( Apice, G; Azzarelli, A; Barbieri, E; Bonetti, M; Buonadonna, A; Comandone, A; De Paoli, A; Frustaci, S; Gherlinzoni, F; Olmi, P; Picci, P; Pignatti, G; Serraino, D; Zmerly, H, 2001) |
| "Etoposide monotherapy was successful in 8%; the effectiveness of cisplatin was 5-23%." | 2.69 | The efficacy of a combination of etoposide, ifosfamide, and cisplatin in the treatment of patients with soft tissue sarcoma. ( Bodoky, G; Eckhardt, S; Láng, I; Pápai, Z; Poller, I; Rahóty, P; Szántó, J; Szendroi, M, 2000) |
| "Gemcitabine was administered as a 360 min infusion on days 1, 8 and 15 of a 28 day cycle." | 2.69 | Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas. ( Dietzmann, A; Genvresse, I; Grunewald, R; Koschuth, A; Possinger, K; Späth-Schwalbe, E, 2000) |
| "Patients with non-resectable soft tissue sarcomas of the extremities do not live longer if they are treated by amputation or disarticulation." | 2.69 | Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities. ( Bejkos, D; Bischof-Delaloye, A; Chassot, PG; Chiolero, R; Genton, A; Guillou, L; Landry, M; Lejeune, FJ; Leyvraz, PF; Leyvraz, S; Liénard, D; Mirimanoff, RO; Mosimann, F; Pujol, N; Raffoul, W, 2000) |
| "Ifosfamide (5 g/m2) was compared with its parent analogue cyclophosphamide (1." | 2.67 | Cyclophosphamide versus ifosfamide: a randomized phase II trial in adult soft-tissue sarcomas. The European Organization for Research and Treatment of Cancer [EORTC], Soft Tissue and Bone Sarcoma Group. ( Blackledge, G; Bramwell, VH; Dombernowsky, P; Mouridsen, HT; Onsrud, M; Santoro, A; Somers, R; Sylvester, R; Thomas, D; Verweij, J, 1993) |
| "Ifosfamide dosage was not increased." | 2.67 | Epirubicin and ifosfamide in advanced soft tissue sarcoma: a phase II study. ( Chevallier, B; Facchini, T; Fargeot, P; Leyvraz, S; Olivier, JP; Vo Van, ML, 1993) |
| "Patients with localized high-risk soft tissue sarcoma are at high risk for both local recurrence and distant metastases despite optimal surgical treatment." | 2.61 | [Multimodal treatment of sarcomas: standards and new aspects in pharmacological and radio-oncological treatment]. ( Lindner, LH, 2019) |
| "Localized soft tissue sarcoma may be cured with complete tumor excision, but overall, outcomes are sub-optimal." | 2.58 | Selection of Patients With Localized Extremity Soft Tissue Sarcoma for Treatment With Perioperative Chemotherapy. ( Charlson, J, 2018) |
| "Soft tissue sarcomas are rare tumours in adults and therefore require a multidisciplinary approach for optimal management." | 2.47 | Systemic management strategies for metastatic soft tissue sarcoma. ( Movva, S; Verschraegen, C, 2011) |
| "Synovial sarcoma is a malignant soft-tissue neoplasm, usually arising in close association with the joints and generally carrying a poor prognosis." | 2.43 | Bilateral metastatic renal synovial sarcoma. ( Matin, SF; Pollock, RE; Stage, AC, 2005) |
| "Soft tissue sarcomas are a heterogeneous group of malignancies arising from mesenchymal tissues." | 2.42 | Emerging treatments for soft tissue sarcoma of adults. ( Fahn, W; Issels, RD, 2004) |
| "Extraskeletal Ewing's sarcoma (EES) is rare and has not been previously described about the cervical spine." | 2.41 | Extraskeletal Ewing's sarcoma: a case report and review of the literature. ( Caulfield, R; Eustace, S; Fennelly, DJ; Hurson, B; Kennedy, JG; O'Rourke, KS, 2000) |
| "The first chemotherapy study of soft tissue sarcoma (STS) by the Scandinavian Sarcoma Group was started in 1981 (SSG I)." | 2.40 | Chemotherapy in soft tissue sarcoma. The Scandinavian Sarcoma Group experience. ( Alvegård, TA; Fernberg, JO; Hall, KS; Monge, O; Saeter, G; Strander, H; Wiklund, T, 1999) |
| "The role of chemotherapy for soft tissue sarcoma with the exception of rhabdomyosarcoma remains controversial." | 2.38 | [Chemotherapy for soft tissue sarcoma--current concepts and review]. ( Hatakeyama, K; Ishii, T; Umeda, T; Wakita, H, 1993) |
| "Sarcomas are a relatively rare and heterogeneous group of malignant tumors of principally mesenchymal origin." | 2.38 | The clinical management of soft tissue sarcomas. ( Elias, AD, 1992) |
| "Thoracic sarcomas are rare malignancies, with limited data for unresectable/advanced scenarios." | 1.91 | Epirubicin, cisplatin plus ifosfamide versus standard chemotherapeutic regimens for advanced/unresectable primary thoracic sarcomas. ( Alatorre-Alexander, JA; Carrasco-CaraChards, S; Cruz-Zermeño, M; de Jesús Rodríguez-Zea, I; Godina-Flores, A; Green-Renner, D; Guzmán-Casta, J; Guzmán-Huesca, J; Imaz-Olguin, V; Juarez-Vignon Whaley, JJ; Martínez-Barrera, LM; Riera-Sala, R; Rodriguez-Cid, JR; Sánchez-Domínguez, G; Sánchez-Ríos, CP; Santillán-Doherty, PJ; Seidman-Sorsby, A; Sosa-Sánchez, R, 2023) |
| "Treatment of highly malignant soft tissue sarcomas (STSs) requires multicomponent therapy including surgery, radiotherapy, and chemotherapy." | 1.91 | Perspectives of Cell Sensitivity/Resistance Assay in Soft Tissue Sarcomas Chemotherapy. ( Anastasia, TA; Belitsky, GA; Bokhyan, BY; Fetisov, TI; Khazanova, SA; Kirsanov, KI; Lovenger, AA; Marshall, VI; Rogozhin, DV; Shtompel, PA; Trapeznikova, ES; Yakubovskaya, MG; Zinovieva, VY, 2023) |
| "However, because sarcoma is very rare, there is little evidence regarding the management of elderly patients with sarcoma." | 1.72 | Management of elderly patients with bone and soft tissue sarcomas: JCOG Bone and Soft Tissue Tumor Study Group. ( Ozaki, T; Tanaka, K, 2022) |
| "Pancreatic Ewing's sarcoma is not reported commonly, with inconsistent clinical manifestations." | 1.72 | Rare presentation in a rare case of pancreatic extraosseous Ewing's sarcoma: A case report. ( Chan, WT; Hou, JY; Jiang, CB; Lee, HC; Liu, HC; Liu, YC; Sheu, JC; Wu, PS; Yeh, TC; Yeung, CY, 2022) |
| "Liposarcoma is very rare in female genital tract, and more rare for dedifferentiated liposarcoma in gynecologic field." | 1.62 | Primary dedifferentiated Liposarcoma of vagina: a first case report. ( Shen, Y; Xie, C, 2021) |
| "Myxofibrosarcoma is an aggressive soft tissue neoplasm, classified as a variant of malignant fibrous histiocytoma." | 1.46 | A rare presentation of myxofibrosarcoma as a Pancoast tumor: a case report. ( Abboud, A; Chedrawy, EG; Hussain, Z; Jevremovic, V; Yousuf, A, 2017) |
| "On multivariate analysis, positive surgical margins negatively impacted LRC, DFS, and OS (hazard ratio [HR]=10." | 1.43 | The Impact of Perioperative Chemotherapy Timing in Conjunction With Postoperative External-Beam Radiation Therapy on Extremity Soft-Tissue Sarcomas Outcome. ( Benedetto, P; Conway, S; Dosch, A; Fernandez, G; Kwon, D; Mahmoud, O; Pitcher, JD; Temple, HT; Trent, J; Wolfson, AH, 2016) |
| "Extraosseous osteosarcoma is rare, and the most appropriate therapy is unclear because there are few studies regarding its treatment." | 1.42 | Should High-grade Extraosseous Osteosarcoma Be Treated With Multimodality Therapy Like Other Soft Tissue Sarcomas? ( Fan, Z; Guadagnolo, BA; Lewis, VO; Lin, PP; Patel, S, 2015) |
| "Soft tissue sarcomas are a heterogeneous group of malignant tumors." | 1.40 | Chemotherapy influences the pseudocapsule composition in soft tissue sarcomas. ( Cheng, EY; Clohisy, DR; Manivel, JC; O'Donnell, PW, 2014) |
| "Alveolar soft part sarcomas are rarely seen and highly malignant tumors, and the prognosis of stage IV ASPS is poor." | 1.38 | [Treatment and prognosis of stage IV alveolar soft part sarcoma]. ( Yang, Y; Zhao, J, 2012) |
| "Ifosfamide is an alkylating agent with well-demonstrated efficacy against STS, and dose-dependent activity." | 1.37 | High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients. ( Baek, KK; Chang, MH; Han, B; Lee, J; Lee, SH; Lim, T; Park, JO, 2011) |
| "Soft tissue sarcoma is a malignant connective tissue tumor that may arise anywhere in the body and from diverse mesenchymal elements." | 1.35 | Should patients with high-risk soft tissue sarcoma receive adjuvant chemotherapy? ( Patel, S; Schuetze, SM, 2009) |
| "The response of adult soft tissue sarcoma (STS) to chemotherapy is uncertain." | 1.34 | [Responses of 109 adult soft tissue sarcoma patients to chemotherapy]. ( Guan, ZZ; Huang, HQ; Jiang, WQ; Li, FH; Lin, TY; Luo, HY; Qiu, MZ; Sun, XF; Wang, F; Wang, SS; Xu, F; Xu, GC; Xu, RH, 2007) |
| "Alveolar soft part sarcoma is a rare malignant tumor with unusual clinical behavior." | 1.33 | Alveolar soft part sarcoma: a rare and enigmatic entity. ( Anderson, ME; Gebhardt, MC; Hornicek, FJ; Mankin, HJ; Raskin, KA, 2005) |
| "Embryonal rhabdomyosarcoma is the most common soft tissue sarcoma of childhood but is rarely seen in adults." | 1.32 | Embryonal rhabdomyosarcoma presenting in an adult: a case report and discussion of immunohistochemical staining. ( Barnette, DJ; Feldman, BD; Graham, BS; Hardaway, CA, 2003) |
| "Thirty-seven patients had distant metastases at presentation." | 1.32 | Alveolar soft part sarcoma in Japan: multi-institutional study of 57 patients from the Japanese Musculoskeletal Oncology Group. ( Hatano, H; Hotta, T; Kawashima, H; Morita, T; Ogose, A; Ueda, T; Yazawa, Y, 2003) |
| "In patients with metastatic breast cancer (MBC), early dose intensification with multiple cycles of peripheral blood stem cell-supported high-dose chemotherapy (HDCT) seems superior to a late dose-intensification strategy." | 1.31 | Comparison of double and triple high-dose chemotherapy with autologous blood stem cell transplantation in patients with metastatic breast cancer. ( Bastert, G; Egerer, G; Goerner, R; Grischke, EM; Haas, R; Hensel, M; Ho, AD; Hohaus, S; Khbeis, T; Schneeweiss, A; Solomayer, E, 2001) |
| "The role and value of chemotherapy for soft tissue sarcomas remain unclear." | 1.30 | [Chemotherapy for pulmonary metastases of soft tissue sarcoma]. ( Kito, M; Umeda, T, 1998) |
| " A critical question in comparing an experimental treatment to a standard is how much increase in an adverse event rate is an acceptable trade-off for achieving a targeted improvement in efficacy, or vice versa." | 1.30 | Treatment comparisons based on two-dimensional safety and efficacy alternatives in oncology trials. ( Cheng, SC; Thall, PF, 1999) |
| "Ifosfamide is a newly available analog of cyclophosphamide in the oxazaphosphorine drug class." | 1.28 | Ifosfamide vs cyclophosphamide in cancer therapy. ( Weiss, RB, 1991) |
| " We have studied in patients with advanced cancer the feasibility and bioavailability of a subcutaneously administered isotonic and neutral (pH 7) IFO solution given continuously over 10 h for up to 5 days." | 1.28 | Bioavailability of subcutaneous ifosfamide and feasibility of continuous outpatient application in cancer patients. ( Brunner, KW; Cerny, T; Küpfer, A; Zeugin, T, 1990) |
| "Between 1982 and 1986, 38 patients with soft tissue sarcomas were treated with a combination of ADM/DTIC (group A), another 45 (group B) received ADM/IFO between 1986 and 1990." | 1.28 | Chemotherapy of metastatic soft tissue sarcoma with a combination of adriamycin and DTIC or adriamycin and ifosfamide. ( Dietel, M; Hossfeld, DK; Schwarz, R; Weh, HJ; Wingberg, D; Zornig, C; Zügel, M, 1990) |
| "Ifosfamide and mesna were administered to 77 patients with advanced malignancies." | 1.27 | Prediction of ifosfamide/mesna associated encephalopathy. ( Blackledge, G; Blake, AE; Honigsberger, L; Kelly, KA; Meanwell, CA, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 32 (11.19) | 18.7374 |
| 1990's | 94 (32.87) | 18.2507 |
| 2000's | 70 (24.48) | 29.6817 |
| 2010's | 60 (20.98) | 24.3611 |
| 2020's | 30 (10.49) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, JH | 1 |
| Kim, SH | 1 |
| Jeon, MK | 1 |
| Kim, JE | 1 |
| Kim, KH | 1 |
| Yun, KH | 1 |
| Jeung, HC | 1 |
| Rha, SY | 2 |
| Ahn, JH | 3 |
| Kim, HS | 1 |
| Benjamin, RS | 6 |
| Pasquali, S | 1 |
| Palmerini, E | 2 |
| Quagliuolo, V | 6 |
| Martin-Broto, J | 3 |
| Lopez-Pousa, A | 6 |
| Grignani, G | 3 |
| Brunello, A | 2 |
| Blay, JY | 5 |
| Tendero, O | 2 |
| Diaz-Beveridge, R | 1 |
| Ferraresi, V | 1 |
| Lugowska, I | 1 |
| Infante, G | 1 |
| Braglia, L | 1 |
| Merlo, DF | 1 |
| Fontana, V | 1 |
| Marchesi, E | 1 |
| Donati, DM | 1 |
| Palassini, E | 3 |
| Bianchi, G | 1 |
| Marrari, A | 1 |
| Morosi, C | 2 |
| Stacchiotti, S | 4 |
| Bagué, S | 1 |
| Coindre, JM | 2 |
| Dei Tos, AP | 5 |
| Picci, P | 5 |
| Bruzzi, P | 1 |
| Miceli, R | 2 |
| Casali, PG | 5 |
| Gronchi, A | 7 |
| Fiore, M | 2 |
| Sambri, A | 1 |
| Spinnato, P | 1 |
| Zucchini, R | 1 |
| Giannini, C | 1 |
| Caldari, E | 1 |
| Pirini, MG | 1 |
| De Paolis, M | 1 |
| Goy, BW | 1 |
| Syed, S | 1 |
| Padmanabhan, A | 1 |
| Burchette, RJ | 1 |
| Helmstedter, CS | 1 |
| Oda, Y | 2 |
| Tanaka, K | 5 |
| Hirose, T | 1 |
| Hasegawa, T | 2 |
| Hiruta, N | 1 |
| Hisaoka, M | 1 |
| Yoshimoto, M | 1 |
| Otsuka, H | 1 |
| Bekki, H | 1 |
| Ishii, T | 5 |
| Endo, M | 1 |
| Kunisada, T | 1 |
| Hiruma, T | 2 |
| Tsuchiya, H | 1 |
| Katagiri, H | 2 |
| Matsumoto, Y | 2 |
| Kawai, A | 4 |
| Nakayama, R | 2 |
| Kawashima, H | 3 |
| Takenaka, S | 3 |
| Emori, M | 2 |
| Watanuki, M | 2 |
| Yoshida, Y | 1 |
| Okamoto, T | 1 |
| Mizusawa, J | 2 |
| Fukuda, H | 3 |
| Ozaki, T | 5 |
| Iwamoto, Y | 4 |
| Nojima, T | 1 |
| Acem, I | 1 |
| van Houdt, WJ | 1 |
| Grünhagen, DJ | 1 |
| van der Graaf, WTA | 1 |
| Rueten-Budde, AJ | 1 |
| Gelderblom, H | 2 |
| Verhoef, C | 1 |
| van de Sande, MAJ | 1 |
| Miller, D | 1 |
| Livingston, JA | 1 |
| Park, Y | 1 |
| Posey, K | 1 |
| Godbole, S | 1 |
| Skubitz, K | 1 |
| Robinson, SI | 1 |
| Agulnik, M | 1 |
| Davis, LE | 1 |
| Van Tine, BA | 1 |
| Hirbe, AC | 1 |
| Parkes, A | 1 |
| Sparber-Sauer, M | 1 |
| Ferrari, A | 3 |
| Kosztyla, D | 1 |
| Ladenstein, R | 1 |
| Cecchetto, G | 1 |
| Kazanowska, B | 2 |
| Scarzello, G | 2 |
| Ljungman, G | 1 |
| Milano, GM | 1 |
| Niggli, F | 1 |
| Alaggio, R | 2 |
| Vokuhl, C | 1 |
| Casanova, M | 2 |
| Klingebiel, T | 3 |
| Zin, A | 1 |
| Koscielniak, E | 5 |
| Bisogno, G | 4 |
| Machida, R | 1 |
| Tsukushi, S | 1 |
| Asanuma, K | 1 |
| Hiraga, H | 3 |
| Hiraoka, K | 1 |
| Yonemoto, T | 2 |
| Abe, S | 2 |
| Nishida, Y | 1 |
| Nagano, A | 1 |
| Suehara, Y | 1 |
| Kawano, M | 1 |
| Morii, T | 1 |
| Hatano, H | 2 |
| Toguchida, J | 1 |
| Okuma, T | 2 |
| Takeyama, M | 1 |
| Akisue, T | 1 |
| Furuta, T | 1 |
| Outani, H | 2 |
| Yamamoto, T | 1 |
| Kataoka, T | 1 |
| Miao, L | 1 |
| Ma, ST | 1 |
| Jiang, X | 1 |
| Zhang, HH | 1 |
| Wang, YM | 1 |
| Li, M | 1 |
| Liu, X | 1 |
| Jiang, S | 1 |
| Wang, H | 1 |
| Wu, X | 1 |
| Yan, W | 1 |
| Chen, Y | 2 |
| Xu, Y | 1 |
| Wang, C | 3 |
| Yao, W | 2 |
| Wang, J | 2 |
| Yu, L | 1 |
| Miao, J | 1 |
| Chen, H | 1 |
| Xia, J | 1 |
| Huang, M | 1 |
| Zhang, X | 1 |
| Luo, Z | 1 |
| Han, X | 1 |
| Li, Q | 1 |
| Wang, EH | 1 |
| Liu, N | 1 |
| Liu, YC | 3 |
| Yeh, TC | 3 |
| Wu, PS | 3 |
| Sheu, JC | 3 |
| Lee, HC | 3 |
| Yeung, CY | 3 |
| Jiang, CB | 3 |
| Liu, HC | 3 |
| Hou, JY | 3 |
| Chan, WT | 3 |
| Rodriguez-Cid, JR | 3 |
| Juarez-Vignon Whaley, JJ | 3 |
| Sánchez-Domínguez, G | 3 |
| Guzmán-Casta, J | 3 |
| Carrasco-CaraChards, S | 3 |
| Guzmán-Huesca, J | 3 |
| Riera-Sala, R | 3 |
| Sánchez-Ríos, CP | 3 |
| Cruz-Zermeño, M | 3 |
| Seidman-Sorsby, A | 3 |
| de Jesús Rodríguez-Zea, I | 3 |
| Alatorre-Alexander, JA | 3 |
| Martínez-Barrera, LM | 3 |
| Santillán-Doherty, PJ | 3 |
| Godina-Flores, A | 3 |
| Imaz-Olguin, V | 3 |
| Sosa-Sánchez, R | 3 |
| Green-Renner, D | 3 |
| Merjaneh, N | 1 |
| Kim, H | 1 |
| Escoto, H | 1 |
| Metts, J | 1 |
| Ray, A | 1 |
| Bukowinski, A | 1 |
| LeBlanc, Z | 1 |
| Fair, D | 1 |
| Watanbe, M | 1 |
| Alva, E | 1 |
| Todd, K | 1 |
| Daley, J | 1 |
| Hartt, D | 1 |
| Cramer, SL | 1 |
| Szabo, S | 1 |
| Pressey, JG | 1 |
| Gutierrez-Sainz, L | 1 |
| Martinez-Fdez, S | 1 |
| Pedregosa-Barbas, J | 1 |
| Peña, J | 1 |
| Alameda, M | 1 |
| Viñal, D | 1 |
| Villamayor, J | 1 |
| Martinez-Recio, S | 1 |
| Perez-Wert, P | 1 |
| Pertejo-Fernandez, A | 1 |
| Gallego, A | 1 |
| Martinez-Marin, V | 1 |
| Zamora, P | 1 |
| Espinosa, E | 1 |
| Mendiola, M | 1 |
| Feliu, J | 1 |
| Redondo, A | 1 |
| Veltsista, PD | 1 |
| Oberacker, E | 1 |
| Ademaj, A | 1 |
| Corradini, S | 1 |
| Eckert, F | 2 |
| Flörcken, A | 1 |
| Kaul, D | 1 |
| Lindner, LH | 4 |
| Issels, R | 1 |
| Ott, OJ | 1 |
| Pink, D | 1 |
| Potkrajcic, V | 1 |
| Reichardt, P | 3 |
| Roohani, S | 1 |
| Spalek, MJ | 1 |
| Riesterer, O | 1 |
| Zips, D | 2 |
| Ghadjar, P | 2 |
| Fetisov, TI | 1 |
| Khazanova, SA | 1 |
| Shtompel, PA | 1 |
| Trapeznikova, ES | 1 |
| Zinovieva, VY | 1 |
| Marshall, VI | 1 |
| Lovenger, AA | 1 |
| Rogozhin, DV | 1 |
| Anastasia, TA | 1 |
| Bokhyan, BY | 1 |
| Belitsky, GA | 1 |
| Yakubovskaya, MG | 1 |
| Kirsanov, KI | 1 |
| Salah, S | 1 |
| Abuhijla, F | 1 |
| Ismail, T | 1 |
| Yaser, S | 1 |
| Sultan, I | 1 |
| Halalsheh, H | 1 |
| Shehadeh, A | 1 |
| Abdelal, S | 1 |
| Almousa, A | 1 |
| Jaber, O | 1 |
| Abu-Hijlih, R | 1 |
| Hammer, KJ | 1 |
| Copeland, VC | 1 |
| Loggers, ET | 1 |
| Pollack, SM | 1 |
| Wagner, MJ | 1 |
| Cranmer, LD | 1 |
| Nakamura, Y | 1 |
| Takemasa, A | 1 |
| Kushima, Y | 1 |
| Soda, S | 1 |
| Ikeda, N | 1 |
| Arai, R | 1 |
| Chibana, K | 1 |
| Nakazato, Y | 1 |
| Yokose, T | 1 |
| Shimizu, Y | 1 |
| Niho, S | 1 |
| Filleron, T | 1 |
| Le Guellec, S | 1 |
| Chevreau, C | 2 |
| Cabarrou, B | 1 |
| Lesluyes, T | 1 |
| Lodin, S | 1 |
| Massoubre, A | 1 |
| Mounier, M | 1 |
| Poublanc, M | 1 |
| Chibon, F | 1 |
| Valentin, T | 1 |
| Imai, K | 1 |
| Yamasaki, T | 1 |
| Sakamoto, H | 1 |
| Nakamura, K | 1 |
| Mizowaki, T | 1 |
| Ogawa, O | 1 |
| Aoyama, T | 1 |
| Xie, C | 1 |
| Shen, Y | 1 |
| Spałek, MJ | 1 |
| Koseła-Paterczyk, H | 1 |
| Borkowska, A | 1 |
| Wągrodzki, M | 1 |
| Szumera-Ciećkiewicz, A | 2 |
| Czarnecka, AM | 1 |
| Castaneda-Wysocka, P | 1 |
| Kalinowska, I | 1 |
| Poleszczuk, J | 1 |
| Dąbrowska-Szewczyk, E | 1 |
| Cieszanowski, A | 1 |
| Rutkowski, P | 2 |
| Hindi, N | 1 |
| Tian, Z | 1 |
| Yang, J | 1 |
| Zhang, P | 1 |
| Wang, X | 1 |
| Zhang, F | 1 |
| Li, P | 1 |
| Teepen, JC | 1 |
| van Leeuwen, FE | 1 |
| Tissing, WJ | 1 |
| van Dulmen-den Broeder, E | 1 |
| van den Heuvel-Eibrink, MM | 1 |
| van der Pal, HJ | 1 |
| Loonen, JJ | 1 |
| Bresters, D | 1 |
| Versluys, B | 1 |
| Neggers, SJCMM | 1 |
| Jaspers, MWM | 1 |
| Hauptmann, M | 1 |
| van der Heiden-van der Loo, M | 1 |
| Visser, O | 1 |
| Kremer, LCM | 1 |
| Ronckers, CM | 1 |
| Issels, RD | 6 |
| Verweij, J | 18 |
| Wessalowski, R | 1 |
| Wust, P | 1 |
| Hohenberger, P | 2 |
| Angele, M | 1 |
| Salat, C | 2 |
| Vujaskovic, Z | 1 |
| Daugaard, S | 1 |
| Mella, O | 1 |
| Mansmann, U | 1 |
| Dürr, HR | 1 |
| Knösel, T | 1 |
| Abdel-Rahman, S | 4 |
| Schmidt, M | 1 |
| Hiddemann, W | 2 |
| Jauch, KW | 3 |
| Belka, C | 1 |
| García Del Muro, X | 2 |
| Maurel, J | 3 |
| Martínez Trufero, J | 1 |
| Lavernia, J | 1 |
| López Pousa, A | 1 |
| de Las Peñas, R | 3 |
| Cubedo, R | 2 |
| Berros, JP | 1 |
| Casado Herráez, A | 1 |
| de Juan, A | 1 |
| Martín Broto, J | 2 |
| Fagerstedt, KW | 1 |
| Salonen, T | 1 |
| Zhao, F | 1 |
| Kytölä, S | 1 |
| Böhling, T | 1 |
| Andersson, LC | 2 |
| Jones, RL | 2 |
| Arndt, CAS | 1 |
| Charlson, J | 1 |
| Lu, E | 1 |
| Ryan, CW | 2 |
| Spunt, SL | 2 |
| Francotte, N | 1 |
| De Salvo, GL | 1 |
| Chi, YY | 1 |
| Zanetti, I | 2 |
| Hayes-Jordan, A | 1 |
| Kao, SC | 1 |
| Orbach, D | 1 |
| Brennan, B | 1 |
| Weiss, AR | 1 |
| van Noesel, MM | 1 |
| Million, L | 1 |
| Parham, DM | 2 |
| Kelsey, A | 1 |
| Randall, RL | 1 |
| McCarville, MB | 1 |
| Hawkins, DS | 2 |
| Wakamatsu, T | 1 |
| Kakunaga, S | 1 |
| Hamada, K | 1 |
| Imura, Y | 1 |
| Hori, Y | 1 |
| Naka, N | 1 |
| Kudawara, I | 1 |
| Yoshikawa, H | 1 |
| Ueda, T | 2 |
| Chawla, SP | 2 |
| Staddon, A | 1 |
| Hendifar, A | 1 |
| Messam, CA | 1 |
| Patwardhan, R | 1 |
| Kamel, YM | 1 |
| Gani, C | 1 |
| Kluba, T | 2 |
| Mayer, F | 1 |
| Kopp, HG | 2 |
| Bamberg, M | 1 |
| Müller, AC | 1 |
| O'Donnell, PW | 1 |
| Manivel, JC | 1 |
| Cheng, EY | 1 |
| Clohisy, DR | 1 |
| Yoo, C | 1 |
| Lee, J | 2 |
| Park, KH | 1 |
| Kim, TM | 1 |
| Kim, YJ | 1 |
| Lee, HJ | 2 |
| Lee, KH | 1 |
| Sio, TT | 1 |
| Vu, CC | 1 |
| Sohawon, S | 1 |
| Van Houtte, P | 1 |
| Thariat, J | 1 |
| Novotny, PJ | 1 |
| Miller, RC | 1 |
| Bar-Sela, G | 1 |
| Okuno, S | 1 |
| Petersen, I | 1 |
| Shives, T | 1 |
| Mahoney, M | 1 |
| Haddock, M | 1 |
| Sim, F | 1 |
| O'Connor, MI | 2 |
| Markovic, SN | 1 |
| Maples, W | 1 |
| Judson, I | 3 |
| Hartmann, JT | 1 |
| Schöffski, P | 3 |
| Kerst, JM | 1 |
| Sufliarsky, J | 1 |
| Whelan, J | 1 |
| Krarup-Hansen, A | 2 |
| Alcindor, T | 1 |
| Marreaud, S | 1 |
| Litière, S | 1 |
| Hermans, C | 2 |
| Fisher, C | 3 |
| Hogendoorn, PC | 2 |
| van der Graaf, WT | 1 |
| Baumann, D | 1 |
| Amann, K | 1 |
| Schlatter, E | 1 |
| Ciarimboli, G | 1 |
| Müller, M | 1 |
| Bakos, G | 1 |
| Steinke, I | 1 |
| Bunz, H | 1 |
| Weyrich, P | 1 |
| Artunc, F | 1 |
| Mahmoud, O | 1 |
| Dosch, A | 1 |
| Kwon, D | 1 |
| Pitcher, JD | 1 |
| Conway, S | 1 |
| Benedetto, P | 1 |
| Fernandez, G | 1 |
| Trent, J | 1 |
| Temple, HT | 1 |
| Wolfson, AH | 1 |
| Roeder, F | 2 |
| Lehner, B | 2 |
| Schmitt, T | 3 |
| Kasper, B | 4 |
| Egerer, G | 4 |
| Sedlaczek, O | 1 |
| Grüllich, C | 1 |
| Mechtersheimer, G | 2 |
| Wuchter, P | 3 |
| Hensley, FW | 1 |
| Huber, PE | 1 |
| Debus, J | 1 |
| Bischof, M | 2 |
| Kataoka, K | 1 |
| Kimura, A | 1 |
| Matsunobu, T | 1 |
| Matsumine, A | 1 |
| Araki, N | 2 |
| Ibrahim, ZA | 1 |
| Chan, WH | 1 |
| Wong, SL | 2 |
| Ong, EJ | 1 |
| Narihan, MZ | 1 |
| Brunetto, AL | 1 |
| Castillo, LA | 1 |
| Petrilli, AS | 1 |
| Macedo, CD | 1 |
| Boldrini, E | 1 |
| Costa, C | 1 |
| Almeida, MT | 1 |
| Kirst, D | 1 |
| Rodriguez-Galindo, C | 1 |
| Pereira, WV | 1 |
| Watanabe, FM | 1 |
| Pizza, M | 1 |
| Benites, E | 1 |
| Morais, V | 1 |
| Gadelha, A | 1 |
| Nakasato, A | 1 |
| Abujamra, AL | 1 |
| Gregianin, LJ | 1 |
| Liu, YP | 1 |
| Jin, J | 1 |
| Wang, WH | 1 |
| Wang, SL | 1 |
| Song, YW | 1 |
| Fang, H | 1 |
| Ren, H | 1 |
| Liu, XF | 1 |
| Yu, ZH | 1 |
| Li, YX | 1 |
| Schuler, M | 1 |
| Davis, EJ | 1 |
| Chugh, R | 3 |
| Zhao, L | 1 |
| Lucas, DR | 1 |
| Biermann, JS | 2 |
| Zalupski, MM | 3 |
| Feng, M | 1 |
| Jacobson, J | 2 |
| Zyczynski, L | 1 |
| Reinke, D | 1 |
| Metko, G | 1 |
| Baker, LH | 4 |
| Schuetze, SM | 2 |
| Fan, Z | 1 |
| Patel, S | 2 |
| Lewis, VO | 1 |
| Guadagnolo, BA | 1 |
| Lin, PP | 1 |
| Ferrari, S | 2 |
| Verderio, P | 3 |
| De Paoli, A | 5 |
| Comandone, A | 5 |
| Sangalli, C | 1 |
| De Sanctis, R | 1 |
| Bottelli, S | 1 |
| Libertini, M | 1 |
| Mulder, RL | 3 |
| Paulides, M | 3 |
| Langer, T | 3 |
| Kremer, LC | 3 |
| van Dalen, EC | 3 |
| Noujaim, J | 1 |
| Constantinidou, A | 1 |
| Messiou, C | 1 |
| Thway, K | 1 |
| Miah, A | 1 |
| Benson, C | 1 |
| Rizzato, MD | 1 |
| Rastrelli, M | 1 |
| Roma, A | 1 |
| Maruzzo, M | 1 |
| Basso, U | 1 |
| Fiduccia, P | 1 |
| Buzzaccarini, MS | 1 |
| Rossi, CR | 1 |
| Zagonel, V | 1 |
| Mascarenhas, L | 1 |
| Felgenhauer, JL | 1 |
| Bond, MC | 1 |
| Villaluna, D | 1 |
| Femino, JD | 1 |
| Laack, NN | 1 |
| Ranganathan, S | 1 |
| Meyer, J | 2 |
| Womer, RB | 1 |
| Gorlick, R | 2 |
| Krailo, MD | 1 |
| Marina, N | 2 |
| Stubbe, F | 1 |
| Agaimy, A | 1 |
| Ott, O | 1 |
| Lettmaier, S | 1 |
| Vassos, N | 1 |
| Croner, R | 1 |
| Hohenberger, W | 1 |
| Fietkau, R | 1 |
| Semrau, S | 1 |
| Wang, B | 1 |
| Yu, X | 1 |
| Xu, S | 1 |
| Xu, M | 1 |
| Moon, JY | 1 |
| Baek, SW | 1 |
| Ryu, H | 1 |
| Choi, YS | 1 |
| Song, IC | 1 |
| Yun, HJ | 1 |
| Jo, DY | 1 |
| Kim, S | 1 |
| Stoeckle, E | 1 |
| Michot, A | 1 |
| Rigal, L | 1 |
| Babre, F | 1 |
| Sargos, P | 1 |
| Henriques de Figueiredo, B | 1 |
| Brouste, V | 1 |
| Italiano, A | 2 |
| Toulmonde, M | 2 |
| Le Loarer, F | 1 |
| Kind, M | 2 |
| Jevremovic, V | 1 |
| Yousuf, A | 1 |
| Hussain, Z | 1 |
| Abboud, A | 1 |
| Chedrawy, EG | 1 |
| Saponara, M | 1 |
| Frapolli, R | 1 |
| Tortoreto, M | 1 |
| Cominetti, D | 1 |
| Provenzano, S | 2 |
| Negri, T | 1 |
| Dagrada, GP | 1 |
| Colombo, C | 1 |
| Vincenzi, B | 1 |
| Badalamenti, G | 2 |
| Zuco, V | 1 |
| Renne, SL | 1 |
| Collini, P | 1 |
| Bello, E | 1 |
| Pilotti, S | 1 |
| D'Incalci, M | 1 |
| Zaffaroni, N | 1 |
| Dantonello, TM | 1 |
| Int-Veen, C | 2 |
| Harms, D | 1 |
| Leuschner, I | 2 |
| Schmidt, BF | 1 |
| Herbst, M | 1 |
| Juergens, H | 1 |
| Scheel-Walter, HG | 1 |
| Bielack, SS | 1 |
| Dickerhoff, R | 1 |
| Kirsch, S | 1 |
| Brecht, I | 1 |
| Schmelzle, R | 1 |
| Greulich, M | 1 |
| Gadner, H | 2 |
| Greiner, J | 1 |
| Marky, I | 2 |
| Treuner, J | 3 |
| Fra, J | 2 |
| Martín, J | 5 |
| Cruz, J | 1 |
| Casado, A | 3 |
| Poveda, A | 3 |
| Martínez-Trufero, J | 2 |
| Balañá, C | 2 |
| Gómez, MA | 1 |
| Gallego, O | 1 |
| Rubio-Viqueira, B | 1 |
| Rubió, J | 1 |
| Andrés, R | 1 |
| Sevilla, I | 1 |
| de la Cruz, JJ | 1 |
| Del Muro, XG | 1 |
| Buesa, JM | 3 |
| Granowetter, L | 1 |
| Womer, R | 1 |
| Devidas, M | 2 |
| Krailo, M | 1 |
| Bernstein, M | 1 |
| Leavey, P | 1 |
| Gebhardt, M | 2 |
| Healey, J | 1 |
| Shamberger, RC | 1 |
| Goorin, A | 1 |
| Miser, J | 2 |
| Arndt, CA | 1 |
| Sailer, S | 1 |
| Marcus, K | 1 |
| Perlman, E | 1 |
| Dickman, P | 1 |
| Grier, HE | 3 |
| Benz, MR | 1 |
| Czernin, J | 1 |
| Allen-Auerbach, MS | 1 |
| Tap, WD | 1 |
| Dry, SM | 1 |
| Elashoff, D | 1 |
| Chow, K | 1 |
| Evilevitch, V | 1 |
| Eckardt, JJ | 2 |
| Phelps, ME | 1 |
| Weber, WA | 1 |
| Eilber, FC | 4 |
| Stahl, R | 1 |
| Wang, T | 1 |
| Santl, M | 1 |
| Reiser, MF | 1 |
| Ptaszyński, K | 1 |
| Zakrzewska, K | 1 |
| Tuziak, T | 1 |
| Mrozkowiak, A | 1 |
| Paulino, AC | 1 |
| Pappo, A | 1 |
| Ho, AD | 3 |
| Sleijfer, S | 2 |
| Ouali, M | 1 |
| van Glabbeke, M | 5 |
| Rodenhuis, S | 1 |
| Le Cesne, A | 1 |
| Jung, S | 1 |
| Pavageau, AH | 1 |
| Croué, A | 1 |
| Reguerre, Y | 1 |
| Rialland, X | 1 |
| Rousselet, MC | 1 |
| Bui-Nguyen, B | 1 |
| Contreras Ibáñez, JA | 1 |
| Navas García, N | 1 |
| Díaz Gómez, L | 1 |
| De Pas, T | 2 |
| Rosati, G | 1 |
| Spitaleri, G | 1 |
| Boni, C | 1 |
| Tucci, A | 1 |
| Frustaci, S | 6 |
| Scalamogna, R | 1 |
| Radice, D | 1 |
| Boselli, S | 1 |
| Toffalorio, F | 1 |
| Catania, C | 1 |
| Noberasco, C | 1 |
| Delmonte, A | 1 |
| Vecchio, F | 1 |
| de Braud, F | 2 |
| Reed, D | 1 |
| Altiok, S | 1 |
| Lee, SH | 1 |
| Chang, MH | 1 |
| Baek, KK | 1 |
| Han, B | 1 |
| Lim, T | 1 |
| Park, JO | 1 |
| Mirza, T | 1 |
| Ameerally, P | 1 |
| Movva, S | 1 |
| Verschraegen, C | 1 |
| Dietrich, S | 1 |
| Dimitrakopoulou-Strauss, A | 1 |
| Strauss, LG | 1 |
| Yang, Y | 2 |
| Shi, Y | 1 |
| Mercuri, M | 1 |
| Mariani, L | 1 |
| Valagussa, P | 1 |
| Longhi, A | 1 |
| Kushner, BH | 1 |
| Modak, S | 1 |
| Kramer, K | 1 |
| Basu, EM | 1 |
| Roberts, SS | 1 |
| Cheung, NK | 1 |
| Ferraro, A | 1 |
| Majò, J | 1 |
| Pizzamiglio, S | 1 |
| Zhao, J | 1 |
| Incorvaia, L | 1 |
| Bronte, G | 1 |
| Leto, G | 1 |
| Fulfaro, F | 1 |
| Maltese, G | 1 |
| Serrone, L | 3 |
| Nardoni, C | 2 |
| Gelibter, A | 1 |
| Felici, A | 1 |
| Cognetti, F | 3 |
| Felgenhauer, J | 2 |
| Park, J | 1 |
| Kreissman, S | 1 |
| Thomson, B | 2 |
| Douglas, J | 1 |
| Rowley, SD | 1 |
| Gooley, T | 1 |
| Sanders, JE | 1 |
| Pendergrass, TW | 1 |
| van Oosterom, AT | 9 |
| Mouridsen, HT | 6 |
| Nielsen, OS | 3 |
| Dombernowsky, P | 7 |
| Krzemieniecki, K | 1 |
| Svancarova, L | 1 |
| Spooner, D | 3 |
| Chen, LK | 1 |
| Xu, GC | 2 |
| Teng, XY | 1 |
| Liang, Y | 1 |
| Liu, JL | 1 |
| Zhou, XM | 1 |
| Huang, YH | 1 |
| Wen, XP | 1 |
| Hu, L | 1 |
| Hardaway, CA | 1 |
| Graham, BS | 1 |
| Barnette, DJ | 1 |
| Feldman, BD | 1 |
| Wodowski, K | 1 |
| Hill, DA | 1 |
| Pappo, AS | 5 |
| Shochat, SJ | 1 |
| Kun, LE | 1 |
| Wall, N | 1 |
| Starkhammar, H | 1 |
| O'Sullivan, B | 1 |
| Bell, RS | 1 |
| DeLaney, TF | 2 |
| Spiro, IJ | 1 |
| Suit, HD | 1 |
| Gebhardt, MC | 2 |
| Hornicek, FJ | 2 |
| Mankin, HJ | 2 |
| Rosenberg, AL | 1 |
| Rosenthal, DI | 1 |
| Miryousefi, F | 1 |
| Ancukiewicz, M | 1 |
| Harmon, DC | 1 |
| Ogose, A | 1 |
| Yazawa, Y | 1 |
| Hotta, T | 1 |
| Morita, T | 1 |
| Mace, JR | 1 |
| Keohan, ML | 1 |
| Bernardy, H | 1 |
| Junge, K | 1 |
| Niebch, G | 1 |
| Romeis, P | 1 |
| Thoma, A | 1 |
| Wagner, T | 2 |
| Mueller, U | 1 |
| Demetri, G | 1 |
| Eilber, FR | 3 |
| Eckardt, J | 4 |
| Rosen, G | 5 |
| Riedel, E | 2 |
| Maki, RG | 2 |
| Brennan, MF | 2 |
| Singer, S | 2 |
| Goto, T | 2 |
| Kosaku, H | 1 |
| Kobayashi, H | 1 |
| Hozumi, T | 2 |
| Kondo, T | 2 |
| Chuman, H | 1 |
| Grobmyer, SR | 1 |
| Demetri, GD | 3 |
| Mazumdar, M | 1 |
| Fahn, W | 1 |
| Worden, FP | 2 |
| Taylor, JM | 2 |
| Sondak, VK | 1 |
| Leu, KM | 2 |
| McGinn, CJ | 1 |
| Stage, AC | 1 |
| Pollock, RE | 2 |
| Matin, SF | 1 |
| Takahashi, S | 1 |
| Suzuki, M | 1 |
| Kume, H | 1 |
| Matsumoto, S | 2 |
| Okamoto, N | 1 |
| Nishimatsu, H | 1 |
| Tomita, K | 1 |
| Kitamura, T | 1 |
| Oppenheimer, O | 1 |
| Athanasian, E | 1 |
| Meyers, P | 1 |
| Antonescu, CR | 1 |
| Jenkins, J | 1 |
| Rao, B | 1 |
| Marcus, R | 1 |
| Thomas, P | 1 |
| Pratt, C | 1 |
| Umeda, T | 5 |
| Wada, T | 1 |
| Ihara, K | 1 |
| Isu, K | 1 |
| Sugiura, H | 1 |
| Yabe, H | 1 |
| Tsugane, S | 1 |
| Beppu, Y | 1 |
| Virolainen, P | 1 |
| Inoue, N | 1 |
| Nagao, M | 1 |
| Frassica, FJ | 1 |
| Chao, EY | 1 |
| Anderson, ME | 1 |
| Raskin, KA | 1 |
| Schafmayer, C | 1 |
| Egberts, JH | 1 |
| Kovács, G | 1 |
| Tepel, J | 1 |
| Bölke, E | 1 |
| Ruf, L | 1 |
| Budach, W | 2 |
| Reinecke, P | 1 |
| Röhrborn, A | 1 |
| Pape, H | 2 |
| Schwarz, A | 1 |
| Schmitt, G | 2 |
| Aul, C | 1 |
| Meazza, C | 1 |
| Carli, M | 1 |
| Li, EX | 1 |
| Zhang, YT | 1 |
| Shang, JT | 1 |
| Xu, Z | 1 |
| Geng, Y | 1 |
| Li, SM | 1 |
| Shi, F | 1 |
| Wu, YY | 1 |
| Leyvraz, S | 4 |
| Herrmann, R | 1 |
| Guillou, L | 2 |
| Honegger, HP | 1 |
| Christinat, A | 1 |
| Fey, MF | 1 |
| Sessa, C | 2 |
| Wernli, M | 1 |
| Cerny, T | 3 |
| Dietrich, D | 1 |
| Pestalozzi, B | 1 |
| Schlemmer, M | 1 |
| Wendtner, CM | 1 |
| Falk, M | 1 |
| Licht, T | 1 |
| Baumert, J | 1 |
| Straka, C | 1 |
| Hentrich, M | 1 |
| Griffith, KA | 1 |
| Thomas, DG | 1 |
| Nakada, I | 1 |
| Tascilar, M | 1 |
| Loos, WJ | 1 |
| Seynaeve, C | 1 |
| Qiu, MZ | 1 |
| Xu, F | 1 |
| Wang, SS | 1 |
| Luo, HY | 1 |
| Wang, F | 1 |
| Li, FH | 1 |
| Sun, XF | 1 |
| Lin, TY | 1 |
| Huang, HQ | 1 |
| Jiang, WQ | 1 |
| Guan, ZZ | 1 |
| Xu, RH | 1 |
| Iagaru, A | 1 |
| Masamed, R | 1 |
| Menendez, LR | 1 |
| Fedenko, A | 1 |
| Conti, PS | 1 |
| Boos, J | 1 |
| Beske, F | 1 |
| Hallmen, E | 1 |
| Dantonello, T | 1 |
| Montag, AG | 1 |
| Hosenpud, JR | 1 |
| Samuels, B | 1 |
| Hayden, JB | 1 |
| Hung, AY | 1 |
| Mansoor, A | 1 |
| Peabody, TD | 1 |
| Mundt, AJ | 1 |
| Undevia, S | 1 |
| Takeuchi, S | 1 |
| Akahoshi, Y | 1 |
| Kasai, C | 1 |
| Nishimoto, Y | 1 |
| Stuart-Harris, R | 3 |
| Harper, PG | 2 |
| Kaye, SB | 2 |
| Wiltshaw, E | 5 |
| Stuart-Harris, RC | 1 |
| Parsons, CA | 1 |
| Mooney, CA | 1 |
| Gowing, NF | 1 |
| Burkert, H | 1 |
| Utracka-Hutka, B | 1 |
| Czownicki, Z | 1 |
| Elias, AD | 3 |
| Eilber, F | 2 |
| Forscher, C | 3 |
| Selch, M | 4 |
| Fu, YS | 1 |
| Schleicher, UM | 1 |
| Adam, G | 1 |
| Casser, HR | 1 |
| Füzesi, L | 1 |
| Ruymann, FB | 2 |
| Vietti, T | 1 |
| Gehan, E | 1 |
| Wiener, E | 2 |
| Wharam, M | 3 |
| Newton, WA | 1 |
| Maurer, H | 2 |
| Bui, BN | 1 |
| Chevallier, B | 2 |
| Krakowski, I | 1 |
| Peny, AM | 1 |
| Thyss, A | 1 |
| Maugard-Louboutin, C | 1 |
| Cupissol, D | 1 |
| Fargeot, P | 2 |
| Bonichon, F | 1 |
| Shinozaki, T | 1 |
| Matsushita, M | 1 |
| Kusawake, H | 1 |
| Watanabe, H | 1 |
| Arita, S | 1 |
| Chigira, M | 1 |
| Udagawa, E | 1 |
| Kawaguchi, N | 1 |
| Manabe, J | 1 |
| Kuroda, H | 1 |
| Shimoji, T | 1 |
| Raney, B | 1 |
| Ensign, LG | 1 |
| Foreman, J | 1 |
| Khan, F | 1 |
| Newton, W | 1 |
| Ortega, J | 1 |
| Ragab, A | 1 |
| Patel, SR | 6 |
| Burgess, MA | 4 |
| Plager, C | 3 |
| Papadopoulos, NE | 1 |
| Linke, KA | 1 |
| Stuschke, M | 1 |
| Hatakeyama, K | 1 |
| Wakita, H | 1 |
| Skubitz, KM | 1 |
| Hamdan, H | 1 |
| Thompson, RC | 1 |
| Foladore, S | 1 |
| Buonadonna, A | 2 |
| Crivellari, D | 1 |
| Carbone, A | 1 |
| Sorio, R | 1 |
| Morassut, S | 1 |
| Monfardini, S | 1 |
| Steward, W | 2 |
| Mouridsen, H | 3 |
| Edmonson, JH | 2 |
| Ryan, LM | 1 |
| Blum, RH | 2 |
| Brooks, JS | 1 |
| Shiraki, M | 1 |
| Frytak, S | 1 |
| Parkinson, DR | 1 |
| Antman, K | 1 |
| Crowley, J | 1 |
| Balcerzak, SP | 2 |
| Rivkin, SE | 1 |
| Weiss, GR | 1 |
| Elias, A | 3 |
| Natale, RB | 1 |
| Cooper, RM | 1 |
| Barlogie, B | 1 |
| Trump, DL | 1 |
| González-Manzano, R | 1 |
| Vieitez, JM | 1 |
| Tangco, E | 1 |
| Fernandez de Alava, E | 1 |
| Herranz, P | 1 |
| Garcia-Foncillas, J | 1 |
| Hibi, S | 1 |
| Naya, M | 1 |
| Takaya, K | 1 |
| Morimoto, M | 1 |
| Kataoka, Y | 1 |
| Todo, S | 1 |
| Imashuku, S | 1 |
| Kynaston, JA | 1 |
| Malcolm, AJ | 1 |
| Craft, AW | 1 |
| Davies, SM | 1 |
| Jones, PH | 1 |
| King, DJ | 1 |
| Mitchell, CD | 1 |
| Oakhill, A | 1 |
| Stiller, CA | 1 |
| Bosse, D | 1 |
| Starck, M | 1 |
| Schildberg, FW | 1 |
| Wilmanns, W | 2 |
| Kampe, CE | 1 |
| Lowenbraun, S | 1 |
| Foster, J | 1 |
| Steward, WP | 5 |
| Somers, R | 9 |
| Kerbrat, P | 2 |
| Clavel, M | 4 |
| Crowther, D | 2 |
| Rouesse, J | 3 |
| Tursz, T | 3 |
| Tueni, E | 2 |
| Gilard, V | 2 |
| Malet-Martino, MC | 2 |
| de Forni, M | 2 |
| Niemeyer, U | 2 |
| Ader, JC | 1 |
| Martino, R | 2 |
| Kitoh, M | 2 |
| Tatezaki, S | 2 |
| Satoh, T | 2 |
| Legha, SS | 1 |
| Nicaise, C | 1 |
| Bramwell, VH | 3 |
| Santoro, A | 9 |
| Blackledge, G | 9 |
| Onsrud, M | 2 |
| Thomas, D | 7 |
| Sylvester, R | 3 |
| Weh, HJ | 2 |
| Agarwal, K | 1 |
| Zornig, C | 2 |
| Schwarz, R | 2 |
| Dietel, M | 2 |
| Hossfeld, DK | 2 |
| Dalley, D | 1 |
| Bell, DR | 1 |
| Levi, J | 1 |
| Simes, RJ | 1 |
| Schütte, J | 5 |
| Kellner, R | 1 |
| Seeber, S | 1 |
| Azzarelli, A | 4 |
| Casali, P | 3 |
| Fissi, S | 1 |
| Montalto, F | 1 |
| Budd, GT | 1 |
| Metch, B | 1 |
| Weiss, SA | 1 |
| Weick, JK | 1 |
| Fabian, C | 1 |
| Stephens, RL | 1 |
| Harstrick, A | 2 |
| Bokemeyer, C | 2 |
| Schmoll, HJ | 2 |
| Köhne-Wömpner, CH | 2 |
| Knipp, H | 1 |
| Anagnou, J | 1 |
| Wipperman, B | 1 |
| Neumann, S | 1 |
| Poliwoda, H | 2 |
| Pastorino, U | 2 |
| Bertulli, R | 1 |
| Zucchinelli, P | 2 |
| Devizzi, L | 2 |
| Toma, S | 4 |
| Palumbo, R | 3 |
| Canavese, G | 2 |
| Albanese, E | 1 |
| Cantoni, E | 1 |
| Barisone, A | 1 |
| Reggiardo, G | 1 |
| Rosso, R | 2 |
| Santi, L | 2 |
| Edmonson, J | 1 |
| Ryan, L | 3 |
| Pelletier, L | 1 |
| Olivier, JP | 1 |
| Facchini, T | 1 |
| Vo Van, ML | 1 |
| Vantongelen, K | 1 |
| Bui, NB | 1 |
| Stöckle, E | 1 |
| Kantor, G | 1 |
| Thomas, L | 1 |
| Wexler, LH | 1 |
| Tsokos, M | 1 |
| Avila, N | 1 |
| Steinberg, SM | 1 |
| Weaver-McClure, L | 1 |
| Jarosinski, P | 1 |
| Hijazi, YM | 1 |
| Balis, FM | 1 |
| Horowitz, ME | 1 |
| Boddy, AV | 1 |
| English, M | 1 |
| Pearson, AD | 1 |
| Idle, JR | 1 |
| Skinner, R | 1 |
| Erkisi, M | 1 |
| Erkurt, E | 1 |
| Ozbarlas, S | 1 |
| Burgut, R | 1 |
| Doran, F | 1 |
| Seyrek, E | 1 |
| Lokiec, F | 1 |
| Santoni, J | 1 |
| Weill, S | 1 |
| Tubiana-Hulin, M | 1 |
| Baranzelli, MC | 1 |
| Pichon, F | 1 |
| Gourmel, B | 1 |
| N'Guyen, M | 1 |
| Deligny, N | 1 |
| Demaille, MC | 1 |
| Saboorian, MH | 1 |
| Ashfaq, R | 1 |
| Vandersteenhoven, JJ | 1 |
| Schneider, NR | 1 |
| Vadhan-Raj, S | 1 |
| Papadopolous, N | 1 |
| Hays, C | 1 |
| Bellmunt, J | 2 |
| Eres, N | 1 |
| Ribas, A | 1 |
| Casado, S | 1 |
| Albanell, J | 1 |
| Baselga, J | 1 |
| Therasse, P | 1 |
| Saeter, G | 2 |
| Alvegård, TA | 2 |
| Monge, OR | 1 |
| Strander, H | 2 |
| Turesson, I | 1 |
| Klepp, R | 1 |
| Söderberg, M | 1 |
| Wist, E | 1 |
| Raabe, N | 1 |
| Erlanson, M | 1 |
| Solheim, OP | 1 |
| Hannisdal, E | 1 |
| Palmeri, S | 1 |
| Antimi, M | 1 |
| Gatti, C | 2 |
| Raffo, P | 1 |
| Villani, G | 1 |
| Walter, AW | 1 |
| Shearer, PD | 1 |
| Greenwald, CA | 1 |
| Rao, BN | 2 |
| Bowman, LC | 1 |
| Furman, WL | 1 |
| Gajjar, A | 1 |
| Jenkins, JJ | 1 |
| Pratt, CB | 2 |
| Theis, JG | 1 |
| Chan, HS | 1 |
| Greenberg, ML | 1 |
| Malkin, D | 1 |
| Karaskov, V | 1 |
| Moncica, I | 1 |
| Koren, G | 1 |
| Doyle, J | 1 |
| Lévy, E | 1 |
| Thirion, P | 1 |
| Piedbois, P | 1 |
| Kito, M | 1 |
| Antón, A | 1 |
| García del Muro, J | 1 |
| Arranz, F | 1 |
| Valentí, V | 1 |
| Escudero, P | 1 |
| Menéndez, D | 1 |
| Bacchi, M | 1 |
| Lissoni, A | 1 |
| Bressoud, A | 1 |
| Hermann, R | 1 |
| Orlando, L | 1 |
| Nolè, F | 1 |
| Munzone, E | 1 |
| Zampino, MG | 1 |
| Fazio, N | 1 |
| Aapro, MS | 1 |
| Goldhirsch, A | 1 |
| Leone, L | 1 |
| Oliva, C | 1 |
| Monteleone, M | 1 |
| Colussi, AM | 1 |
| Dal Canton, O | 1 |
| Bergnolo, P | 1 |
| Boglione, A | 1 |
| Bumma, C | 1 |
| Yalçin, S | 1 |
| Fernberg, JO | 1 |
| Wiklund, T | 1 |
| Monge, O | 1 |
| Hall, KS | 1 |
| Marina, NM | 1 |
| Cain, AM | 1 |
| Poquette, CA | 1 |
| Greenwald, C | 1 |
| Meyer, WH | 1 |
| Hawkins, D | 1 |
| Radich, J | 1 |
| Shetty, AK | 1 |
| Yu, LC | 1 |
| Gardner, RV | 1 |
| Warrier, RP | 1 |
| Sawyer, M | 1 |
| Bramwell, V | 3 |
| Brodowicz, T | 2 |
| Köstler, WJ | 2 |
| Wiltschke, C | 1 |
| Zielinski, CC | 2 |
| Huuhtanen, RL | 1 |
| Wiklund, TA | 2 |
| Blomqvist, CP | 2 |
| Böhling, TO | 1 |
| Virolainen, MJ | 1 |
| Tribukait, B | 1 |
| Dinçol, D | 1 |
| Samur, M | 1 |
| Pamir, A | 1 |
| Sencan, O | 1 |
| Akbulut, H | 1 |
| Yalçin, B | 1 |
| Onur, H | 1 |
| Demirkazik, A | 1 |
| Senler, FC | 1 |
| Içli, F | 1 |
| Kerbusch, T | 1 |
| Huitema, AD | 1 |
| Ouwerkerk, J | 1 |
| Keizer, HJ | 1 |
| Mathôt, RA | 1 |
| Schellens, JH | 1 |
| Beijnen, JH | 1 |
| Pápai, Z | 1 |
| Bodoky, G | 1 |
| Szántó, J | 1 |
| Poller, I | 1 |
| Rahóty, P | 1 |
| Eckhardt, S | 1 |
| Láng, I | 1 |
| Szendroi, M | 1 |
| Kennedy, JG | 1 |
| Eustace, S | 1 |
| Caulfield, R | 1 |
| Fennelly, DJ | 1 |
| Hurson, B | 1 |
| O'Rourke, KS | 1 |
| Späth-Schwalbe, E | 1 |
| Genvresse, I | 1 |
| Koschuth, A | 1 |
| Dietzmann, A | 1 |
| Grunewald, R | 1 |
| Possinger, K | 1 |
| Gwyther, SJ | 1 |
| Judson, IR | 1 |
| Meric, F | 1 |
| Milas, M | 1 |
| Hunt, KK | 2 |
| Hess, KR | 1 |
| Pisters, PW | 2 |
| Hildebrandt, G | 1 |
| Papadopolous, NE | 1 |
| Feig, BW | 2 |
| Bouhour, D | 1 |
| Ray-Coquard, I | 1 |
| Dumontet, C | 2 |
| Philip, T | 2 |
| Biron, P | 2 |
| Lejeune, FJ | 1 |
| Pujol, N | 1 |
| Liénard, D | 1 |
| Mosimann, F | 1 |
| Raffoul, W | 1 |
| Genton, A | 1 |
| Landry, M | 1 |
| Chassot, PG | 1 |
| Chiolero, R | 1 |
| Bischof-Delaloye, A | 1 |
| Mirimanoff, RO | 1 |
| Bejkos, D | 1 |
| Leyvraz, PF | 1 |
| Nelson, SD | 2 |
| Gherlinzoni, F | 1 |
| Bonetti, M | 1 |
| Olmi, P | 1 |
| Pignatti, G | 1 |
| Barbieri, E | 1 |
| Apice, G | 1 |
| Zmerly, H | 1 |
| Serraino, D | 1 |
| Schneeweiss, A | 1 |
| Hensel, M | 1 |
| Goerner, R | 1 |
| Khbeis, T | 1 |
| Hohaus, S | 1 |
| Solomayer, E | 1 |
| Haas, R | 1 |
| Grischke, EM | 1 |
| Bastert, G | 1 |
| Thall, PF | 1 |
| Cheng, SC | 1 |
| Zeuli, M | 2 |
| Gamucci, T | 1 |
| Nardi, M | 1 |
| Mochizuki, K | 1 |
| Katayama, K | 1 |
| Kikuchi, F | 1 |
| Saito, I | 1 |
| Homori, M | 1 |
| Dorey, F | 1 |
| Lovett, BD | 1 |
| Lo Nigro, L | 1 |
| Rappaport, EF | 1 |
| Blair, IA | 1 |
| Osheroff, N | 1 |
| Zheng, N | 1 |
| Megonigal, MD | 1 |
| Williams, WR | 1 |
| Nowell, PC | 1 |
| Felix, CA | 1 |
| Papaldo, P | 1 |
| Pacetti, U | 1 |
| Attems, Y | 1 |
| Hejna, M | 1 |
| Tomek, S | 1 |
| Amann, G | 1 |
| Fiebiger, WC | 1 |
| Wiltschke, CH | 1 |
| Krainer, M | 1 |
| Cormier, JN | 1 |
| Herzog, CE | 1 |
| Ballo, MT | 1 |
| Raney, RB | 3 |
| Zagars, GK | 1 |
| Anderson, JR | 1 |
| Barr, FG | 1 |
| Donaldson, SS | 2 |
| Qualman, SJ | 1 |
| Wiener, ES | 1 |
| Maurer, HM | 2 |
| Crist, WM | 2 |
| Breitfeld, PP | 1 |
| Lyden, E | 1 |
| Teot, LA | 1 |
| Lobe, T | 1 |
| Petersen, IA | 1 |
| Shives, TC | 1 |
| Mahoney, MR | 1 |
| Rock, MG | 1 |
| Haddock, MG | 1 |
| Sim, FH | 1 |
| Maples, WJ | 1 |
| Gunderson, LL | 1 |
| Foo, ML | 1 |
| Pritchard, DJ | 1 |
| Buckner, JC | 1 |
| Stafford, SL | 1 |
| van Oosterom, A | 2 |
| Buesa, J | 1 |
| Van Glabekke, M | 1 |
| Bouffet, E | 1 |
| Meckenstock, R | 1 |
| Chauvin, F | 1 |
| Philip, I | 1 |
| Brunat-Mentigny, M | 1 |
| Antman, KH | 5 |
| Crasnier, F | 1 |
| Chouini-Lalanne, N | 1 |
| Virolainen, M | 1 |
| Elomaa, I | 1 |
| Sogno, G | 1 |
| Venturino, A | 1 |
| Bignami, P | 1 |
| Bonadonna, G | 1 |
| Weiss, RB | 1 |
| Pinkerton, CR | 1 |
| Stornes, I | 1 |
| Mejlholm, I | 1 |
| Jakobsen, A | 1 |
| Greifenberg, B | 1 |
| Soedirman, J | 1 |
| Shaw, PJ | 1 |
| Eden, T | 1 |
| Coialbu, T | 1 |
| Biassoni, L | 1 |
| Folco, U | 1 |
| Giacchero, A | 1 |
| Prenninger, SW | 1 |
| Nagele, A | 1 |
| Boehm, E | 1 |
| Sauer, H | 1 |
| Denecke, H | 1 |
| Berger, H | 1 |
| Peter, K | 1 |
| Zaidi, SH | 1 |
| Iqbal, Z | 1 |
| Mallick, JA | 1 |
| Küpfer, A | 1 |
| Zeugin, T | 1 |
| Brunner, KW | 1 |
| Zügel, M | 1 |
| Wingberg, D | 1 |
| Stewart, W | 2 |
| Dirix, LY | 2 |
| Budach, V | 1 |
| Scheulen, M | 1 |
| Czeglarski, G | 1 |
| Sherman, D | 1 |
| Willemse, PH | 1 |
| de Vries, EG | 1 |
| Sulkes, A | 1 |
| Collins, J | 1 |
| Aisner, J | 1 |
| Boven, E | 1 |
| Calame, JJ | 1 |
| Molthoff, CF | 1 |
| Pinedo, HM | 3 |
| Keim, M | 1 |
| Troxler, M | 1 |
| Quirt, I | 1 |
| Warr, D | 1 |
| Verma, S | 1 |
| Young, V | 1 |
| Knowling, M | 1 |
| Eisenhauer, E | 1 |
| Meanwell, CA | 1 |
| Blake, AE | 1 |
| Kelly, KA | 1 |
| Honigsberger, L | 1 |
| Westbury, G | 1 |
| Harmer, C | 1 |
| McKinna, A | 1 |
| Klein, HO | 1 |
| Dias Wickramanayake, P | 1 |
| Coerper, C | 1 |
| Christian, E | 1 |
| Cantwell, BM | 1 |
| Carmichael, J | 1 |
| Ghani, S | 1 |
| Harris, AL | 1 |
| Mansi, JL | 1 |
| MacMillan, S | 1 |
| King, M | 1 |
| Zamboglou, N | 1 |
| Fürst, G | 1 |
| Bannach, B | 1 |
| Molls, M | 1 |
| Cavalli, F | 1 |
| Verwey, J | 1 |
| von Oosterom, A | 1 |
| Hartlapp, JH | 2 |
| Münch, HJ | 2 |
| Illiger, HJ | 2 |
| Wolter, H | 2 |
| Jensen, JC | 2 |
| de Kraker, J | 1 |
| Voûte, PA | 1 |
| Magrath, I | 1 |
| Sandlund, J | 1 |
| Raynor, A | 1 |
| Rosenberg, S | 1 |
| Arasi, V | 1 |
| Brade, WP | 1 |
| Herdrich, K | 1 |
| Varini, M | 1 |
| Montella, D | 1 |
| Rosenbaum, C | 1 |
| Schwen, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Study of Pemetrexed Plus Cisplatin in Patients With Refractory Soft Tissue Sarcoma[NCT03809637] | Phase 2 | 37 participants (Actual) | Interventional | 2017-01-10 | Active, not recruiting | ||
| Analyzing Engagement Trends in Rhabdomyosarcoma Clinical Trials: A Study of Participation Patterns Among Those Affected by the Disorder[NCT06029465] | 500 participants (Anticipated) | Observational | 2024-10-31 | Not yet recruiting | |||
| Pegylated-liposome Doxorubicin Combined With Ifosfamide As First-line Treatment for Patients With Advanced or Metastatic Soft Tissue Sarcoma[NCT03268772] | Phase 2 | 40 participants (Actual) | Interventional | 2015-04-01 | Active, not recruiting | ||
| Interest of Peri Operative CHemotherapy In Patients With CINSARC High-risk Localized Soft Tissue Sarcoma[NCT04307277] | Phase 3 | 600 participants (Anticipated) | Interventional | 2020-10-09 | Recruiting | ||
| Randomized Study Comparing Neoadjuvant Chemotherapy Etoposide + Ifosfamide + Adriamycin (EIA) Combined With Regional Hyperthermia (RHT) Versus Neoadjuvant Chemotherapy Alone in the Treatment of High-Risk Soft Tissue Sarcomas in Adults[NCT00003052] | Phase 3 | 340 participants (Anticipated) | Interventional | 1997-07-31 | Completed | ||
| Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age[NCT00346164] | Phase 3 | 588 participants (Actual) | Interventional | 2007-02-05 | Completed | ||
| An Open-label, Dose Ranging Study to Assess the Safety, Efficacy, and Pharmacokinetics of an Oral Thrombopoietin Receptor Agonist (Eltrombopag) Administered to Subjects Receiving Adriamycin and Ifosfamide (AI) Regimen[NCT00358540] | Phase 1 | 18 participants (Actual) | Interventional | 2006-06-01 | Completed | ||
| An Evaluation of PET/CT Imaging as a Predictor of Disease Free Survival Following Neo-Adjuvant Chemotherapy for Soft Tissue Sarcoma[NCT00346125] | 70 participants (Actual) | Interventional | 2006-04-10 | Completed | |||
| A Phase II Multicenter Trial of RAD001 in Patients With Metastatic or Recurrent Sarcomas[NCT01830153] | Phase 2 | 41 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| A Phase II Trial of Apatinib in Relapsed and Unresectable High-grade Osteosarcoma After Failure of Standard Multimodal Therapy[NCT02711007] | Phase 2/Phase 3 | 37 participants (Actual) | Interventional | 2016-03-31 | Completed | ||
| Randomised Trial Of Single Agent Doxorubicin Versus Doxorubicin Plus Ifosfamide In The First Line Treatment Of Advanced Or Metastatic Soft Tissue Sarcoma[NCT00061984] | Phase 3 | 455 participants (Actual) | Interventional | 2003-04-30 | Completed | ||
| Trabectedin in Soft Tissue Sarcomas. A Retrospective Observational Analysis (TrObs)[NCT02793050] | 510 participants (Actual) | Observational | 2016-06-15 | Completed | |||
| RNASARC - Molecular Screening Program of Soft Tissue Sarcomas With Complex Genomic Profile to Detect NTRK1/2/3, ROS1 or ALK Gene Fusions.[NCT03375437] | 376 participants (Actual) | Interventional | 2018-02-15 | Active, not recruiting | |||
| A Phase II Study Evaluating Neo-/Adjuvant EIA Chemotherapy, Surgical Resection and Radiotherapy in High-risk Soft Tissue Sarcoma[NCT01382030] | Phase 2 | 50 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy[NCT01710176] | Phase 3 | 550 participants (Actual) | Interventional | 2011-06-01 | Active, not recruiting | ||
| A Randomised Phase-III Trial of the Cooperative Weichteilsarkom Study Group (CWS) for Localised High-risk Rhabdomyosarcoma and Localised Rhabdomyosarcoma-like Soft Tissue Sarcoma in Children, Adolescents, and Young Adults[NCT00876031] | Phase 3 | 195 participants (Actual) | Interventional | 2009-07-01 | Completed | ||
| The Use of Ifosfamide, Doxorubicin and Hypofractionated Radiotherapy in Neoadjuvant Treatment of High-grade Extremity Soft Tissue and Non-metastatic Sarcomas[NCT02812654] | Phase 2 | 70 participants (Anticipated) | Interventional | 2015-03-31 | Recruiting | ||
| Evaluation of Individual Radiosensitivity of Cancer Patients to be Treated by Radiotherapy or Radiochemotherapy Per-operative[NCT02797405] | 97 participants (Actual) | Interventional | 2016-10-31 | Terminated (stopped due to Withdrawal of analysis study Partner.) | |||
| First in Man Study Investigating the Biodistribution, the Safety and Optimal Recommended Dose of a New Radiolabelled Monoclonal Antibody Targeting Frizzled Homolog 10 (FZD10) in Patients With Relapsed or Refractory Non Resectable Synovial Sarcomas[NCT01469975] | Phase 1 | 20 participants (Actual) | Interventional | 2011-12-31 | Terminated (stopped due to Too slow accrual.) | ||
| A Phase II Trial In Which Patients With Metastatic Alveolar Soft Part Sarcoma Are Randomized to Either Sunitinib or Cediranib Monotherapy, With Cross-Over at Disease Progression[NCT01391962] | Phase 2 | 34 participants (Actual) | Interventional | 2011-07-18 | Active, not recruiting | ||
| Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft Tissue Sarcoma After Pre-treatment Failure: an Open-label, Multicenter Phase II Study[NCT01136499] | Phase 2 | 53 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| A Phase 2 Study of Cabozantinib (XL184), a Dual Inhibitor of MET and VEGFR, in Patients With Metastatic Refractory Soft Tissue Sarcoma[NCT01755195] | Phase 2 | 55 participants (Actual) | Interventional | 2013-01-15 | Active, not recruiting | ||
| Determination of Tumor Response Rate by RECIST and FDG-PET Criteria to Dacarbazine in Metastatic Soft Tissue and Bone Sarcoma[NCT00802880] | Phase 2 | 80 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| Comparing the Effectiveness and Toxicity for Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma Patients Who Had Received Total Dose of Anthracycline Antibiotics More Than 300mg/m2 With Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus[NCT03342300] | Phase 2/Phase 3 | 0 participants (Actual) | Interventional | 2017-11-06 | Withdrawn (stopped due to No participants enrolled) | ||
| A Pilot Study Investigating Neoadjuvant Temozolomide-based Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas[NCT00881595] | Phase 2 | 0 participants (Actual) | Interventional | 2009-02-28 | Withdrawn (stopped due to No patients accrued since study opened) | ||
| A Phase II Study on Preoperative Administration of Gleevec in Patients With Initially Non-Resectable Gastrointestinal Stromal Tumor[NCT00290485] | Phase 2 | 50 participants | Interventional | 2005-08-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Tumor response by imaging. Complete Response (CR): Complete disappearance of the tumor. Partial Response (PR): At least 64% decrease in volume compared to the measurement obtained at study enrollment. Overall Response (OR)=CR+PR. (NCT00346164)
Timeframe: 13 weeks
| Intervention | percentage of patients (Number) |
|---|---|
| Arm D | 33.1 |
Probability of no relapse, secondary malignancy or death after 5 years since enrollment. (NCT00346164)
Timeframe: 5 years
| Intervention | Probability (Number) |
|---|---|
| Non-metastatic | 0.7758 |
| Metastatic | 0.1960 |
Probability of no relapse, secondary malignancy or death after 5 years since enrollment (NCT00346164)
Timeframe: 5 years
| Intervention | Probability (Number) |
|---|---|
| Histologic Grade 1 | 0.9636 |
| Histologic Grade 2 | 0.8505 |
| Histologic Grade 3 | 0.6136 |
Percent of patients who had distant metastasis. (NCT00346164)
Timeframe: Up to 10 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Non-metastatic | 10.59 |
| Metastatic | 60.87 |
| Histologic Grade 1 | 0.00 |
| Histologic Grade 2 | 5.06 |
| Histologic Grade 3 | 23.38 |
Probability of survival after 5 years since enrollment. (NCT00346164)
Timeframe: 5 years
| Intervention | Probability (Number) |
|---|---|
| Non-metastatic | 0.8752 |
| Metastatic | 0.3153 |
Probability of survival after 5 years since enrollment. (NCT00346164)
Timeframe: 5 years
| Intervention | Probability (Number) |
|---|---|
| Less Than Total Resection | 0.5975 |
| Negative Margins | 0.9353 |
| Positive Margins | 0.7764 |
Percent tumor necrosis by pathology review. (NCT00346164)
Timeframe: 13 weeks
| Intervention | percentage of tumor necrosis (Mean) |
|---|---|
| Arm D | 59.4 |
Probability of no relapse, secondary malignancy or death after 5 years since enrollment. (NCT00346164)
Timeframe: 5 years
| Intervention | Probability of EFS at 5 years (Number) |
|---|---|
| Arm A: No Adjuvant Treatment | 0.8984 |
| Arm B: Low Risk; Adjuvant Radiotherapy | 0.7647 |
| Arm C: Intermediate & High Risk; Adjuvant Chemoradiotherapy | 0.6079 |
| Arm D: Intermediate & High Risk; Neoadjuvant Chemoradiotherapy | 0.4873 |
Percentage of Arm D patients experiencing grade 4+ adverse events. (NCT00346164)
Timeframe: 13 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Arm D | 3.06 |
POG and FNCLCC grades were determined by pathologists based on published standards. A higher grade is associated with a more severe disease. (NCT00346164)
Timeframe: At diagnosis
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Histologic grade 1 by POG | Histologic grade 2 by POG | Histologic grade 3 by POG | |
| Histologic Grade 1 by FNCLCC | 46 | 24 | 9 |
| Histologic Grade 2 by FNCLCC | 8 | 69 | 145 |
| Histologic Grade 3 by FNCLCC | 1 | 0 | 240 |
Histologic grades were determined by the central pathology reviewers and institutional pathologists based on published standards. A higher grade is associated with a more severe disease. (NCT00346164)
Timeframe: At Diagnosis
| Intervention | Participants (Number) | ||
|---|---|---|---|
| Histologic grade 1 by central pathology reviewers | Histologic grade 2 by central pathology reviewers | Histologic grade 3 by central pathology reviewers | |
| Histologic Grade 1 by Enrolling Institution | 38 | 4 | 3 |
| Histologic Grade 2 by Enrolling Institution | 5 | 56 | 10 |
| Histologic Grade 3 by Enrolling Institution | 1 | 9 | 268 |
Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01755195)
Timeframe: Date treatment consent signed to date off study, approximately 86 months and 3 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Cabozantinib | 53 |
Objective response was assessed by the Response Evaluation Criteria in Solid Tumors RECIST) v1.1. Complete Response is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Partial Response is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. (NCT01755195)
Timeframe: Date treatment consent signed to date off study, approximately 86 months and 3 days.
| Intervention | percentage of particpants (Number) |
|---|---|
| Cabozantinib | 11.1 |
Progression in participants with soft tissue sarcomas treated with cabozantinib was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Progression is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. The appearance of one or more new lesions is also considered progressions. (NCT01755195)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Cabozantinib | 49.3 |
Blood samples were collected before treatment on the first day of cycles 1 and 2 to determine circulating levels of HGF. HGF protein content (in picograms; pg) in blood plasma (in milliliters; mL) was measured for each sample with a two-site immunoassay and the difference from before to after treatment for each patient was reported. A change in this biomarker from the baseline value has not been linked to clinical outcomes; that is, it is neither a good or a bad outcome. (NCT01755195)
Timeframe: Baseline to Cycle 1 Day 1 and baseline to Cycle 2 Day 1
| Intervention | pg/mL (Mean) | |
|---|---|---|
| Baseline to Cycle 1 Day 1 | Baseline to Cycle 2 Day 1 | |
| Cabozantinib | -51.3 | 344.8 |
Blood samples were collected before treatment on the first day of cycles 1 and 2 to determine circulating levels of soluble MET (sMET). sMET protein content (in nanograms; ng) in blood plasma (in milliliters; mL) was measured for each sample with a two-site immunoassay and the difference from before to after treatment for each patient was reported. A change in this biomarker from the baseline value has not been linked to clinical outcomes; that is, it is neither a good or a bad outcome. (NCT01755195)
Timeframe: Baseline to Cycle 1 Day 1 and baseline to Cycle 2 Day 1
| Intervention | ng/mL (Mean) | |
|---|---|---|
| Baseline to Cycle 1 Day 1 | Baseline to Cycle 2 Day1 | |
| Cabozantinib | -6.1 | 16.4 |
Blood samples were collected before treatment on the first day of cycles 1 and 2 to determine circulating levels of soluble VEGFR2 (sVEGFR-2). sVEGFR-2 protein content (in nanograms; ng) in blood plasma (in milliliters; mL) was measured for each sample with a two-site immunoassay and the difference from before to after treatment for each patient was reported. A change in this biomarker from the baseline value has not been linked to clinical outcomes; that is, it is neither a good or a bad outcome.. (NCT01755195)
Timeframe: Baseline to Cycle 1 Day 1 and baseline to Cycle 2 Day 1
| Intervention | ng/mL (Mean) | |
|---|---|---|
| Baseline to Cycle 1 Day 1 | Baseline to Cycle 2 Day 1 | |
| Cabozantinib | -1.0 | -10.9 |
Blood samples were collected before treatment on the first day of cycles 1 and 2 to determine circulating levels of VEGF-A. VEGF-A protein content (in picograms; pg) in blood plasma (in milliliters; mL) was measured for each sample with a two-site immunoassay and the difference from before to after treatment for each patient was reported. A change in this biomarker from the baseline value has not been linked to clinical outcomes; that is, it is neither a good or a bad outcome. (NCT01755195)
Timeframe: Baseline to Cycle 1 Day 1 and baseline to Cycle 2 Day 1
| Intervention | pg/mL (Mean) | |
|---|---|---|
| Baseline to Cycle 1 Day 1 | Baseline to Cycle 2 Day 1 | |
| Cabozantinib | 5.6 | 32.5 |
(NCT00802880)
Timeframe: Until completion of follow-up or patient death (estimated to be 1 year)
| Intervention | months (Median) |
|---|---|
| Dacarbazine | 8.09 |
Approximately 18 weeks (NCT00802880)
Timeframe: Completion of 6 cycles of treatment (18 weeks)
| Intervention | percentage of participants (Number) |
|---|---|
| Dacarbazine | 22.5 |
"Grade 3 neutropenia = absolute neutrophil count of <1000 - 500/mm^3~Grade 4 neutropenia = absolute neutrophil count of <500/mm^3" (NCT00802880)
Timeframe: Completion of 6 cycles of treatment (18 weeks)
| Intervention | percentage of participants (Number) |
|---|---|
| Dacarbazine | 7.5 |
-Progression - At least a 20% increase in the sum of the longest diameter (LD) of target lesions taking as references the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. (NCT00802880)
Timeframe: Until completion of follow-up (estimated to be 1 year)
| Intervention | months (Median) |
|---|---|
| Dacarbazine | 2.07 |
"Complete response (CR): disappearance of all target lesions, disappearance of all non-target lesions, normalization of tumor level marker~Partial response (PR): at least 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD, persistence of one or more non-target lesion and/or maintenance of tumor marker level above the upper limits of normal~Stable disease (SD): neither sufficient shrinkage in target lesions to qualify for PR nor sufficient increase to qualify for progressive disease taking as references the smallest sum LD since the treatment started, persistence of one or more non-target lesion and/or maintenance of tumor marker level above the normal limits of normal~Progressive disease (PD): at least 20% increase in the sum of the LD of target lesions and/or appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions" (NCT00802880)
Timeframe: After completion of 3 cycles
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Complete response | Partial response | Stable disease | Progressive disease | |
| Dacarbazine | 0 | 2 | 22 | 30 |
(NCT00802880)
Timeframe: Baseline and after every three cycles of treatment (up to 1 year)
| Intervention | standard uptake value (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | End of cycle 3 | End of cycle 6 | End of cycle 9 | End of cycle 12 | |
| Dacarbazine | 7.42 | 7.57 | 7.7 | 6.89 | 7.48 |
(NCT00802880)
Timeframe: Completion of follow-up (estimated to be 1 year)
| Intervention | months (Median) | ||
|---|---|---|---|
| Partial response | Stable disease | Progressive disease | |
| Dacarbazine | 18.16 | 14.77 | 7.96 |
(NCT00802880)
Timeframe: Completion of follow-up (estimated to be 1 year)
| Intervention | months (Median) | ||
|---|---|---|---|
| Partial metabolic response | Stable metabolic disease | Progressive metabolic disease | |
| Dacarbazine | 18.16 | 18.59 | 8.75 |
-Progression - At least a 20% increase in the sum of the longest diameter (LD) of target lesions taking as references the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. (NCT00802880)
Timeframe: Completion of follow-up (estimated to be 1 year)
| Intervention | months (Median) | ||
|---|---|---|---|
| Partial response | Stable disease | Progressive disease | |
| Dacarbazine | NA | 4.14 | 1.97 |
(NCT00802880)
Timeframe: After completion of 3 cycles
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| PR | SD | PD | Total | |
| Partial Metabolic Response | 1 | 2 | 1 | 4 |
| Progressive Metabolic Disease | 1 | 8 | 24 | 33 |
| Stable Metabolic Disease | 0 | 10 | 2 | 12 |
| Total | 2 | 20 | 27 | 49 |
-Progression - At least a 20% increase in the sum of the longest diameter (LD) of target lesions taking as references the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. (NCT00802880)
Timeframe: Completion of follow-up (estimated to be 1 year)
| Intervention | months (Median) | ||
|---|---|---|---|
| Partial metabolic response | Stable metabolic disease | Progressive metabolic disease | |
| Dacarbazine | 3.95 | 5.30 | 2.07 |
(NCT00802880)
Timeframe: 12 months
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Complete response | Partial response | Stable disease | Progressive disease | |
| Dacarbazine | 0 | 0 | 5 | 1 |
"Complete metabolic response (CMR)-complete resolution of all metabolically active target and non-target lesions, and no interval development of new lesions.~Partial metabolic response (PMR)~Target lesions: 20% or greater decrease in maximum SUV from baseline. No unequivocal metabolic progression of non-target disease, and no unequivocal new lesions.~Non-target lesions: decrease in total number of non-target lesions, without complete resolution of metabolically active disease, or unequivocal decrease in degree of FDG activity within >50% of the lesions. No unequivocal new lesions.~Stable metabolic disease (SMD): does not qualify for CMR, PMR, or PMD.~Progressive metabolic disease (PMD):~Unequivocal development of one more new metabolically active lesions~Target lesion: 20% or greater increase in maximum SUV from baseline.~Non-target lesions: unequivocal increase in FDG activity" (NCT00802880)
Timeframe: After completion of 3 cycles
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| CMR | PMR | SMD | PMD | |
| Dacarbazine | 0 | 4 | 13 | 34 |
49 reviews available for ifosfamide and Soft Tissue Neoplasms
| Article | Year |
|---|---|
The Biology of Synovial Sarcoma: State-of-the-Art and Future Perspectives.
Topics: Anthracyclines; Antineoplastic Agents; Chemotherapy, Adjuvant; Epigenomics; Gene Expression Regulati | 2021 |
Hyperthermia in the treatment of high-risk soft tissue sarcomas: a systematic review.
Topics: Combined Modality Therapy; Humans; Hyperthermia, Induced; Ifosfamide; Sarcoma; Soft Tissue Neoplasms | 2023 |
What is the standard indication of adjuvant or neoadjuvant chemotherapy in localized soft-tissue sarcoma?
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Tri | 2021 |
Fifty years of rhabdomyosarcoma studies on both sides of the pond and lessons learned.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Dactinomycin; Europe; Human | 2018 |
Selection of Patients With Localized Extremity Soft Tissue Sarcoma for Treatment With Perioperative Chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; D | 2018 |
[Multimodal treatment of sarcomas: standards and new aspects in pharmacological and radio-oncological treatment].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; H | 2019 |
Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients.
Topics: Adult; Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Cyclophosphamide; Humans; Ifosfamid | 2015 |
Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Tr
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Epid | 2010 |
Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Tr
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Epid | 2010 |
Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Tr
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Epid | 2010 |
Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Tr
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Epid | 2010 |
Palifosfamide, a bifunctional alkylator for the treatment of sarcomas.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Clinical Trials as Topic; Drug Evaluation, Preclinic | 2010 |
Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients.
Topics: Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Cyclophosphamide; Humans; Ifosfamide; Sarc | 2010 |
[Chemotherapy options for patients with advanced soft-tissue sarcoma beyond anthracyclines].
Topics: Antineoplastic Agents; Dacarbazine; Deoxycytidine; Dioxoles; Docetaxel; Doxorubicin; Gemcitabine; Hu | 2010 |
Metastatic soft tissue sarcoma chemotherapy: an opportunity for personalized medicine.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Doxorubici | 2011 |
Leiomyosarcoma of the tongue with multiple metastases: a case report and review of literature.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy | 2012 |
Systemic management strategies for metastatic soft tissue sarcoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dioxoles; Doxo | 2011 |
The activity of the Bone and Soft Tissue Tumor Study Group of the Japan Clinical Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; Cisplatin; C | 2012 |
Ifosfamide, carboplatin, and etoposide for neuroblastoma: a high-dose salvage regimen and review of the literature.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Carboplati | 2013 |
Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients.
Topics: Adult; Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Cyclophosphamide; Humans; Ifosfamid | 2012 |
A chemosensitive pediatric extraosseous osteosarcoma: case report and review of the literature.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Doxorubicin; Female; Human | 2003 |
[Soft tissue sarcoma: postoperative chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality Therapy; Cyclophos | 2004 |
[Current strategy of chemotherapy for reflactory bone and soft tissue sarcomas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Carboplatin; Cisplatin; | 2004 |
Emerging treatments for soft tissue sarcoma of adults.
Topics: Adult; Antineoplastic Agents; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Ther | 2004 |
Bilateral metastatic renal synovial sarcoma.
Topics: Amputation, Surgical; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Female; Forearm; | 2005 |
Malignant ectomesenchymoma in the wrist of a child: case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin | 2005 |
The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas.
Topics: Adult; Antineoplastic Agents; Clinical Trials as Topic; Disease Progression; Doxorubicin; Drug Thera | 2007 |
Ifosfamide: European perspective.
Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Administrat | 1982 |
Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Implications for decision making in the clinic.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clini | 1995 |
Preoperative therapy for soft tissue sarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials a | 1995 |
[Chemotherapy for soft tissue sarcoma--current concepts and review].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Doxorubicin; Humans; Ifosfam | 1993 |
Single-agent ifosfamide studies in sarcomas of soft tissue and bone: the M.D. Anderson experience.
Topics: Acetylcysteine; Bone Neoplasms; Fluid Therapy; Humans; Ifosfamide; Mesna; Randomized Controlled Tria | 1993 |
Perspectives on anthracyclines plus ifosfamide in advanced soft tissue sarcomas.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase | 1993 |
High-dose ifosfamide in the treatment of sarcomas of soft tissues and bone.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; C | 1996 |
[Locally developed sarcoma of the thoracic wall].
Topics: Antineoplastic Combined Chemotherapy Protocols; Back; Chemotherapy, Adjuvant; Combined Modality Ther | 1996 |
[Adjuvant chemotherapy of soft tissue sarcoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dacarbazine; Doxorubicin; Fo | 1997 |
Chemotherapy in soft tissue sarcoma. The Scandinavian Sarcoma Group experience.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; | 1999 |
The treatment of distant metastases in soft tissue sarcoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Combined Modality | 1999 |
Extraskeletal Ewing's sarcoma: a case report and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cervical Vertebrae; Combined Modality Therapy | 2000 |
Concurrent ifosfamide-based chemotherapy and irradiation. Analysis of treatment-related toxicity in 43 patients with sarcoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Child, Preschool; Combined Mo | 2001 |
Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisplatin; Clin | 2001 |
Experience with ifosfamide in the EORTC Soft Tissue and Bone Sarcoma Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Europe; Humans; Ifosfamide; Sarcoma; | 1992 |
The clinical management of soft tissue sarcomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Doxorubicin; Humans; Ifosfam | 1992 |
Chemotherapy of advanced sarcomas of bone and soft tissue.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Clinical Trials as Topic; Dacarbazin | 1992 |
Doxorubicin (or epidoxorubicin) combined with ifosfamide in the treatment of adult advanced soft tissue sarcomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Epirubicin; Humans; Ifosfamide; Sarcoma | 1992 |
Megatherapy for soft tissue sarcomas. EBMT experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cyclophosphamide; Dacti | 1991 |
Ifosfamide in paediatric oncology: tried but not tested?
Topics: Child; Cyclophosphamide; Evaluation Studies as Topic; Humans; Ifosfamide; Neoplasms; Prognosis; Sarc | 1990 |
The role of ifosfamide in the treatment of adult soft tissue sarcomas, Ewing's sarcoma, and osteosarcoma: a review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Ifosfamide; Osteosarcoma; Sarcoma; Sarcoma, | 1990 |
The role of ifosfamide in the treatment of sarcomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Humans; Ifosfamide; Osteosarcoma; Sarcoma; Sa | 1989 |
Chemotherapy of advanced soft-tissue sarcomas.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; Dru | 1988 |
The treatment of soft tissue sarcomas with focus on chemotherapy: a review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; | 1986 |
Ifosfamide--pharmacology, safety and therapeutic potential.
Topics: Animals; Biotransformation; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Evalu | 1985 |
104 trials available for ifosfamide and Soft Tissue Neoplasms
| Article | Year |
|---|---|
Pemetrexed plus cisplatin in patients with previously treated advanced sarcoma: a multicenter, single-arm, phase II trial.
Topics: Cisplatin; Humans; Ifosfamide; Pemetrexed; Sarcoma; Soft Tissue Neoplasms | 2021 |
Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Humans; Ifosfamide; N | 2022 |
Long-term results from the multicentric European randomized phase 3 trial CWS/RMS-96 for localized high-risk soft tissue sarcoma in children, adolescents, and young adults.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Dactinomycin; Doxorubicin; Humans | 2022 |
Perioperative Adriamycin plus ifosfamide vs. gemcitabine plus docetaxel for high-risk soft tissue sarcomas: randomised, phase II/III study JCOG1306.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Doxorubicin; Febrile Neutr | 2022 |
Pegylated Liposomal Doxorubicin Combined with Ifosfamide for Treating Advanced or Metastatic Soft-tissue Sarcoma: A Prospective, Single-arm Phase II Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Humans; Ifosfamide; Neoplasms, Second P | 2022 |
Value of peri-operative chemotherapy in patients with CINSARC high-risk localized grade 1 or 2 soft tissue sarcoma: study protocol of the target selection phase III CHIC-STS trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Doxorubicin; Hum | 2020 |
Combined Preoperative Hypofractionated Radiotherapy With Doxorubicin-Ifosfamide Chemotherapy in Marginally Resectable Soft Tissue Sarcomas: Results of a Phase 2 Clinical Trial.
Topics: Adult; Aged; Dose Fractionation, Radiation; Doxorubicin; Female; Humans; Ifosfamide; Male; Middle Ag | 2021 |
Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 2018 |
Phase II trial of ifosfamide in combination with the VEGFR inhibitor sorafenib in advanced soft tissue sarcoma: a Spanish group for research on sarcomas (GEIS) study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Fema | 2018 |
Clinical features and outcomes of young patients with epithelioid sarcoma: an analysis from the Children's Oncology Group and the European paediatric soft tissue Sarcoma Study Group prospective clinical trials.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined | 2019 |
Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Dose- | 2013 |
Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Bone Neoplasms; E | 2013 |
Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Bone Neoplasms; E | 2013 |
Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Bone Neoplasms; E | 2013 |
Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Bone Neoplasms; E | 2013 |
Chemotherapy, Irradiation, and Surgery for Function-preserving Curative Therapy of Primary Extremity Soft Tissue Sarcomas: Initial Treatment With I-MAP and Inhalation GM-CSF During Preoperative Irradiation and Postoperatively.
Topics: Administration, Inhalation; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 2016 |
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free | 2014 |
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free | 2014 |
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free | 2014 |
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free | 2014 |
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free | 2014 |
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free | 2014 |
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free | 2014 |
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free | 2014 |
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free | 2014 |
Excellent local control with IOERT and postoperative EBRT in high grade extremity sarcoma: results from a subgroup analysis of a prospective trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemothe | 2014 |
A randomized phase II/III trial of perioperative chemotherapy with adriamycin plus ifosfamide versus gemcitabine plus docetaxel for high-grade soft tissue sarcoma: Japan Clinical Oncology Group Study JCOG1306.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; D | 2014 |
Carboplatin in the treatment of Ewing sarcoma: Results of the first Brazilian collaborative study group for Ewing sarcoma family tumors-EWING1.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brazil; Carboplatin; Chi | 2015 |
A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; | 2015 |
Feasibility of Preoperative Chemotherapy With or Without Radiation Therapy in Localized Soft Tissue Sarcomas of Limbs and Superficial Trunk in the Italian Sarcoma Group/Grupo Español de Investigación en Sarcomas Randomized Clinical Trial: Three Versus Fiv
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 2015 |
Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined | 2009 |
Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dise | 2009 |
Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; | 2009 |
Comparison of radiological and pathohistological response to neoadjuvant chemotherapy combined with regional hyperthermia (RHT) and study of response dependence on the applied thermal parameters in patients with soft tissue sarcomas (STS).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Com | 2009 |
Comparison of radiological and pathohistological response to neoadjuvant chemotherapy combined with regional hyperthermia (RHT) and study of response dependence on the applied thermal parameters in patients with soft tissue sarcomas (STS).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Com | 2009 |
Comparison of radiological and pathohistological response to neoadjuvant chemotherapy combined with regional hyperthermia (RHT) and study of response dependence on the applied thermal parameters in patients with soft tissue sarcomas (STS).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Com | 2009 |
Comparison of radiological and pathohistological response to neoadjuvant chemotherapy combined with regional hyperthermia (RHT) and study of response dependence on the applied thermal parameters in patients with soft tissue sarcomas (STS).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Com | 2009 |
Optimizing clinical care in patients with advanced soft tissue sarcoma: a phase II study of a new schedule of high-dose continuous infusion ifosfamide and doxorubicin combination.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Schedu | 2011 |
A phase II study evaluating neo-/adjuvant EIA chemotherapy, surgical resection and radiotherapy in high-risk soft tissue sarcoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modali | 2011 |
Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplas | 2012 |
Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Disease Progression; Dose-Response Relationship, Dru | 2002 |
[Preliminary result of advanced soft tissue sarcoma treated by MAID regimen].
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; Fem | 2002 |
Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Dox | 2003 |
Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Cross-Over Studies; Female; Hu | 2003 |
Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS).
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined | 2004 |
Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemothe | 2004 |
Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma.
Topics: Adolescent; Adult; Aged; Anemia; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Ant | 2005 |
Combination chemotherapy of docetaxel, ifosfamide and cisplatin (DIP) in patients with metastatic urothelial cancer: a preliminary report.
Topics: Aged; Aged, 80 and over; Agranulocytosis; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bo | 2005 |
Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; Doxoru | 2005 |
Alternating sequential chemotherapy with high-dose ifosfamide and doxorubicin/cyclophosphamide for adult non-small round cell soft tissue sarcomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; | 2005 |
Full-dose ifosfamide can be safely administered to outpatients.
Topics: Adolescent; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool | 2008 |
Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, | 2006 |
Efficacy of consolidation high-dose chemotherapy with ifosfamide, carboplatin and etoposide (HD-ICE) followed by autologous peripheral blood stem cell rescue in chemosensitive patients with metastatic soft tissue sarcomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Etopo | 2006 |
Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma.
Topics: Antineoplastic Agents, Alkylating; Area Under Curve; Breath Tests; Cytochrome P-450 CYP3A; Cytochrom | 2007 |
Treatment of children with metastatic soft tissue sarcoma with oral maintenance compared to high dose chemotherapy: report of the HD CWS-96 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Cyclophosphami | 2008 |
Histologic response of dose-intense chemotherapy with preoperative hypofractionated radiotherapy for patients with high-risk soft tissue sarcomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dose Fractio | 2008 |
Ifosfamide: European perspective.
Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Administrat | 1982 |
[Preliminary evaluation of the effectiveness of holoxan in the treatment of malignant soft tissue and bone neoplasms].
Topics: Adolescent; Adult; Antineoplastic Agents; Bone Neoplasms; Child; Child, Preschool; Clinical Trials a | 1981 |
Cyclophosphamide dose escalation in combination with vincristine and actinomycin-D (VAC) in gross residual sarcoma. A pilot study without hematopoietic growth factor support evaluating toxicity and response.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cyclophosphamide; Dact | 1995 |
Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Double-Blind Met | 1995 |
[Ifosfamide-induced hemorrhagic cystitis and its prevention by mesna].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; | 1995 |
Renal toxicity of ifosfamide in pilot regimens of the intergroup rhabdomyosarcoma study for patients with gross residual tumor.
Topics: Acute Kidney Injury; Adolescent; Adult; Chemotherapy, Adjuvant; Child; Child, Preschool; Creatinine; | 1994 |
[Value of neoadjuvant radiochemotherapy in undifferentiated soft tissue sarcomas].
Topics: Adjuvants, Immunologic; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemothe | 1994 |
Ambulatory continuous infusion ifosfamide with oral etoposide in advanced sarcomas.
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; | 1993 |
Epirubicin and ifosfamide in advanced soft tissue sarcomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Feasibility Stu | 1993 |
Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases | 1993 |
Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases | 1993 |
Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases | 1993 |
Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases | 1993 |
Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases | 1993 |
Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases | 1993 |
Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases | 1993 |
Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases | 1993 |
Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases | 1993 |
An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neo | 1993 |
An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neo | 1993 |
An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neo | 1993 |
An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neo | 1993 |
Phase II evaluation of doxorubicin, ifosfamide, and dacarbazine plus amphotericin B in the treatment of metastatic soft tissue sarcomas. A pilot study.
Topics: Adolescent; Adult; Amphotericin B; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxo | 1993 |
Synovial sarcoma. A study of intensive chemotherapy in 14 patients with localized disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin | 1993 |
Cyclophosphamide versus ifosfamide: a randomized phase II trial in adult soft-tissue sarcomas. The European Organization for Research and Treatment of Cancer [EORTC], Soft Tissue and Bone Sarcoma Group.
Topics: Adolescent; Adult; Aged; Chi-Square Distribution; Cyclophosphamide; Female; Humans; Ifosfamide; Leuk | 1993 |
Ifosfamide plus doxorubicin in previously untreated patients with advanced soft-tissue sarcoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administr | 1993 |
Preoperative doxorubicin plus ifosfamide in primary soft-tissue sarcomas of the extremities.
Topics: Actuarial Analysis; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arm; Ch | 1993 |
Phase II trial of ifosfamide and cisplatin in the treatment of metastatic sarcomas: a Southwest Oncology Group study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cispl | 1993 |
Efficacy of ifosfamide in combination with doxorubicin for the treatment of metastatic soft-tissue sarcoma. The Eastern Cooperative Oncology Group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Drug Administration S | 1993 |
Epirubicin and ifosfamide in advanced soft tissue sarcoma: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Epirubici | 1993 |
Chemotherapy administration and data collection in an EORTC collaborative group--can we trust the results?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Data Collection; Doxorubicin; Granulocyte-Mac | 1993 |
High-dose ifosfamide in the treatment of advanced soft tissue sarcomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dose-Response Relationship, Drug; Female; Humans; If | 1996 |
Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cyclophosp | 1996 |
Ifosfamide nephrotoxicity: limited influence of metabolism and mode of administration during repeated therapy in paediatrics.
Topics: Acute Disease; Adolescent; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Chronic Disea | 1996 |
The use of recombinant human granulocyte colony-stimulating factor in combination with single or fractionated doses of ifosfamide and doxorubicin in patients with advanced soft tissue sarcoma.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplas | 1996 |
Phenobarbital administration does not affect high-dose ifosfamide pharmacokinetics in humans.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Area Under Curve; Chromatography, High Pressur | 1996 |
[High dose ifosfamide at 15 g/m2/cycle: a feasibility study in 10 patients].
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents, Alkylating; Clonazepam; Dose-Response Relations | 1997 |
High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Bone Neoplasms; Dose-Response Relationsh | 1997 |
Ifosfamide and continuous infusion etoposide in advanced adult soft tissue sarcoma. A Scandinavian Sarcoma Group Phase II Study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Th | 1997 |
Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Drug Administration Schedule; Female; Granulocyte Co | 1997 |
A pilot study of vincristine, ifosfamide, and doxorubicin in the treatment of pediatric non-rhabdomyosarcoma soft tissue sarcomas.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Child; Child, Pr | 1998 |
Increased systemic toxicity of sarcoma chemotherapy due to combination with the P-glycoprotein inhibitor cyclosporin.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Membe | 1998 |
Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS)
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Female; Granulocyte-Macrophage Colony-Stimulating Fa | 1998 |
Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas. Swiss Group for Clinical Research (SAKK).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Dose-Respon | 1998 |
High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: is it feasible?
Topics: Adolescent; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Feasib | 1998 |
Chemotherapy dose-intensification for pediatric patients with Ewing's family of tumors and desmoplastic small round-cell tumors: a feasibility study at St. Jude Children's Research Hospital.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 1999 |
Role of chemotherapy in the treatment of infantile fibrosarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Dactinomycin; Disease | 1999 |
Prospective randomized comparison of morning versus night daily single subcutaneous administration of granulocyte-macrophage-colony stimulating factor in patients with soft tissue or bone sarcoma.
Topics: Adult; Anti-Bacterial Agents; Antineoplastic Agents, Alkylating; Bone Neoplasms; Chi-Square Distribu | 2000 |
Evaluation of the autoinduction of ifosfamide metabolism by a population pharmacokinetic approach using NONMEM.
Topics: Adult; Aged; Algorithms; Antineoplastic Agents, Alkylating; Area Under Curve; Computer Simulation; F | 2000 |
The efficacy of a combination of etoposide, ifosfamide, and cisplatin in the treatment of patients with soft tissue sarcoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule | 2000 |
Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Doxorubicin; Drug Therapy, Combination; | 2000 |
Radiologist review versus group peer review of claimed responses in a phase II study on high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the EORTC Soft Tissue and Bone Sarcoma Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Humans; Ifosfamide; Middle Aged; Peer Re | 2000 |
High-dose chemotherapy with autologous hematopoietic stem-cell transplantation for advanced soft tissue sarcoma in adults.
Topics: Adolescent; Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combin | 2000 |
Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chemotherapy, C | 2000 |
Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dis | 2001 |
A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule.
Topics: Adolescent; Adult; Aged; Alopecia; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemot | 2001 |
Ifosfamide and epirubicin combination in untreated sarcomas: two treatment schedules.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, | 2001 |
Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: results of a phase II trial.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Child; Child, Preschool; Disease Pro | 2001 |
Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bronchiolit | 2001 |
Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony-stimulating factor.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined | 2002 |
Experience with ifosfamide in the EORTC Soft Tissue and Bone Sarcoma Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Europe; Humans; Ifosfamide; Sarcoma; | 1992 |
Ifosfamide, vincristine, doxorubicin and dacarbazine in adult patients with advanced soft-tissue sarcoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; Drug Administ | 1992 |
Doxorubicin (or epidoxorubicin) combined with ifosfamide in the treatment of adult advanced soft tissue sarcomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Epirubicin; Humans; Ifosfamide; Sarcoma | 1992 |
Doxorubicin plus ifosfamide with rhGM-CSF in the treatment of advanced adult soft-tissue sarcomas: preliminary results of a phase II study from the EORTC Soft-Tissue and Bone Sarcoma Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Evaluation; Female; G | 1991 |
Epidoxorubicin plus ifosfamide in advanced and/or metastatic soft-tissue sarcomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, | 1990 |
Ifosfamide in soft tissue sarcoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Dactinomycin; Doxorubicin; Etoposide; | 1990 |
Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Clinical Trials as Topic; Female; Hematuria; Human | 1989 |
Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Bra | 1989 |
Comparison of the rates of response to ifosfamide and cyclophosphamide in primary unresectable rhabdomyosarcomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Dactinom | 1989 |
Cyclophosphamide versus ifosfamide: preliminary report of a randomized phase II trial in adult soft tissue sarcomas.
Topics: Adolescent; Adult; Aged; Cyclophosphamide; Drug Evaluation; Female; Humans; Ifosfamide; Infections; | 1986 |
The treatment of soft tissue sarcomas with focus on chemotherapy: a review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; | 1986 |
Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas.
Topics: Adolescent; Adult; Aged; Cyclophosphamide; Drug Evaluation; Female; Humans; Ifosfamide; Male; Middle | 1987 |
Ifosfamide--pharmacology, safety and therapeutic potential.
Topics: Animals; Biotransformation; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Evalu | 1985 |
138 other studies available for ifosfamide and Soft Tissue Neoplasms
| Article | Year |
|---|---|
There is more to soft tissue sarcomas than just grade and size.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Ifosfamide; Sarcoma; Soft Tissue Neoplasms | 2022 |
The role of Ifosfamide-doxorubicin chemotherapy in histology-specific, high grade, locally advanced soft tissue sarcoma, a 14-year experience.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Humans; Ifosfamide; Retrospectiv | 2021 |
Standardization of evaluation method and prognostic significance of histological response to preoperative chemotherapy in high-grade non-round cell soft tissue sarcomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Doxorubicin; Dr | 2022 |
The role of perioperative chemotherapy in primary high-grade extremity soft tissue sarcoma: a risk-stratified analysis using PERSARC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Extremities; Humans; Ifosfamide; Retrospective Studi | 2022 |
Management of elderly patients with bone and soft tissue sarcomas: JCOG Bone and Soft Tissue Tumor Study Group.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Doxorubicin; Humans; Ifosfamid | 2022 |
Pregnancy outcomes related to the treatment of sarcomas with anthracyclines and/or ifosfamide during pregnancy.
Topics: Adolescent; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protoc | 2022 |
Prediction of the therapeutic efficacy of epirubicin combined with ifosfamide in patients with lung metastases from soft tissue sarcoma based on contrast-enhanced CT radiomics features.
Topics: Epirubicin; Humans; Ifosfamide; Lung Neoplasms; Retrospective Studies; Sarcoma; Soft Tissue Neoplasm | 2022 |
Clear cell sarcoma of soft tissue with plasmacytoid morphology: A rare case report.
Topics: Adolescent; Doxorubicin; Extremities; Humans; Ifosfamide; Male; Sarcoma, Clear Cell; Soft Tissue Neo | 2022 |
Rare presentation in a rare case of pancreatic extraosseous Ewing's sarcoma: A case report.
Topics: Adolescent; Cyclophosphamide; Dysuria; Epirubicin; Etoposide; Flank Pain; Humans; Ifosfamide; Male; | 2022 |
Rare presentation in a rare case of pancreatic extraosseous Ewing's sarcoma: A case report.
Topics: Adolescent; Cyclophosphamide; Dysuria; Epirubicin; Etoposide; Flank Pain; Humans; Ifosfamide; Male; | 2022 |
Rare presentation in a rare case of pancreatic extraosseous Ewing's sarcoma: A case report.
Topics: Adolescent; Cyclophosphamide; Dysuria; Epirubicin; Etoposide; Flank Pain; Humans; Ifosfamide; Male; | 2022 |
Rare presentation in a rare case of pancreatic extraosseous Ewing's sarcoma: A case report.
Topics: Adolescent; Cyclophosphamide; Dysuria; Epirubicin; Etoposide; Flank Pain; Humans; Ifosfamide; Male; | 2022 |
Epirubicin, cisplatin plus ifosfamide versus standard chemotherapeutic regimens for advanced/unresectable primary thoracic sarcomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Humans; Ifosfamide; Prospecti | 2023 |
Epirubicin, cisplatin plus ifosfamide versus standard chemotherapeutic regimens for advanced/unresectable primary thoracic sarcomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Humans; Ifosfamide; Prospecti | 2023 |
Epirubicin, cisplatin plus ifosfamide versus standard chemotherapeutic regimens for advanced/unresectable primary thoracic sarcomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Humans; Ifosfamide; Prospecti | 2023 |
Epirubicin, cisplatin plus ifosfamide versus standard chemotherapeutic regimens for advanced/unresectable primary thoracic sarcomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Humans; Ifosfamide; Prospecti | 2023 |
Strategies for the Treatment of Infantile Soft Tissue Sarcomas With BCOR Alterations.
Topics: Biomarkers, Tumor; Carboplatin; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Ifosfamide; Infant | 2023 |
Efficacy of second and third lines of treatment in advanced soft tissue sarcomas: a real-world study.
Topics: Dacarbazine; Deoxycytidine; Gemcitabine; Humans; Ifosfamide; Retrospective Studies; Sarcoma; Soft Ti | 2023 |
Perspectives of Cell Sensitivity/Resistance Assay in Soft Tissue Sarcomas Chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Humans; Ifosfamide; Sarcoma; Soft Tissu | 2023 |
Outcomes of extraskeletal vs. skeletal Ewing sarcoma patients treated with standard chemotherapy protocol.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality Therapy; Cyclophos | 2020 |
Doxorubicin and Olaratumab Versus Doxorubicin, Ifosfamide, and Mesna for Treatment of Advanced Soft Tissue Sarcomas.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antineoplastic Combined Chemothera | 2020 |
A case of spindle cell dominant histiocytic sarcoma showing a complete remission after first-line chemotherapy with doxorubicin and ifosfamide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Doxorubicin; Histiocytic Sarc | 2020 |
[A Case of Primary Ewing Sarcoma of the Kidney Treated with Multidisciplinary Approach].
Topics: Female; Homeobox Protein Nkx-2.2; Homeodomain Proteins; Humans; Ifosfamide; In Situ Hybridization, F | 2020 |
Primary dedifferentiated Liposarcoma of vagina: a first case report.
Topics: Adult; Antineoplastic Agents; Disease-Free Survival; Doxorubicin; Drug Therapy, Combination; Female; | 2021 |
Apatinib with doxorubicin and ifosfamide as neoadjuvant therapy for high-risk soft tissue sarcomas: a retrospective cohort study.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant | 2021 |
Adjuvant and neoadjuvant chemotherapy for osteosarcoma: JCOG Bone and Soft Tissue Tumor Study Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; Cisplatin; D | 2021 |
Long-Term Risk of Subsequent Malignant Neoplasms After Treatment of Childhood Cancer in the DCOG LATER Study Cohort: Role of Chemotherapy.
Topics: Adolescent; Adult; Adult Survivors of Child Adverse Events; Aged; Antineoplastic Agents; Bone Neopla | 2017 |
Establishment of a spontaneously transformed cell line (JU-PI) from a myxoinflammatory fibroblastic sarcoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Transformed; Cell Proliferation; D | 2018 |
The Value of Neoadjuvant Chemotherapy in Localized High-Risk Soft-Tissue Sarcoma of the Extremities and Trunk.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Extremities; | 2018 |
ASO Author Reflections: Chemoradiation for High-Risk Soft Tissue Sarcomas.
Topics: Chemoradiotherapy; Epirubicin; Humans; Ifosfamide; Sarcoma; Soft Tissue Neoplasms | 2018 |
Prognostic implication of adjuvant/neoadjuvant chemotherapy consisting of doxorubicin and ifosfamide in patients with extraskeletal osteosarcoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; | 2019 |
Effect of concurrent chemotherapy and hyperthermia on outcome of preoperative radiotherapy of high-risk soft tissue sarcomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Combined Modal | 2013 |
Chemotherapy influences the pseudocapsule composition in soft tissue sarcomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy; | 2014 |
Extraskeletal Osteosarcoma: An International Rare Cancer Network Study.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protoc | 2016 |
[End-stage renal disease after sarcoma therapy - case 3/2014].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Diagnosis, Differential | 2014 |
The Impact of Perioperative Chemotherapy Timing in Conjunction With Postoperative External-Beam Radiation Therapy on Extremity Soft-Tissue Sarcomas Outcome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemorad | 2016 |
Extraskeletal myxoid chondrosarcoma of the thigh in a child: a case report.
Topics: Amputation, Surgical; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Chondrosar | 2014 |
A retrospective analysis of lung metastasis in 64 patients with alveolar soft part sarcoma.
Topics: Adolescent; Adult; Age Factors; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Chem | 2015 |
Trabectedin clinical cases: use according to indication in diverse clinical scenarios.
Topics: Anthracyclines; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; C | 2015 |
Should High-grade Extraosseous Osteosarcoma Be Treated With Multimodality Therapy Like Other Soft Tissue Sarcomas?
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; | 2015 |
Successful Ifosfamide Rechallenge in Soft-Tissue Sarcoma.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Cohort Studies; Databases, Factual; Disease | 2018 |
Adjuvant chemotherapy for soft tissue sarcomas: a 10-year mono-institutional experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2016 |
Pilot Study of Adding Vincristine, Topotecan, and Cyclophosphamide to Interval-Compressed Chemotherapy in Newly Diagnosed Patients With Localized Ewing Sarcoma: A Report From the Children's Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cyclophosphamide; Doxorubicin | 2016 |
Effective local control of advanced soft tissue sarcoma with neoadjuvant chemoradiotherapy and surgery: A single institutional experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Doxorubici | 2016 |
Singapore Cancer Network (SCAN) Guidelines for the Initial Evaluation, Diagnosis, and Management of Extremity Soft Tissue Sarcoma and Osteosarcoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Neoplasms; Chemotherapy, Adjuvan | 2015 |
Combination of Cisplatin, Ifosfamide, and Adriamycin as Neoadjuvant Chemotherapy for Extremity Soft Tissue Sarcoma: A Report of Twenty-Eight Patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin | 2016 |
VIP (etoposide, ifosfamide, and cisplatin) in patients with previously treated soft tissue sarcoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2017 |
The risk of postoperative complications and functional impairment after multimodality treatment for limb and trunk wall soft-tissue sarcoma: Long term results from a monocentric series.
Topics: Abdominal Wall; Activities of Daily Living; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplast | 2017 |
A rare presentation of myxofibrosarcoma as a Pancoast tumor: a case report.
Topics: Antineoplastic Agents, Alkylating; Biopsy, Large-Core Needle; Blepharoptosis; Fibrosarcoma; Head and | 2017 |
Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cerebellar | 2017 |
FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas.
Topics: Adult; Aged; Aged, 80 and over; Deoxycytidine; Doxorubicin; Female; Fluorodeoxyglucose F18; Follow-U | 2009 |
Her2, EGFR and TOPIIA gene amplification and protein expression in synovial sarcoma before and after combined treatment.
Topics: Adolescent; Adult; Antineoplastic Agents; Combined Modality Therapy; DNA Topoisomerases, Type II; DN | 2009 |
Alveolar rhabdomyosarcoma of the extremity and nodal metastasis: Is the in-transit lymphatic system at risk?
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Camptothecin; Child; Combined Mod | 2009 |
[Positron emission tomography as a tool for early prediction of therapy outcome in soft tissue sarcoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Doxorubicin; Etoposide; | 2009 |
Should patients with high-risk soft tissue sarcoma receive adjuvant chemotherapy?
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Mod | 2009 |
[A rare tumour with a distinctive histological appearance].
Topics: Adolescent; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemo | 2010 |
Mestastatic gastric cancer from malignant fibrous histiocytoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Dio | 2011 |
High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Bone Neoplasms; Disease-Free Survival; Female; Human | 2011 |
Adjuvant chemotherapy decreases and postpones distant metastasis in extremity stage IIB/III synovial sarcoma patients.
Topics: Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2012 |
Quality of surgery and neoadjuvant combined therapy in the ISG-GEIS trial on soft tissue sarcomas of limbs and trunk wall.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Epi | 2013 |
[Treatment and prognosis of stage IV alveolar soft part sarcoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Dacarbazine; | 2012 |
Lenograstim in preventing chemotherapy-induced febrile neutropenia in patients with soft tissue sarcoma.
Topics: Adjuvants, Immunologic; Adult; Aged; Antineoplastic Agents; Epirubicin; Female; Granulocyte Colony-S | 2013 |
Salvage chemotherapy for advanced sarcoma patients: a single-institution experience survey.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dacarbazine; D | 2002 |
Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modali | 2002 |
[Continuous-infusion high dose ifosfamide as salvage treatment for pre-treated soft tissue sarcoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Dose-Response Relationship, Drug; Female | 2002 |
Embryonal rhabdomyosarcoma presenting in an adult: a case report and discussion of immunohistochemical staining.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Co | 2003 |
Chemotherapy of soft tissue sarcoma--a clinical evaluation of treatment over ten years.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dacarbazin | 2003 |
Has "MAID" made it in the management of high-risk soft-tissue sarcoma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dacarbazine; Doxorubicin; Ex | 2003 |
Alveolar soft part sarcoma in Japan: multi-institutional study of 57 patients from the Japanese Musculoskeletal Oncology Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisp | 2003 |
The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Anti | 2004 |
The effect of multidrug chemotherapy on bone graft augmented prosthesis fixation.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Che | 2005 |
Alveolar soft part sarcoma: a rare and enigmatic entity.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cyclophos | 2005 |
[Emergent treatment of a malignant peripheral epineurial tumour].
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemo | 2006 |
Tandem high-dose chemotherapy supported by autologous peripheral blood stem-cell transplantation and radiotherapy for recurrent malignant fibrous histiocytoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Doxorubicin; Femal | 2005 |
[Effect of modified MAID regimen for patients with advanced soft tissue sarcoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; F | 2006 |
[Preoperative adjuvant therapy for primary malignant bone tumors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; Dactinomycin; Doxo | 2007 |
[Responses of 109 adult soft tissue sarcoma patients to chemotherapy].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemothe | 2007 |
F-18 FDG PET and PET/CT evaluation of response to chemotherapy in bone and soft tissue sarcomas.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Bone Neoplasms; Female; Fluorodeoxyglucose F18 | 2008 |
[Clinical evaluation on the sensitivity test for anti-cancer agents in malignant bone and soft-tissue tumors].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; | 1984 |
High-dose ifosfamide by infusion with mesna in advanced soft tissue sarcoma.
Topics: Adolescent; Adult; Aged; Cyclophosphamide; Female; Humans; Ifosfamide; Male; Mercaptoethanol; Mesna; | 1983 |
High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma.
Topics: Adolescent; Adult; Aged; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combination; Female; Human | 1983 |
[Extraosseous Ewing's sarcoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dactinomycin; Diag | 1995 |
[Combination effect of pirarubicin, ifosfamide, and vincristine sulfate in the treatment of advanced synovial sarcoma--report of a case].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Buttocks; Cystitis; Doxorubicin; Female; Hemo | 1995 |
Myxoid liposarcoma. Experience with chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophospha | 1994 |
Selection of large and objectively measurable target lesions in EORTC phase II trials: impact on recruitment and response rate. EORTC Soft Tissue and Bone Sarcoma Group (STBSG).
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Doxorubicin; Gra | 1993 |
[Intensive chemotherapy for alveolar soft part sarcoma with lung metastasis in a child].
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cisplatin; Cyclophosphamide; Dactinomycin; Do | 1993 |
Chemotherapy in the management of infantile fibrosarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dactinomycin; Doxorubic | 1993 |
[Soft tissue tumors: indications and results of hyperthermia].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modali | 1993 |
Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Grou
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Disea | 1993 |
Determination of the urinary excretion of ifosfamide and its phosphorated metabolites by phosphorus-31 nuclear magnetic resonance spectroscopy.
Topics: Adult; Aged; Humans; Ifosfamide; Magnetic Resonance Spectroscopy; Middle Aged; Phosphorus; Phosphory | 1993 |
[Toxic effects of ifosfamide in the treatment of bone and soft tissue sarcomas].
Topics: Administration, Intravesical; Adolescent; Adult; Aluminum Hydroxide; Bone Neoplasms; Child, Preschoo | 1993 |
Treatment results obtained in metastatic soft-tissue sarcoma with a combination of doxorubicin and dacarbazine or doxorubicin and ifosfamide.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; F | 1993 |
Ifosfamide combination regimens for soft-tissue sarcoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Etoposide; Fem | 1993 |
Ifosfamide in the treatment of soft-tissue sarcomas: experience at the West German Tumor Center, Essen.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Dru | 1993 |
A pilot study of rapidly alternating epirubicin/dacarbazine and ifosfamide as first-line therapy for metastatic soft-tissue sarcoma in adults.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Administration Schedu | 1993 |
Ifosfamide plus epirubicin at escalating doses in the treatment of locally advanced and/or metastatic sarcomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone | 1993 |
The use of recombinant human granulocyte-macrophage colony-stimulating factor with combination chemotherapy in the treatment of advanced adult soft-tissue sarcomas: early results from the EORTC Soft-Tissue and Bone Sarcoma Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Doxorubicin; Fema | 1993 |
Cytogenetics as an adjunct in establishing a definitive diagnosis of synovial sarcoma by fine-needle aspiration.
Topics: Adult; Biopsy, Needle; Cytogenetics; Diagnosis, Differential; DNA, Neoplasm; Humans; Ifosfamide; Kar | 1997 |
Feasibility trial of high-dose 7-day continuous-infusion ifosfamide given on an outpatient basis.
Topics: Antineoplastic Agents, Alkylating; Bone Neoplasms; Breast Neoplasms; Carcinoma, Transitional Cell; D | 1997 |
The use of a systemic therapy checklist improves the quality of data acquisition and recording in multicentre trials. A study of the EORTC Soft Tissue and Bone Sarcoma Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Data Collection; Doxorubicin; Granul | 1997 |
[The effects of high-dose ifosfamide in the treatment of bone and soft tissue sarcomas].
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Drug Administration Sch | 1997 |
[Chemotherapy for pulmonary metastases of soft tissue sarcoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Drug Administra | 1998 |
High-dose ifosfamide for soft tissue sarcomas: set the scene, or senescence?
Topics: Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Dose-Response Relationship, Drug; Human | 1998 |
Pharmacokinetics of ifosfamide administered according to three different schedules in metastatic soft tissue and bone sarcomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biot | 1998 |
Treatment of soft-tissue sarcomas: high-dose ifosfamide or combination of ifosfamide and etoposide?
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 1999 |
RT-PCR evaluation of peripheral blood, bone marrow and peripheral blood stem cells in children and adolescents undergoing VACIME chemotherapy for Ewing's sarcoma and alveolar rhabdomyosarcoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Purging; Bone N | 1999 |
Efficacy of docetaxel in the second-line treatment of locally advanced or metastatic soft tissue sarcoma after failure of chemotherapy with anthracycline or ifosfamide.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, | 1999 |
A high proliferation rate measured by cyclin A predicts a favourable chemotherapy response in soft tissue sarcoma patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Div | 1999 |
Impact of neoadjuvant chemotherapy on postoperative morbidity in soft tissue sarcomas.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy | 2000 |
Large, deep, high-grade extremity sarcomas: treating tumors of the flexor fossae.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axilla; Combined Modality Therapy; Dose Fractionatio | 1999 |
Comparison of double and triple high-dose chemotherapy with autologous blood stem cell transplantation in patients with metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Dose-Response | 2001 |
Treatment comparisons based on two-dimensional safety and efficacy alternatives in oncology trials.
Topics: Antineoplastic Agents, Alkylating; Biometry; Clinical Trials as Topic; Humans; Ifosfamide; Leukemia, | 1999 |
Immunoglobulin D myeloma presenting as an extraosseous soft tissue tumor.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; Humans; Ifosfamide; | 2001 |
Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; C | 2001 |
Near-precise interchromosomal recombination and functional DNA topoisomerase II cleavage sites at MLL and AF-4 genomic breakpoints in treatment-related acute lymphoblastic leukemia with t(4;11) translocation.
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Catechols; Child; Chromosome Bre | 2001 |
Systemic therapy for advanced soft-tissue sarcomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Doxorubicin; G | 2002 |
High dose chemotherapy with ABMT in soft tissue sarcomas: a report of 22 cases.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chil | 1992 |
Epirubicin/dacarbazine rapidly alternated with ifosfamide in the treatment of metastatic soft tissue sarcomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Epirubicin; Fe | 1992 |
A new approach to the study of ifosfamide metabolism by the analysis of human body fluids with 31P nuclear magnetic resonance spectroscopy.
Topics: Body Fluids; Humans; Ifosfamide; Magnetic Resonance Spectroscopy; Sarcoma; Soft Tissue Neoplasms | 1992 |
Epirubicin plus ifosfamide and dacarbazine (EID) in advanced soft tissue sarcomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Epirubicin; Follow-U | 1992 |
Ifosfamide vs cyclophosphamide in cancer therapy.
Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cyclophosphamide; Female; Genital Neoplasms, | 1991 |
Chemotherapy in perineal leiomyosarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Schedule; Female; H | 1992 |
Ifosfamide plus etoposide combined with regional hyperthermia in patients with locally advanced sarcomas: a phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Co | 1990 |
Bioavailability of subcutaneous ifosfamide and feasibility of continuous outpatient application in cancer patients.
Topics: Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Drug | 1990 |
Chemotherapy of metastatic soft tissue sarcoma with a combination of adriamycin and DTIC or adriamycin and ifosfamide.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Dos | 1990 |
Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. The EORTC Soft Tissue and Bone Sarcoma Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Evaluatio | 1990 |
Primary chemosensitivity and secondary drug resistance of xenografted soft part sarcomas.
Topics: Animals; Bleomycin; Doxorubicin; Drug Resistance; Female; Histiocytoma, Benign Fibrous; Humans; Ifos | 1989 |
Mesna: continuous or bolus infusion?
Topics: Drug Administration Schedule; Humans; Ifosfamide; Infusions, Intravenous; Injections, Intravenous; M | 1989 |
Characterization and chemotherapy of human soft tissue sarcoma (STS) lines grown in nude mice.
Topics: Animals; Cyclophosphamide; Doxorubicin; Female; Fibrosarcoma; Histiocytoma, Benign Fibrous; Humans; | 1989 |
[A case from practice (134). Patient: Mr. J.D., 1956, electrician].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Doxorubicin; Heart Neoplasms | 1989 |
Combination chemotherapy with doxorubicin, dacarbazine, and ifosfamide in advanced adult soft tissue sarcoma. Canadian Sarcoma Group--National Cancer Institute of Canada Clinical Trials Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; F | 1989 |
Prediction of ifosfamide/mesna associated encephalopathy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Electroencephalography; Female; Huma | 1986 |
Ifosfamide plus mesna with and without adriamycin in soft tissue sarcoma.
Topics: Adolescent; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Pre | 1986 |
Treatment of advanced soft tissue and osteogenic sarcomas with continuous infusion of ifosfamide and mesna.
Topics: Female; Humans; Ifosfamide; Infusions, Intravenous; Male; Mercaptoethanol; Mesna; Middle Aged; Osteo | 1986 |
A phase II study of ifosfamide/mesna with doxorubicin for adult soft tissue sarcoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain; Doxorubicin; Drug Ev | 1988 |
A phase I-II study of ifosfamide in combination with adriamycin in the treatment of adult soft tissue sarcoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Evaluatio | 1988 |
[Results of whole lung irradiation and chemotherapy in comparison with partial lung irradiation in metastasizing, undifferentiated soft tissue sarcomas].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; F | 1988 |
Ifosfamide: an old drug recently rediscovered.
Topics: Cyclophosphamide; Drug Evaluation; Female; Humans; Ifosfamide; Male; Neoplasms; Sarcoma; Soft Tissue | 1988 |
Phase II study of ifosfamide + adriamycin in advanced soft tissue sarcoma in adults. A preliminary analysis.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Evaluatio | 1986 |
Alternatives to CYVADIC combination therapy of soft tissue sarcomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dacarbazin | 1986 |
The role of ifosfamide in paediatric soft tissue sarcomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Dactinomycin; Drug Evaluation; Humans; Ifosfa | 1986 |
A phase II study of ifosfamide in the treatment of recurrent sarcomas in young people.
Topics: Adolescent; Adult; Bone Neoplasms; Child; Child, Preschool; Cyclophosphamide; Drug Evaluation; Femal | 1986 |
Alternatives to CYVADIC-combination therapy of soft tissue sarcomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dacarbazin | 1985 |
Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cystitis; Drug | 1985 |